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Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of 
fatal neurodegenerative diseases affecting humans and animal species. Prion diseases 
are characterized by the conversion of the host encoded prion protein (PrPC) into a 
disease-associated isoform (PrPSc), which (according to the prion hypothesis) is 
thought to be the main component of the infectious agent. PrPSc has been 
traditionally distinguished from PrPC by its biochemical properties, such as partial 
resistance to proteolysis and detergent-insolubility. In the absence of a foreign 
nucleic acid genome associated with prion diseases, efforts to provide a molecular 
basis for the biological diversity of prions have focused on biochemical 
characterization of PrPSc. In Creutzfeldt-Jakob disease (CJD) and other forms of 
human prion disease, the biochemical characterization of PrPSc has been largely 
restricted to the analysis of PK-resistant fragments of PrPSc (PrPres) by Western blot. 
However, given recent findings on the complexity of PrPSc identified in laboratory 
prion strains, PrPres analysis alone may not provide a complete description of PrPSc 
present in CJD brains. For a more complete characterization of PrPSc in human prion 
diseases, this study investigated biochemical properties of PrPSc in different forms of 
CJD by employing approaches that differ in principle from conventional Western 
blot analysis of PrPres. The novel biochemical approaches used in this study have 
identified further complexity of PrPSc accumulated in CJD brains, not only between 
different forms of CJD but also within single cases of individual disease entities. In 
this study, the two biochemical criteria most frequently used to define PrPSc (3F4 
epitope accessibility versus resistance to limited proteolysis) did not always correlate, 
indicating probable non-uniform distribution of PK-sensitive isoform of PrPSc within 
the same CJD brains. In variant CJD (vCJD) brains, the thalamic region, which is 
characterized by distinct neuropathological features, could also be distinguished from 
frontal cortex and cerebellum by the sedimentation profiles of PrPC and PrPSc on 
sucrose step gradients. Moreover, the conformational stability of PrPSc was found not 
to be uniform among human prion diseases and did not correlate with PrPres type or 
 v
prion protein genotype. Taken together, the results from this study provide a more 
complete description of PrPSc species occurring in CJD brains and contribute to a 




A117V  Alanine (A) to valine (V) mutation at PRNP codon 117  
ACDP  Advisory committee on dangerous pathogens  
BASE  Bovine amyloidotic spongiform encephalopathy  
BSA  Bovine serum albumin  
BSE  Bovine spongiform encephalopathy 
Cb  Cerebellum 
CD  Circular dichroism 
CDI  Conformation-dependent immunoassay 
CJD  Creutzfeldt-Jakob disease 
CNS  Central nervous system 
cps  counts per second 
CSA  Conformation stability assay 
CWD  Chronic wasting disease 
cyPrP PrP that is localized in the cytosol as a result of inefficient 
translocation into the endoplasmic reticulum 
ctmPrP  a transmembrane form of PrP in which central hydrophobic domain 
spans the membrane with its N-terminus exposed to the cytosol  
D178N  Aspartic acid (D) to asparagine (N) mutation at PRNP codon 178  
E200K  Glutamic acid (E) to lysine (K) mutation at PRNP codon 200   
E219K  Glutamic acid (E) to lysine (K) mutation at PRNP codon 219   
ELISA  Enzyme-linked immunosorbent assay 
ER  Endoplasmic reticulum 
F198S   Phenylalanine (F) to serine (S) mutation at PRNP codon 198  
FC  Frontal cortex 
fCJD  Familial Creutzfeldt-Jakob disease 
FFI  Fatal familial insomnia   
FTIR  Fourier transform infrared spectroscopy 
GABA  Gamma-aminobutyric acid 
GdnHCl Guanidine hydrochloride 
GPI  Glycosylphosphatidylinositol 
GSS  Gerstmann-Straussler-Scheinker Disease 
iCJD  Iatrogenic Creutzfeldt-Jakob disease 
kDa  Kilo Dalton 
LDS  Lithium dodecyl sulfate 
mAb  monoclonal antibody 
MM  Methionine homozygote at PRNP codon 129 
MM1  MM1 subtype of sporadic CJD 
MM2  MM2 subtype of sporadic CJD 
MRI  Magnetic resonance imaging (MRI) 
MV  Methionine/Valine heterozygote at PRNP codon 129 
MV1  MV1 subtype of sporadic CJD 
 vii
MV2  MV2 subtype of sporadic CJD 
NaPTA Sodium phosphotungstic acid 
NCJDSU National CJD Surveillance Unit  
NMR  Nuclear magnetic resonance  
NOG  n-octyl-β-D-glucopyranoside 
OD  Optical density  
ORF  Open reading frame  
P102L   Proline (P) to leucine (L) mutation at PRNP codon 102  
P105L   Proline (P) to leucine (L) mutation at PRNP codon 105  
PBS  Phosphate buffered saline 
PIPLC  Phosphatidylinositol-specific phospholipase C 
PMCA  Protein misfolding cyclic amplification  
PMI   Post mortem interval 
PK  Proteinase K 
PRNP  Human prion protein gene  
PrP  prion protein 
PrPc  Normal cellular form of prion protein 
PrPres  Protease-resistant prion protein 
PrPSc  Disease-associated form of prion protein 
PSPr  Protease-sensitive prionopathy  
PVDF  Polyvinylidene fluoride  
rpm  Revolutions per minute 
sCJD  Sporadic Creutzfeldt-Jakob disease 
sFI  Sporadic fatal insomnia  
T183A  Theronine (T) to alanine (A) mutation at PRNP codon 183  
TBS  Tris buffered saline 
TBST  Tris buffered saline + 0.1% Tween 20 
Th  Thalamus 
TME  Transmissible mink encephalopathy 
TRF  Time-resolved fluorescence 
TSE  Transmissible spongiform encephalopathy 
UK  United Kingdom 
vCJD  Variant Creutzfeldt-Jakob disease 
V180I   Valine (P) to isoleucine (L) mutation at PRNP codon 180  
V210I   Valine (P) to isoleucine (L) mutation at PRNP codon 210  
VV  Valine homozygote at PRNP codon 129 
VV2  VV2 subtype of sporadic CJD 
WB Western blot  











Table of contents..…………………………………….....…………...........…............…......viii  
List of figures…...…………………………………….....…………....…...…............…......xiv  
List of tables…....…….....……………………………………………….......…..................xvii  




1.1 Overview…..…...……………..........……..........…………………..…...……....…...........2     
1.2 Prion protein gene…....…..…...……...........….…………..…...……………….................3 
1.3 Prion protein…………..…...…………………..…...…………………..............................6 
1.3.1 Cellular prion protein (PrPC) .......…..…...…………………..…...…..........................6 
1.3.2 Disease-associated prion protein (PrPSc) …………..…...………................................8 
1.3.3 Two models describing the self-propagation of PrPSc …………..…........................10 
1.4 Strain variation in prion diseases………..…...…………………..….............................11 
1.5 Biochemical analysis of PrPSc for prion strain/phenotype discrimination........................13   
1.5.1 TME prion strains…………..…...…………………..…...………............................13 
1.5.2 Human prion diseases…………..…...…………………..…...……...…...................14 
1.5.3 BSE in cattle and other species …………..…...…………………..…......................16 
1.5.4 Atypical/Nor98 scrapie in small ruminants……………..…...………......................17 
 1.5.5 Atypical bovine prion diseases………..…...……………..…...……......................17 
1.6 Human prion diseases…………..…...…………………..…...………..............................19 
1.6.1 Sporadic prion disease: sCJD and sFI......…………..…...……….............................20 
1.6.2 Variant CJD.…………..…...…………………..…...…………………....................25 
 1.6.3 Other forms of acquired human prion disease: Kuru and iCJD …………..…..........27 
1.6.4 Familial (genetic) forms of human prion disease…………..…...….......................28 
1.7 Complicated biochemical properties of PrPSc…………......…...………..........................32 
     1.7.1 PK-sensitive isoform of PrPSc…………..…...……….....…………..........................32      
 ix
1.7.2 Various sizes of PrPSc…………..…...……….....…………..…...…….....................34     
 1.7.3 Conformational stability of PrPSc…………..…...……….....………….....................35 
1.8 Biochemical approaches for PrPSc analysis............…..…...………..................................37 
1.9 Aims..........................………..…...…………………..…...………................................,.40 
                
Chapter 2 
Abnormal prion protein in CJD brains: comparison of a conformation change with  
resistance to limited proteolysis.....................…………..…………………………............41 
2.1 Introduction…....…………………..…...….......………………..…...………..................42     
2.2 Materials and methods..…..…...……………….......…...…...………………...................44 
2.2.1 Laboratory requirement in handling human TSE material.............….......................44 
2.2.2 Human brain materials…………..…...……...................................….......................44 
2.2.2.1 Case selection criteria...........................................…...………...........................44 
2.2.2.2 Case details............................................………..…...………............................45 
2.2.2.3 Brain samples for analysis.................…...………............................................46 
2.2.3 Methods ………………..….……..….……..….…........…..….……..…...................51 
2.2.3.1 Conformation-dependent immunoassay (CDI)..................................................51 
2.2.3.1.1 History and methodological speculation...................................................51 
2.2.3.1.2 CDI procedures.....………..…...………...................................................53 
2.2.3.2 Other methods......…............................…...………............................................57 
2.3 Results.............………..…...…………………..…...………............……........................60 
2.3.1 Analysis of brain homogenates by CDI without additional pre-treatment................60 
2.3.1.1 Non-CJD (neurological control) cases...………..…...………...........................60 
2.3.1.2 vCJD cases.............................................………..…...………............................63 
2.3.1.3 sCJD cases.............................………..…...………............................................66 
2.3.2 PrPC and PrPSc in CJD brains with different disease phenotypes..............................69 
2.3.2.1 PrPC in CJD brains with different disease phenotypes…...…............................70 
2.3.2.2 PrPSc in CJD brains: comparison of a conformational change (CDI) with 
            resistance to limited proteolysis(WB)....…...…...………..................................73 
2.3.2.2.1 vCJD......................………..…...………...................................................73 
2.3.2.2.2 MM1 sCJD............………..…...………...................................................77 
2.3.2.2.3 MM2 sCJD............………..…...………...................................................81 
2.3.2.2.4 MV1 sCJD............………..…...………....................................................85 
 x
2.3.2.2.5 MV2 sCJD..........………..…...………......................................................89 
2.3.3 Further analysis of CJD brains: comparison before and after proteolysis.................94 
2.3.3.1 Non-CJD brains............................................................…...…...........................94 
2.3.3.2 CJD brains....................................................................…...…...........................96 
2.3.4 Further characterization of proteolytic fragments of PrPSc in Western blot............101 
2.3.4.1 PrPres type analysis.......................................................…...…..........................101 
2.3.4.2 A small proteolytic fragment of PrPSc in MV2-2..........…...…........................105 
2.3.5 Supplementary data..........................................…………..…..................................107 
2.3.5.1 Liner range investigation in CDI.................................…...…..........................107 
2.3.5.2 Liner range investigation in Western blot analysis of PrPres............................110 
2.3.5.3 Analytical precision......................................................…...….........................112 
2.4 Discussion.......………..…...…………………..…...…………………..........................114 
2.4.1 PrPC in CJD brains..................................…………..…...………............................114 
2.4.2 CDI-based distinction between non-CJD and CJD brains: FC tissue analysis........116 
2.4.3 PrPSc in CJD brains determined by CDI or resistance to limited proteolysis (WB)...118 
2.4.3.1 Analysis of multiple samples from different brain regions…..........................118 
2.4.3.2 A conformational change (CDI) versus resistance to limited proteolysis (WB)....119 
2.4.3.3 CDI analysis following limited proteolysis........................…..........................120 
2.4.3.4 Speculation on the distribution profiles of PrPSc/PrPres in CJD brains.............122 
2.4.4 PK-resistant fragments of PrPSc (PrPres)...................................................................124 
2.4.4.1 Mixed PrPres types.............................................................................................124 
2.4.4.2 PrPres migrating between type 1 and type 2 standards......................................125 
2.4.4.3 PK-resistant fragment of PrPSc with low molecular mass comparable to that  
             of GSS.............................................................................................................126 
2.4.5 Speculation on potential limitation associated case selection.............................................127 
2.4.6 Analytical sensitivity of CDI...................................................................................128 




Distribution profiles of different PrP conformers after fractionation in sucrose step 
gradient.............................................................…………..…………………………..........131 
3.1 Introduction…....….......………………..…...………............…………..…...………....132     
 xi
3.2 Materials and methods..........…..…...…………………..…...............……………….....134 
3.2.1 Human brain materials….......………..…...…….......................................…..........134 
3.2.2 Methods ………………..….........……..….……..….……..….……..….................134 
3.3 Results.............………..…...…………............…..…...…………………......................137 
3.3.1 Distribution profiles of PrPC, total PrP and PrPSc in sucrose gradient.....................137 
3.3.1.1 Distribution profiles of PrPC in sucrose gradient..............................................137 
3.3.1.2 Distribution profiles of total PrP in sucrose gradient.......................................144 
3.3.1.3 Distribution profiles of PrPSc in sucrose gradient.............................................148 
3.3.2 Distribution profiles of PrPSc in sucrose gradient after mild proteolysis.................157 
3.3.2.1 Effect of PK treatment to PrP conformers in fractionated samples..................157 
3.3.2.2 Distribution of PrPSc after digestion with 2.5µg/ml PK...................................161 
3.3.3 Distribution of PrPres in sucrose gradient.................................................................163 
3.3.4 Supplementary data: total protein distribution in sucrose gradient..............................167 
3.4 Discussion.......………..…...…………………..…...…………………..........................170 
3.4.1 PrPC: sedimentation profiles in sucrose gradient.……........................................170 
3.4.1.1 Non-CJD control brains....................................................................................170 
3.4.1.2 CJD brains........................................................................................................171 
3.4.2 Total PrP in CJD brains: sedimentation profiles in sucrose gradient..................172 
3.4.3 PrPSc/PrPres in CJD brains: sedimentation profiles in sucrose gradient..................173 
3.4.3.1 Two possible indicators for PrPSc in CDI D/N ratio and [D-N] values............173 
3.4.3.2 PK digestion of sucrose fractions.....................................................................173 
3.4.3.3 PrPSc/PrPres sedimentation profiles in sucrose gradient: between size and 
density..............................................................................................................175 
3.4.3.4 Further speculations on regional difference of vCJD brains............................177 
3.4.4 Considerable additional experiments using fractionated samples...........................179 
 
Chapter 4 
Conformational stability states of PrPSc measured by CDI in different forms of human 
prion disease.........……........................................................................................................182 
4.1 Introduction…....…………………..…...………………............…..…...………...........183     
4.2 Materials and methods..…..…...…………………..…...……………............….............185 
4.2.1 Human brain materials…………..…...……............................…............................185 
4.2.2 Methods ………………..….……..….……..….……..….……..….........................185 
 xii
4.3 Results.............………..…...…………………..…...…………………..........................189 
4.3.1 GdnHCl-induced denaturation of PrPSc in brain homogenates................................189 
4.3.2 Enrichment of PrPSc by Sarcosyl extraction and centrifugation..............................195 
4.3.3 Conformational stability of PrPSc: comparison between vCJD and sCJD...............199 
4.3.4 Conformational stability of PrPSc: variation between samples................................202 
4.3.5 Analysis of additional cases at concentrations of 1.5M and 2M GdnHCl...............206 
4.3.6 Conformational stability of vCJD PrPSc: comparison between brain regions..........208 
4.3.7 Conformational stability of PrPres............................................................................210 
4.3.8 Conformational stability of PrPSc in GSS cases with P102L mutation....................212 
4.4 Discussion.......………..…...…………………..…...…………………..........................214 
4.4.1 GdnHCl-induced denaturation of brain homogenate containing mixed PrP  
         conformers.................................................................……......................................214 
4.4.2 Conformational stability of PrPSc: analysis of detergent insoluble fraction of  
         PrP...................................................................…….................................................214 
4.4.3 Conformational stability of PrPres...........................…….........................................216 
4.4.4 Conformational stability of PrPres: importance in determining disease incubation  
          periods....................................................…….........................................................217 
4.4.5 Conformational stability of PrPSc/PrPres: limitation in inferring the conformational   
          state...............................................……..................................................................218 
4.4.6 Speculation on effects of the detergent in protein conformation.............................219 





5.1 Summary of findings…...…..…...…............……………..…...………………............223 
5.1.1 PrPC in CJD brains……………..…...............……..............................…................223 
5.1.2 PrPSc in CJD brains: comparison between 3F4-based CDI and resistance to limited  
          proteolysis…………..….........….……..….……............….……..….……..…......224 
5.1.3 Distribution profiles of PrPSc between the three brain regions in CJD brains.........225 
5.1.4 PrPSc in CJD brains: sedimentation profiles in the sucrose step gradient................226 
5.1.5 Conformational stability of PrPSc in CJD brains………………..…........................228 
5.1.6 A proteolytic fragment of ~8 KDa fragment in MV2 sCJD...…........................229 
 xiii
5.2 Outstanding questions and future research......………...……………….........................230 
5.2.1 Further analysis of size distribution of PrPSc in the thalamus of vCJD brains.........230 
5.2.2 Further analysis of conformational stability of PrPSc…….......…............................231 
5.2.3 Abnormal PrP species in FFI.......................………..….......…............................232 





1. Neuropathology of CJD brains..................................…………..…..................................270 
1.1 vCJD......................................................................................…...…..........................270 
1.2 MM1 sCJD..............................................................................…...….........................272 
1.3 MM2 sCJD..............................................................................…...….........................274 
1.4 MV1 sCJD..............................................................................…...….........................276 
1.5 MV2 sCJD..............................................................................…...….........................278 
1.6 Summary.....................................................................................................................282 
2. Papers submitted for publication.................................................…..................................284 
 xiv
List of figures 
 
Chapter 1 
1.1 Primary structure of human cellular prion protein (PrPC)………………………………............8  
1.2 Two models depicting the conformational conversion of PrPC into PrPSc…………................10 
1.3 Lesion profiles in RIII mice infected with BSE or vCJD………………………………...........12  
1.4 Various PK-resistant core fragments of PrPSc observed in human prion diseases………...........15 
1.5 Western blot analysis of types 1 and 2 PrPres………………………………………….............16 
 
Chapter 2 
2.1 Diagram of conformation-dependent immunoassay..............................................…….........56  
2.2 Comparison of CDI results between native and denatured states in non-CJD brains…….........62  
2.3 Comparison of CDI results between native and denatured states in vCJD brains………...........65  
2.4 Comparison of CDI results between native and denatured states in MM1 sCJD brains......68 
2.5 PrPC in CJD brains with MM genotype at codon 129………………………………..............71 
2.6 PrPC in CJD brains with MV genotype at codon 129…………………………………..........72 
2.7 CDI [D-N] values for tissues of FC, Cb and Th from vCJD brains……………………..........75  
2.8 Distribution of PrPres in three regions of vCJD brains…………………………………..........76  
2.9 CDI [D-N] values for tissues of FC, Cb and Th from MM1 sCJD brains……………........….79  
2.10 Distribution of PrPres in three regions of MM1 sCJD brains………………………............80  
2.11 CDI [D-N] values for tissues of FC, Cb and Th from MM2 sCJD brains……………...........83  
2.12 Distribution of PrPres in three regions of MM2 sCJD brains…………………………..........84  
2.13 CDI [D-N] values for tissues of FC, Cb and Th from MV1 sCJD brains...................................87  
2.14 Distribution of PrPres in three regions of MV1 sCJD brains....................................................88  
2.15 CDI [D-N] values for tissues of FC, Cb and Th from MV2 sCJD brains…………….............92 
2.16 Distribution of PrPres in three regions of MV2 sCJD brains…………………………...........93 
2.17 High susceptibility of PrPC to proteolytic treatment in non-CJD brains………………..........95 
2.18 Comparison of CDI results before and after proteolysis…………………………..........98 
2.19 Comparison of CDI D/N ratios before and after proteolysis…………………………..........99 
2.20 Comparison of CDI [D-N] values before and after proteolysis………………………........100 
2.21 Analysis of PrPres type in MM2 sCJD brains…………………………………………......103 
2.22 Analysis of PrPres type in MV2 sCJD brains………………………………………….......104 
2.23 A proteolytic fragment of PrPSc with low molecular weight in a case of MV2 sCJD.............106 
 xv
2.24 Investigation of linear range in CDI…………………………............................................109 
2.25 Investigation of linear range in Western blot analysis of PrPres.............................................111 
2.26 Intra-assay variation in CDI...................................................................................................113 
 
Chapter 3 
3.1 Distribution profiles of PrPC from FC of non-CJD brains after fractionation in sucrose step  
       gradient............................................................................................................................................140  
3.2 Distribution profiles of PrPC from FC of vCJD brains after fractionation in sucrose step  
       gradient............................................................................................................................................141   
3.3 Distribution profiles of PrPC from FC of MM1 sCJD brains after fractionation in sucrose step  
gradient............................................................................................................................................142   
3.4 Comparison of PrPC distribution in sucrose step gradient between non-CJD and CJD brains 
..........................................................................................................................................................143 
3.5 Distribution of total PrP in sucrose step gradient..........................................................................146 
3.6 Comparison of the distribution profiles of total PrP in sucrose step gradient.............................147 
3.7 CDI D/N ratios for fractions from FC of non-CJD brains...........................................................152 
3.8 CDI D/N ratios for fractions from FC of vCJD brains.................................................................153 
3.9 Comparison CDI D/N ratios between fractions derived from different regions of a vCJD  
       brain.................................................................................................................................................154 
3.10 CDI D/N ratios for fractions from FC of MM1 sCJD brains....................................................155 
3.11 Comparison of CDI D/N ratios for fractions derived from different regions of vCJD  
         brains and FC of MM1 sCJD brains...........................................................................................156 
3.12 Absence of detectable PrP in the fractionated samples from FC of non-CJD1 (a) or  
        non-CJD3 (b) after digestion with 2.5µg/ml PK.........................................................................159 
3.13 Effects of PK treatment to different PrP conformers in fractionated samples from different  
         regions of a vCJD brain................................................................................................................160 
3.14 Comparison of CDI D/N ratios for PK-treated fractions between vCJD FC, vCJD Th and  
         MM1 sCJD FC..............................................................................................................................162 
3.15 PrP distribution after fractionation in sucrose step gradient.......................................................165 
3.16 PrP distribution after fractionation in sucrose step gradient.......................................................166 
3.17 Total protein distribution after fractionation in sucrose step gradient.......................................168 
3.18 A standard curve generated using BSA.......................................................................................169 
3.19 Total protein distribution after fractionation in sucrose step gradient.......................................169 
 xvi
Chapter 4 
4.1 Comparison of CDI results between native (N) and denatured (D) states..................................192 
4.2 Change of CDI TRF counts with exposure to increasing concentrations of GdnHCl...............193 
4.3 Change of CDI D/N ratio with exposure to increasing concentrations of GdnHCl........194 
4.4 Distribution of PrPC and PrPSc after Sarcosyl extraction and centrifugation...............................197 
4.5 Enrichment of PrPres in pellets after Sarcosyl extraction and centrifugation...............................198 
4.6 GdnHCl-induced denaturation of PrPSc........................................................................................201 
4.7 Comparison of GdnHCl-induced denaturation of PrPSc between samples.................................204 
4.8 Denatured fraction of PrPSc after treatment with 1.5M or 2M GdnHCl......................................207  
4.9 GdnHCl-induced denaturation of PrPSc from cerebellum or thalamus of vCJD brains...........209 
4.10 Conformational stability of PrPres from frontal cortex of vCJD and MM1 sCJD brains........211 
4.11 Comparison of denaturation profiles of PrPSc between two GSS cases with different  
        PrPres patterns.................................................................................................................213 
 
Appendix 1 
A1.1 Neuropathology in vCJD.............................................................................................................271 
A1.2 Neuropathology in MM1 sCJD…......…............………....................................................273 
A1.3 Neuropathology in MM2 sCJD……..…………………....................................................275 
A1.4 Neuropathology in MV1 sCJD…………………………...................................................277 
A1.5 Neuropathology in MV2 sCJD…………………………...................................................280 





List of tables 
 
Chapter 1 
1.1 Codon 129 genotype frequencies in normal and CJD populations in the UK (%)…....................5 
1.2 Classification of human prion disease..............................................................................................19 
1.3 Classification of sCJD based on genotype at codon 129 and PrPres type.......................................24  
 
Chapter 2 
2.1 Clinical, genetic and biochemical information for vCJD cases.....................................................47 
2.2 Clinical, genetic and biochemical information for sCJD cases......................................................48 
2.3 Clinical, genetic and biochemical information for GSS cases with P102L mutation..................49 
2.4 Clinical, genetic and biochemical information for neurological control cases.............................49  
2.5 Variables of neurological control and CJD cases as a group..........................................................50 
 
Chapter 4 
4.1 GdnHCl1/2 values for PrP
Sc from frontal cortex of vCJD.............................................................205 
4.2 GdnHCl1/2 values for PrP
Sc from frontal cortex of MM1 sCJD...................................................205 
4.3 GdnHCl1/2 values for PrP
Sc from cerebellum and thalamus of vCJD..........................................209 
4.4 Comparison of GdnHCl1/2 values between relevant studies............................................221    
  
Appendix 1 















Transmissible spongiform Encephalopathies (TSEs) or prion diseases are a group of 
fatal neurodegenerative diseases affecting humans and animal species. The prion 
diseases in humans include Creutzfeldt-Jakob disease (CJD), Gertsmann-Straussler-
Scheinker Syndrome (GSS) and fatal familial insomnia (FFI). The prion diseases in 
animals include bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep 
and goats and chronic wasting disease (CWD) in elk and deer. Prion diseases are 
characterized clinically by neurological symptoms such as dementia and ataxia, and 
pathologically by brain lesions showing spongiform degeneration, neuronal loss and 
gliosis (Ironside et al. 2008). More distinctively, an abnormally folded isoform of a 
host encoded protein, the prion protein (PrP) accumulates in the central nervous 
system (CNS) of affected individuals in most forms of prion diseases (Budka 2003; 
Prusiner 1998).  
 
Prion diseases appear to share some pathophysiological features with other 
neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (Aguzzi 
and Calella 2009; Aguzzi and Haass 2003). However, prion diseases are unique in 
that they are transmissible within species and occasionally between species by 
inoculation or by ingestion of infected materials. Although the infectious agent that 
causes TSEs is not fully understood, a wealth of experimental evidence strongly 
supports the "protein-only" or prion hypothesis (Prusiner 1998). Prions can be 
defined as "small proteinaceous infectious particles that are resistant to inactivation 
by most procedures that modify nucleic acids" (Prusiner 1982; Prusiner 1998). The 
misfolded conformer (PrPSc) of cellular PrP (PrPC) is the only known component of 
prion (Bolton et al. 1982; McKinley et al. 1983) and propagates in an autocatalytic 
manner by inducing PrPC to adopt a disease-associated conformation (Caughey 2003; 
Caughey and Raymond 1991; Prusiner 1998). PrPC was shown to be essential for 
prion invasion through the study using mice devoid of PrPC (Bueler et al. 1993; 
Sailer et al. 1994). Since the first discovery of a linkage between GSS and a mutation 
in PrP gene (Hsiao et al. 1989), more than 30 pathogenic mutations in PrP gene have 
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been identified in humans with inherited forms prion disease (Kovacs et al. 2005; 
Mead 2006). No nucleic acids genome has been identified as a constituent 
component of prions (Meyer et al. 1991; Safar et al. 2005b), which make prions 
distinct from all other conventional infectious pathogens such as viruses and bacteria. 
More compelling evidence supporting the prion hypothesis has come from in vitro 
generation of infectious prions. In 2004, Prusiner and co-workers firstly reported the 
generation of synthetic mammalian prions, which were produced by polymerizing 
recombinant mouse PrP into amyloid fibrils (Legname et al. 2004). In the following 
year, Soto and colleagues reported the successful generation of infectious prions by 
amplifying PrPSc in vitro using the methods named protein misfolding cyclic 
amplification (PMCA) (Castilla et al. 2005a). Since then, the successful generation 
of prion infectivity has been reported in various studies from different groups 
(Castilla et al. 2008a; Castilla et al. 2008b; Colby et al. 2009; Colby et al. 2010; 
Deleault et al. 2007; Kim et al. 2010; Makarava et al. 2010; Wang et al. 2010).  
 
1.2 Prion protein gene  
The genes encoding PrP of various species was fully sequenced in 1986 (Basler et al. 
1986; Liao et al. 1986; Locht et al. 1986). The entire open reading frame (ORF) of 
PrP gene was found to be located within a single exon in all examined mammalian 
and avian species (Prusiner 1998). The human PrP gene (PRNP) located on the short 
arm of chromosome 20 is composed of two exons with the ORF in exon 2 (Sparkes 
et al. 1986). In animals including sheep, cattle and mice, the PrP genes contain three 
exons with the ORF in exon 3 that is analogous to exon 2 of the human PrP gene 
(Prusiner 1998). The PrP gene is highly conserved across many mammalian and 
avian species, suggesting the functional importance of PrP (Lee et al. 1998; Wopfner 
et al. 1999). 
   
Genetic variation in the PrP gene can be directly associated with prion diseases 
(pathogenic mutation) or can influence the disease susceptibility and phenotypes 
(polymorphism). In humans, there are more than 30 pathogenic mutations including 
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point mutations resulting in an amino-acid substitution and insertion of additional 
octapeptide repeats (Mead 2006). Additionally, non-pathogenic polymorphisms in 
human PRNP have a profound influence on disease susceptibility and phenotype 
(Collinge et al. 1991; Goldfarb et al. 1992b; Palmer et al. 1991; Parchi et al. 1999b; 
Windl et al. 1996; Zeidler et al. 1997). A polymorphism at codon 129 that encodes 
methionine (M) or valine (V) is a particularly important factor in determining disease 
susceptibility and phenotype. In variant CJD, the effect of polymorphism at codon 
129 is dramatic (Table 1.1). All pathologically confirmed cases of variant CJD 
(vCJD) have been homozygous for methionine at position 129 (Table 1.1)(Brandel et 
al. 2009). In sporadic CJD (sCJD), about  65% of patients are methionine 
homozygotes at PRNP codon 129 (Table 1.1)(Bishop et al. 2009; Head et al. 2004a; 
Parchi et al. 1999b). In comparison, the proportion of methionine homozygotes at 
this position is about 40% in general white population (Bishop et al. 2009; Nurmi et 
al. 2003; Parchi et al. 1999b). Individuals who have a heterozygous MV genotype at 
codon 129 have shown longer incubation periods in acquired forms of prion disease 
such as kuru and iatrogenic CJD (Brown et al. 2000; Cervenakova et al. 1998; Lee et 
al. 2001). Another polymorphism at codon 219 (E219K) is also proposed to be 
associated with susceptibility to sCJD in Japan (Shibuya et al. 1998).  
 
The polymorphic effects of the PrP gene are also well known in sheep scrapie. In 
sheep, the three polymorphic sites of the PrP gene at codons 136, 154 and 171 have 
profound effects on the disease susceptibility and pathogenesis (Hunter 2003; Hunter 
2007). Animals carrying the genotype of V136R154Q171/V136R154Q171 are known to 
most susceptible to classical scrapie (Belt et al. 1995; Hunter et al. 1996); in 
comparison, the presence of the A136R154R171 allele is known to confer a level of 
resistance to scrapie (Houston et al. 2002). In mice, two polymorphic sites of the PrP 
gene at codons 108 and 189 are known to be closely associated with disease 
progression (Moore et al. 1998; Westaway et al. 1987). 
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Table 1.1 Codon 129 genotype frequencies in normal and CJD populations in 
the UK (%) 
Codon 129 genotype MM MV VV          Reference 
   Normal population 42 47 11   (Nurmi et al. 2003) 
   sCJD population 67 19 14   (Head et al. 2004a) 
   vCJD populationa 100 0 0   (Brandel et al. 2009) 
 
Note a. One individual with MV genotype at codon 129 was diagnosed as a possible vCJD 
on the basis of ante-mortem examination. Post-mortem examination was not 
performed for this patient (Kaski et al. 2009). Additionally, one case of preclinical 
vCJD was reported in an individual with MV genotype at codon 129 (Peden et al. 
2004); this patient who had received blood transfusion from a donor later found to 
incubate vCJD died without neuorological symptoms, but the accumulation of PrPres 
was identified in the spleen.  
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1.3 Prion protein  
1.3.1 Cellular prion protein (PrPC)   
The cellular prion protein (PrPC) is a cell-surface glycoprotein which is attached to 
the outer membrane by its glycosylphosphatidylinositol (GPI) anchor (Stahl et al. 
1987). In the CNS, PrPC is expressed at high levels in neurons but also found in glial 
cells (Kretzschmar et al. 1986; Manson et al. 1992; Moser et al. 1995). PrPC is also 
expressed at lower levels in a variety of peripheral tissues including immune cells, 
kidney, heart and skeletal muscle (Caughey et al. 1988; Ford et al. 2002; Mabbott 
and MacPherson 2006). Like other membrane and secreted proteins, PrPC is 
synthesized in the rough endoplasmic reticulum (ER)-attached ribosome, enters ER 
concurrent with its synthesis and is transported along the secretary pathway to the 
cell surface (Hegde and Rane 2003; Westergard et al. 2007). Nascent PrPC undergoes 
post-translational modifications including cleavage of the ER signal peptide and 
cleavage of GPI signal peptide followed by attachment of the GPI anchor (Kang et al. 
2006; Stahl et al. 1987). In humans, a mature form of PrPC consists of 208 amino 
acids (aa) containing the GPI anchor at serine 230. 
 
The structure of PrPC determined by nuclear magnetic resonance (NMR) 
spectroscopy is very similar among various mammalian species; the N-terminal tail 
of the molecule is largely unstructured whereas the C-terminal domain is globular 
and contains three α-helices and two β-sheets (Donne et al. 1997; Lysek et al. 2005; 
Riek et al. 1996; Riek et al. 1997; Zahn et al. 2000). The flexible amino-terminal 
domain of PrPC contains octapeptide repeat region, which is known to play an 
important role in copper binding through its histidine residues (Brown 2001; Viles et 
al. 1999). The insertional mutations of this octapeptide repeat region cause inherited 
forms of prion disease in humans (Mead 2006; Owen et al. 1989). The amino-
terminal portion of PrPC also contains a conserved hydrophobic segment (residues 
111 - 134) that can span the membrane (Hegde et al. 1998; Kim et al. 2001; Stewart 
et al. 2001). The carboxyl-terminal globular domain of PrPC has two glycosylation 
sites at asparagine (N) residues 181 and 197 in the human PrP (Haraguchi et al. 
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1989); thus PrPC can be present in three different glycoforms (di-, mono- and un-
glycosylated PrP) according to the degree of the occupancy of the two potential N-
linked glycosylation sites. Additionally, a disulphide bridge between cysteine 
residues 179 and 214 (in the human protein) is present in the C-terminal domain 
(Turk et al. 1988).  
 
The physiological function remains still unclear, although more than two decades has 
passed since the identification of PrPC as an endogenous cellular protein (Aguzzi and 
Calella 2009; Solomon et al. 2009).  A variety of lines of mice that are devoid of 
PrPC develop normally without showing any severe pathology (Weissmann and 
Flechsig 2003), although subtle abnormalities were reported in several lines of PrP-
deficient mice (Collinge et al. 1994; Nishida et al. 1999; Tobler et al. 1996). Even 
the postnatal deletion of neuronal PrPC does not elicit neurodegeneration in mice 
(Mallucci et al. 2002). One very recent study reported that neuronal expression of 
PrPC is essential for long-term peripheral myelin maintenance (Bremer et al. 2010). 
Significantly, PrP-deficient mice were shown to be fully resistant to prion infection 
(Bueler et al. 1993). Several proposed functions of PrPC include an anti-apoptotic 
activity, protection against oxidative stress, copper transport, a role in synaptic 
formation and function and participation in transmembrane signalling processes 
involved in neuronal survival and neurite outgrowth (Aguzzi et al. 2008; Watts and 
Westaway 2007). 














Figure 1.1 Primary structure of human cellular prion protein (PrPC). The 
secretory signal peptide (1 - 22) is present at the extreme N-terminus. The membrane 
anchor region (MA; 231 - 253) is cleaved when the GPI anchor is attached at serine 
230. The mature form of human PrPC contains 208 amino acids (23 - 230) and has 
two potential sites for N-linked glycosylation at residues 181 and 197 and one 
disulphide bond (S-S) between cysteine residues 179 and 214. OR: octapeptide 
repeats; HC: hydrophobic core. The numbers represent the position of respective 





1.3.2 Disease-associated prion protein (PrPSc)   
According to the prion hypothesis the central phenomenon that characterizes prion 
disease is the conformational conversion of PrPC into a pathogenic conformer of PrP 
(PrPSc), which is thought to be the main constituent of infectious prions (Prusiner 
1998). PrPSc replicates its pathogenic conformation at the expense of PrPC (Bessen et 
al. 1995; Horiuchi et al. 2000; Kocisko et al. 1994) and accumulates in the CNS of 
affected individuals. Demonstration of PrPSc is currently the most reliable diagnostic 
marker of prion propagation. The formation of PrPSc is a post-translation process that 
happens after mature PrPC reaches the cell surface (Caughey 1993; Caughey and 
Raymond 1991); nonetheless, post-translational modifications that distinguish the 
two conformers of PrP remains largely elusive except for few recent findings 












The distinction between PrPC and PrPSc has been largely achieved based on the 
difference in biochemical properties. While PrPC exists as monomers or dimers with 
α-helix-rich structure, PrPSc is present as ß-sheet-rich polymers that often form 
amyloid plaques in the brain (Caughey et al. 1991; Meyer et al. 2000; Pan et al. 
1993; Pergami et al. 1996). The conversion of PrPC into PrPSc accompanies the 
change of biochemical properties such as proteinase-K (PK) resistance or detergent 
solubility. In contrast to PrPC, PrPSc is insoluble to non-denaturing detergents and 
partially resistant to proteolytic digestion (Meyer et al. 1986). Proteolytic treatment 
of PrPSc leaves PK-resistant fragments of PrPSc (PrPres) as a result of the cleavage of 
60 - 70 amino terminal residues (Bolton et al. 1982). This PK-resistant core fragment 
with molecular weight of 27 - 30 KDa (PrP 27-30) in dissociating and denaturing 
condition has been a useful surrogate marker for the diagnosis of prion disease 
(Grassi et al. 2000; Schaller et al. 1999; Wadsworth et al. 2001). 
 
The difference in the secondary structure between PrPC and PrPSc was revealed in 
early studies employing circular dichroism (CD) and/or Fourier transform infrared 
(FTIR) spectroscopy (Pan et al. 1993; Safar et al. 1993). PrPC is predominantly 
composed of α-helices (~40%) with little ß-sheet content (3%), whereas PrPSc has 
greatly increased ß-sheet contents (~40%) and slightly lower amounts of α-helices 
(30%) (Pan et al. 1993). In contrast to PrPC, high-resolution structure is poorly 
determined for PrPSc because of its insolubility (Aguzzi and Polymenidou 2004; 
Riesner 2003). A highly ordered structure of PrPres shown by Wille and colleagues is 
the highest resolution information for PrPSc structure (Caughey et al. 2009; Wille et 
al. 2002). A trimeric arrangement of PrPSc was proposed as a minimal assembly of 





1.3.3 Two models describing the self-propagation of PrPSc  
Currently, the exact mechanism in which PrPC is converted into PrPSc remains 
unclear. Two models have been proposed in order to explain the propagation of PrPSc 
(Figure 1.2). In the "template-directed refolding" model, a spontaneous conversion of 
PrPC into PrPSc is a rare event or may be prevented by a high energy barrier between 
the two conformers of PrP (Aguzzi and Polymenidou 2004; Caughey et al. 2009). 
The pre-existing PrPSc acts as a template for the cellular conformer of PrP to be 
refolded into a pathogenic conformation. In the "seeded nucleation" model, the two 
isoforms of PrP are supposed to co-exist in a balance which is heavily shifted toward 
PrPC in a non-disease condition (Aguzzi and Polymenidou 2004; Caughey et al. 
2009). In this model, a monomeric form of PrPSc is harmless and what is infectious is 













Figure 1.2 Two models depicting the conformational conversion of PrPC into 
PrPSc. Upper row describes the template-directed refolding model and bottom row 





1.4 Strain variation in prion diseases  
Prion strains can be defined as infectious isolates which cause distinct disease 
phenotypes when experimentally inoculated into identical hosts (Aguzzi et al. 2007). 
The presence of prion strains was first recognized by Pattison and Misslon in 1961 
(Pattison and Millson 1961). In this study, scrapie-infected goats were classified into 
two groups according to their clinical manifestation:"drowsy" goats versus "scratch" 
goats. The successful transmission of scrapie to rodents became an important 
milestone in the study of prion diseases (Chandler 1961; Kimberlin and Walker 
1977), which made possible larger scale of transmission studies that had been 
impractical in sheep and goats. Prion strains that have been identified until now are 
mostly based on the disease characteristics obtained by bioassay in rodents 
(particularly in mice). Most commonly used parameters to distinguish prion strains 
are the length of incubation period between the initial infection and development of 
clinical symptoms, and profile of neuropathological changes in the brains of infected 
mice (lesion profile)(Bruce 2003). For the generation of lesion profile, the severity of 
vacuolation is semi-quantitatively scored in defined brain areas (nine grey matter and 
three white matter areas) (Bruce et al. 1991; Fraser and Dickinson 1968). Clinical 
features in laboratory animals may be an additional useful parameter to distinguish 
prion strains, as is the case in the two TME prion strains isolated in hamsters (Bessen 
and Marsh 1992b). Once prion strains are isolated by serial passage, they can retain 
their identities indefinitely on further passages as long as the conditions of passage 
remain constant (Bruce 2003).  
 
The transmission studies of scrapie from a wide range of natural and experimental 
sources into inbred mice revealed the existence of multiple strains of prions 
(Dickinson 1976). About 20 strains of scrapie have been isolated in mice by serial 
passage of scrapie materials, each with phenotypically distinct disease characteristics 
(Bruce 1993; Bruce and Fraser 1991). In transmissible mink encephalopathy (TME), 
two strains termed DY (drowsy) and HY (hyper) were isolated in hamsters by serial 
passage of TME brain materials (Bessen and Marsh 1992b). Transmission studies in 
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wild-type and transgenic mice revealed that cattle BSE, human vCJD and TSEs in 
cats and exotic ungulates were caused by the same prion strain (Figure 1.3)(Bruce et 
al. 1994; Bruce et al. 1997; Hill et al. 1997; Scott et al. 1999). Therefore, vCJD is 
definitely an independent prion strain isolated from prion-infected human brains. 
Except for vCJD, it appears largely elusive how many strains are present in human 
prion diseases (Aguzzi et al. 2007). For example, six subtypes of sCJD were 
suggested to exist on the basis of clinico-pathological phenotype and these were 
proposed to correlate with the combination of PRNP genotype at codon 129 and 
PrPres type (Parchi et al. 1999b). However, each subtype of sCJD has not yet been 
shown to result from an independent prion strain, which would require evidence of 
persistence of strain characteristics on serial passage in experimental animals 
(Aguzzi et al. 2007). Nonetheless, one transmission study using bank voles proposed 
the existence of at least two prion strains in sCJD (Nonno et al. 2006). Additionally, 
another transmission study using transgenic mice suggested that the prion strain 
associated with FFI is identical to that of sporadic form of fatal insomnia (Mastrianni 









Figure 1.3 Lesion profiles in RIII mice infected with BSE or vCJD. Picture (a) 
represents the pooled lesion profile from four cases of cattle BSE and picture (b) 
shows the lesion profiles from three cases of vCJD. Dotted line in (b) represents the 
pooled BSE profile shown in (a). Vacuolar degeneration is semi-quantified on a scale 
of 0 - 5 (vertical axis) in the nine grey matter areas (horizontal axis). Modified from 
reference (Bruce et al. 1997). 
(a) (b)
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1.5 Biochemical analysis of PrPSc for prion strain/phenotype discrimination  
Unlike conventional pathogens such as viruses, the existence of multiple strains in 
prion diseases cannot be explained in terms of genetic variants. The strain 
phenomenon in prion diseases appeared to be difficult to be explained within the 
framework of the prion hypothesis, and was once a powerful argument against the 
protein-only hypothesis (Chesebro 1998; Soto and Castilla 2004). In order to explain 
the strain phenomenon seen in prion diseases, conformational variation of PrPSc has 
been proposed as a main strain determinant (Prusiner 1998). According to this 
concept, each prion strain represents a specific disease-associated conformation of 
PrPSc that can propagate faithfully by imposing the same conformation on new host 
PrPC (Prusiner 1998). The conformational difference of PrPSc between biologically 
distinct prion strains (and between distinct disease phenotypes) has been largely 
inferred from differing biochemical properties of PrPSc including: gel mobility and/or 
glycoform ratio of PrPres (Bessen and Marsh 1994; Collinge et al. 1996; Hill et al. 
2006; Monari et al. 1994; Parchi et al. 1996), the ratio between PK-sensitive form 
and PK-resistant form of PrPSc (Safar et al. 1998) and conformational stability of 
PrPres (Peretz et al. 2001; Peretz et al. 2002). Despite the substantial evidence, 
however, it remains still largely uncertain whether such conformational difference of 
PrPSc is the cause of prion strain phenomenon or simply another pathological 
phenotype of prion diseases (Soto and Castilla 2004). In this context, one exception 
is a recent study performed by Colby and colleagues (Colby et al. 2009), which has 
shown the incubation periods of synthetic prions can be directly modulated by 
varying the conformational stability of recombinant PrP amyloids. 
 
1.5.1 TME prion strains 
The most convincing evidence that biologically distinct prion strains can be 
distinguished by biochemical properties of PrPSc has come from studies that 
examined the HY and DY TME strains isolated in hamsters. When PK-resistant core 
fragments of PrPSc were analysed by Western blot, the unglycosylated fragment of 
DY PrPres migrated faster than that of HY PrPres with the difference of ~2 KDa in 
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molecular weight (Bessen and Marsh 1992a). This difference was shown to result 
from the differential accessibility of PK to the N-terminus of PrPSc (Bessen and 
Marsh 1994), which has been interpreted as indirect evidence of conformational 
difference between HY PrPSc and DY PrPSc. Additionally, the two TME strains were  
distinguishable by the extent of PK resistance and sedimentation profiles (Bessen and 
Marsh 1992a). More directly, structural analysis employing FTIR spectroscopy 
revealed the difference in ß-sheet secondary structure between HY PrPSc and DY 
PrPSc (Caughey et al. 1998).   
 
1.5.2 Human prion diseases 
In human prion diseases, much evidence supporting conformation-based strain 
diversity has been gathered by Western blot analysis of PK-resistant core fragments 
of PrPSc. Two major PrPres types (termed type 1 and type 2) have been recognized 
(Parchi et al. 1996; Parchi et al. 1997). These two PrPres types differ in the degrees of 
their N-terminal truncation following treatment with PK (Figures 1.4 and 1.5). Type 
1 PrPres has a main cleavage site at glycine 82, whereas type 2 PrPres is 
predominantly truncated at serine 97 (Parchi et al. 2000b). In addition to the two 
major variants of PrPres, smaller C-terminal fragments (CTF) of 12 - 13 KDa were 
recently identified in some forms of sCJD (Notari et al. 2008; Zou et al. 2003) and 
internal small fragments of 7 - 8 KDa were found in GSS associated with various 
pathogenic mutations (Parchi et al. 1998; Piccardo et al. 1998; Piccardo et al. 2001). 
A further distinction of PrPres can be achieved on the basis of glycosylation site 
occupancy (referred to type A or type B; Figure 1.5) (Head et al. 2004a; Parchi et al. 
1997). Type B PrPres is characterized by the high occupancy of both potential 
glycosylation sites, whereas type A PrPres has a prominent monoglycosylated (or 
rarely unglycosylated) PrPres species (Head et al. 2004a; Parchi et al. 1997). 
Variation in these parameters has been identified in association with different 
phenotypes of human prion disease (Collinge et al. 1996; Hill et al. 2006; Monari et 
al. 1994; Parchi et al. 1997; Parchi et al. 1996). PrPres types in concert with PRNP 
status at codon 129 have formed a molecular basis in the subclassification of sCJD 
 15
(Hill et al. 2003; Parchi et al. 1999b). When brain extracts from FFI with D178N 
mutation (with type 2 PrPres) or from familial CJD with E200K (with type 1 PrPres) 
were inoculated into transgenic mice expressing a chimeric human-mouse PrP, 
distinct PrPres types remained unchanged in recipient mice implying that 
conformational variation of PrPSc is independent of amino acid sequence of PrP 
















Figure 1.4 Various PK-resistant core fragments of PrPSc observed in human 
prion diseases. Following proteolysis, several forms of PK-resistant core fragment 
of PrPSc can be detected from human brains affected by prions. They include types 1 
and 2 PrPres, a smaller C-terminal fragment of 12 or 13 KDa (CTF 12/13) and an 





















Figure 1.5 Western blot analysis of types 1 and 2 PrPres. Type 1 and type 2A 
PrPres are associated with various forms of sCJD, whereas type 2B PrPres is observed 
in vCJD. Type 1 and type 2 PrPres can be distinguished by their difference in 
migration of unglycosylated species of PrPres. In comparison with type 2A PrPres, 
type 2B PrPres which is characteristic molecular signature of vCJD-affected brains is 
characterized by high occupancy of both potential glycosylation sites. Image is taken 




1.5.3 BSE in cattle and other species 
The BSE agent can retain its biological identity after crossing between species 
naturally or experimentally (Bruce et al. 1994; Bruce et al. 1997). In transmission 
studies to mice, the strain properties of cattle BSE were found to be closely similar to 
those of human vCJD or TSEs in cats and exotic ungulate species (Bruce et al. 1994; 
Bruce et al. 1997). Moreover, the BSE strain properties remained unchanged in 
experimentally infected domestic species such as sheep and pigs (Bruce et al. 1994; 
Green et al. 2005). Similarly, molecular signature of PrPSc seen in cattle BSE is also 
maintained after transmission to other species. In western blot analysis, PrPres in 
cattle BSE is characterized by a faster migrating unglycosylated moiety and the 
abundance of diglycosylated form (Baron et al. 2007). The molecular properties of 
PrPres in cattle BSE was similar to those found in human vCJD, indicating a possible 
linkage between the two (Collinge et al. 1996). The molecular signature in cattle 
21 KDa
19 KDa
Type           1           2A         2B    
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BSE was also retained in sheep experimentally infected with BSE (Hope et al. 1999; 
Stack et al. 2002).  
 
1.5.4 Atypical/Nor98 scrapie in small ruminants  
Active surveillance of TSEs in small ruminants such as sheep and goats has shown 
that atypical/Nor98 scrapie is present not only in many European countries but also 
in other parts of the world (Benestad et al. 2003; Buschmann et al. 2004; Cook 2007; 
Epstein et al. 2005; Everest et al. 2006). These atypical scrapie cases are 
characterized by lower molecular weight fragments of PrPSc following treatment with 
PK. While all classical scrapie cases have shown typical triplet bands migrating 
between 18 and 30 KDa (Benestad et al. 2008), the atypical/Nor98 scarpie cases can 
be characterized by lower molecular weight fragments of PrPSc migrating at 11 - 12 
KDa (Arsac et al. 2007; Benestad et al. 2003) or at 7 - 8 KDa (Klingeborn et al. 
2006). In a transmission study to transgenic mice expressing ovine PrP (Le et al. 
2005), the atypical scrapie isolates were found to share unique biological and 
biochemical features which are different from those of classical scrapie. Currently, 
atypical/Nor98 scrapie is considered as a prion strain affecting small ruminants that 
is distinct from classical scrapie or BSE in sheep (Benestad et al. 2008). 
 
1.5.5 Atypical bovine prion diseases   
Similar to the finding of atypical/Nor98 scrapie in small ruminants, large scale of 
active BSE surveillance has identified two novel forms of TSE in cattle. These 
atypical forms of TSE cases in cattle were distinguishable from classical BSE by the 
Western blot molecular features of PrPres. A French study identified three cattle 
showing a higher molecular weight of unglycosylated form of PrPres when compared 
to classical BSE (H-type)(Biacabe et al. 2004). Another form of bovine prion disease 
was first described in two cattle in Italy in which an unglycosylated PrPres migrated 
slightly faster than that of classical BSE and monoglycosylated form of PrPres 
predominated (L-type)(Casalone et al. 2004); these L-type cases were also 
characterized by the presence of amyloid plaques leading to the term bovine 
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amyloidotic spongiform encephalopathy (BASE). Since then, cases of the two novel 
forms of prion diseases in cattle have also been found in other European countries 
and in North America (Buschmann et al. 2006; Nicholson et al. 2008; Polak et al. 
2008). Prions in the brains of cattle affected by BASE could be efficiently 
transmitted to transgenic mice expressing human PrP (Kong et al. 2008). When 
BASE strain was serially passaged in wild-type mice, lesion profile and PrPres 
signature in the recipient mice was indistinguishable from those of BSE-infected 
mice (Capobianco et al. 2007).  
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1.6 Human prion diseases 
Human prion diseases are a group of fatal neurodegenerative disorders including a 
wide spectrum of clinical and neuropathological phenotypes and can occur as 
sporadic, acquired and familial (genetic) forms (Table 1.2)(Gambetti et al. 2003; 
Ironside and Head 2004; Wadsworth et al. 2003). The sporadic form of human prion 
diseases encompasses two phenotypes: sporadic CJD and sporadic fatal insomnia 
(sFI). Additionally, a new phenotype of prion disease named protease-sensitive 
prionopathy (PSPr) was identified recently (Gambetti et al. 2008). Acquired forms of 
human prion disease can be caused by human-to-human transmission (iatrogenic 
CJD and kuru) or animal-to-human transmission (vCJD) of the infectious agent.  
Familial (or genetic) forms of prion diseases are associated with pathogenic and 




Table 1.2 Classification of human prion disease 
Aetiology Disease Remarks 
Idiopathic Sporadic CJD  





Acquired Variant CJD   Bovine source 
 Iatrogenic CJD   Human source 
 Kuru   Human source 
Familial 
(Genetic) 
Familial CJD   E200K, D178N-129V 




  P102L, A117V, F198S 
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1.6.1 Sporadic prion disease: sCJD and sFI 
sCJD is the most common form of human prion disease, accounting for around 85% 
of cases of human prion disease (Brown et al. 1987). sCJD occurs worldwide with an 
incidence of approximately one to two cases per million of the population per annum 
(Ladogana et al. 2005). This incidence rate is even across a wide range of countries, 
although slightly higher incidence of sCJD was reported in Switzerland in recent 
years (Glatzel et al. 2002; Glatzel et al. 2003). sCJD is an idiopathic disorder in 
which its aetiology remains unknown, although somatic mutation or the spontaneous 
conversion of PrPC into PrPSc as a rare stochastic event were proposed as a possible 
cause (Collinge 1997; Wadsworth et al. 2003).  
 
sCJD is not a uniform disorder but exhibits a wide spectrum of clinical and 
neuropathological phenotype. The majority of sCJD cases are clinically characterized 
by a rapidly progressive dementia and myoclonus with disease duration of several 
months (Brown et al. 1994; Pocchiari et al. 2004). Atypical forms of sCJD include 
cases characterized by ataxia and longer disease duration (Gomori et al. 1973). sFI is 
characterized by insomnia and clinically indistinguishable from FFI (Parchi et al. 
1999a). Spongiform change can be observed in most cases of sCJD with variability 
in its nature, regional distribution and degree of severity (Parchi et al. 1999b). While 
spongiform degeneration is made of fine vacuoles in the majority of cases, 
spongiform change composed of larger, occasionally confluent vacuoles characterize 
a small group of cases (Gambetti et al. 2003). Amyloid plaques are found usually in 
the cerebellum in a less common subtype of sCJD cases (Kovacs and Budka 2009). 
sFI exhibits major pathology in the thalamus that is characterized by severe neuronal 
loss and astrogliosis without spongiform change  (Parchi et al. 1999a). The 
immunostaining of PrPSc after specific treatment of sections shows several deposition 
patterns of PrPSc including: synaptic deposition, perivacuolar deposition, plaques and 
perineuronal staining (Ironside et al. 2005; Kovacs et al. 2002a). Perivacuolar 
staining of PrP is usually observed in the rim of larger, confluent type of vacuoles 
(Parchi et al. 1996). Perineuronal staining of PrP is detected in a minority of cases of 
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sCJD (Kovacs et al. 2002a). In sFI, the PrPSc level is much lower than in sCJD cases 
and immunostaining for PrP is either negative or minimal in limited brain areas 
(Gambetti et al. 2003; Parchi et al. 1999b). 
 
The direct role of codon 129 of PRNP in determining disease phenotype was firstly 
recognized in the study of two inherited forms of prion disease which share a 
pathogenic mutation, but differ significantly in their clinical and pathological 
phenotypes (FFI: D178N-129M; fCJD: D178N-129V) (Goldfarb et al. 1992b). 
Individuals who are homozygotes at PRNP codon 129 were found to be over-
presented in sporadic and acquired forms of CJD (Collinge et al. 1991; Palmer et al. 
1991; Will et al. 1996; Windl et al. 1996). Heterozygosity at the polymorphic site 
codon 129 was shown to be associated with a particular pathological change - 
formation of amyloid plaques - in the cerebellum (Schulz-Schaeffer et al. 1996). 
Distinct PrPres types were also associated with distinct disease phenotypes. PrPres in 
the brains affected by FFI is of type 2, whereas PrPres in fCJD with D178N is of type 
1 (Monari et al. 1994). vCJD was able to be distinguished from various forms of 
sCJD on the basis of PrPres type (Collinge et al. 1996).  
 
Based on these findings, attempts were made to relate distinct phenotypes of sCJD 
with the PRNP codon 129 polymorphism (MM, MV, VV) and PrPres type (type 1 and 
type 2). Parchi and colleagues classified 300 sCJD cases according to the PrPres type 
and the codon 129 genotype, which results in six possible combinations: MM1, 
MM2, MV1, MV2, VV1 and VV2 (Table 1.3)(Parchi et al. 1999b). The individuals 
who are MM homozygous or MV heterozygous and carry type 1 PrPres are combined 
into one subtype due to their similarity in clinical and neuropathological features 
(Gambetti et al. 2003; Parchi et al. 1999b); in comparison, the patients who are MM 
homozygous and carry type 2 PrPres are classified into two subtypes according to 
distinct disease phenotypes: MM2 and sFI. Accordingly, sCJD is classified into six 
subtypes in the classification system proposed by Parchi and Gambetti. Another 
group of investigators have proposed an alternative classification system (Hill et al. 
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2003). When compared to that proposed by Parchi et al., the classification system 
proposed by Collinge and colleagues is based on three (rather than two) PrPres types 
distinguished by electrophoretic mobility (Collinge et al. 1996; Hill et al. 2006; 
Wadsworth et al. 2008b). Despite this difference, however, both systems are in 
substance identical in that they classify sCJD cases based on the M/V polymorphism 
at codon 129 and the PrPres type (Head and Ironside 2009). This study refers to as 
type 1 or type 2 PrPres as defined by Parchi and Gambetti and accordingly follows 
their classification system.  
 
One important issue in classifying sCJD cases is the presence of cases showing both 
PrPres types. This phenomenon was initially identified in about 5% of patients 
affected by sCJD (Parchi et al. 1999b). The subsequent studies have confirmed that 
the co-occurrence of both PrPres types is present in a substantial proportion of 
patients affected by sCJD (Head et al. 2004a; Puoti et al. 1999; Schoch et al. 2006; 
Uro-Coste et al. 2008). It was proposed that all sCJD cases associated with type 2 
PrPres as well as vCJD cases could contain type 1 PrPres on the basis of mAbs 
specifically recognizing type 1 PrPres only (Polymenidou et al. 2005; Yull et al. 
2006). However, this finding was contested in a later study on a methodological 
background (Notari et al. 2007). Two recent studies that carried out an extensive 
investigation of this phenomenon has shown that the co-existence of PrPres type is 
present in 30 ~ 40% of sCJD cases and can be associated with patients who are 
clinically and/or neuropathologically distinguishable from those showing pure PrPres 
types (Cali et al. 2009; Parchi et al. 2009b).  
 
Recently, Gambetti et al. reported a novel form of human prion disease referred to as 
protease-sensitive prionopathy (PSPr)(Gambetti et al. 2008). The PSPr cases have 
shown distinct clinical and neuropathological features (Gambetti et al. 2008); all 
cases were homozygous for valine at codon 129 and did not have any pathogenic 
mutation in PRNP. Abnormal PrP associated with PSPr was found to be largely 
sensitive to PK digestion and less highly aggregated (Gambetti et al. 2008). More 
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interestingly, proteolytic treatment of PrPSc produced a "ladder-like" electrophoretic 
migration profile of PrPres ranging from approximately 6 to 29KDa (Gambetti et al. 
2008). Additional PSPr cases have been identified in the UK and in the Netherlands 









Table 1.3 Classification of sCJD based on genotype at codon 129 and PrPres type (Parchi et al. 1999b) 
sCJD subtype 










Clinical Features Neuropathological Features 
MM1, MV1 Classical CJD 
 
70 65 4 Rapidly progressive 
dementia, early and 
prominent myoclonus 
"Classical CJD" distribution of pathology; often 
prominent involvement of occipital cortex; "synaptic 
type" PrP staining 
VV2 Ataxic variant 16 61.3 6.5 Ataxia at onset, late 
dementia 
Prominent involvement of subcortical, including brain 
stem nuclei; in neocortex, spongiosis is often limited to 
deep layers; PrP staining shows plaque-like, focal 
deposits, as well as prominent perineuronal staining 
MV2 Kuru-plaque 
variant 
9 59.4 17.1 Ataxia in addition to 
progressive dementia, 
long duration (> 2 yr) 
in some cases 
Similar to VV2 but with presence of amyloid-kuru 
plaques in the cerebellum, and more consistent plaque-
like focal PrP deposits 
MM2 Not 
established 
2 64.3 15.7 Progressive dementia Large confluent vacuoles with perivacuolar PrP 




1 39.3 15.3 Progressive dementia Severe pathology in the cerebral cortex and striatum 
with sparing of brain stem nuclei and cerebellum; no 





variant of CJD 
2 52.3 15.6 Insomnia and 
psychomotor 
hyperreactivity, in 
addition to ataxia and 
cognitive impairment 
 
Prominent atrophy of the thalamus and inferior olive 
(no spongiosis) with little pathology in other areas; 
spongiosis may be absent or focal, and PrPSc is detected 
in lower amount than in the other variant  
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1.6.2 Variant CJD                  
In 1996, a new variant form of CJD (vCJD) was identified in 10 patients in the UK, 
raising a possibility that they might be causally linked to BSE (Will et al. 1996). 
Subsequent studies based on biological strain typing and biochemical analysis of 
PrPSc strongly supported this possibility (Bruce et al. 1997; Collinge et al. 1996; Hill 
et al. 1997; Lasmezas et al. 1996; Scott et al. 1999). Additionally, the highly 
characteristic neuropathological features seen in vCJD was not identified in the 
retrospective study of archived brain materials (Budka et al. 2002). It is now widely 
accepted that vCJD and BSE are caused by the same prion strain, most likely 
resulting from the consumption of BSE-contaminated meat products (Ward et al. 
2006; Will 2003). So far, vCJD is the only known example of zoonotic human prion 
disease. As of March 2010, 172 cases of vCJD have been identified in the UK and 47 
cases in other countries (http://www.cjd.ed.ac.uk). 
 
vCJD has been identified mostly in young individuals. The mean age at onset is 28 
years with a mean duration of illness of 15 months (Brandel et al. 2009; Will et al. 
2000). All vCJD cases identified in the UK and France have been homozygous for 
methionine at PRNP codon 129 (Bishop et al. 2009; Brandel et al. 2009; Peden et al. 
2010). One case of pre- or sub-clinical vCJD was identified in a patient with MV 
genotype at codon 129 (Peden et al. 2004). This patient had received a blood 
transfusion from a donor later found to be incubating vCJD, died from a non-
neurological disorder, but infection with the vCJD agent was inferred from the 
accumulation of PrPres in the spleen and lymph node (Peden et al. 2004). In 2009, a 
possible vCJD case was reported in a MV heterozygotes on the basis of ante-mortem 
examination (Kaski et al. 2009). In a large scale-study using anonymized human 
lymphoid samples, the accumulation of abnormal PrP was identified in the appendix 
of three individuals, two of which were later found to be homozygous for VV at 
PRNP codon 129 (Hilton et al. 2004; Ironside et al. 2006). Since the accumulation of 
abnormal PrP in lymphoreticular system is a consistent feature of vCJD in 
comparison with other forms of human prion diseases (Bruce et al. 2001; Head et al. 
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2004b; Hilton et al. 1998), this finding indicated the presence of asymptomatic 
carriers of vCJD, particularly individuals with MV or VV genotypes at codon 129 
(Hilton 2006; Ironside et al. 2006). This possibility was further supported by a recent 
transmission study using gene-targeted human transgenic mice (Bishop et al. 2006). 
Collectively, individuals who are heterozygous or homozygous for valine at PRNP 
codon 129 appears to susceptible to vCJD/BSE prions, but may have more prolonged 
incubation periods compared to MM individuals (Ironside et al. 2006; Kaski et al. 
2009). In kuru, another form of acquired prion disease in humans, individuals with 
MV or VV genotype were found to frequently have a longer incubation period (up to 
decades) and to develop disease at a later stage of the epidemic (Collinge et al. 2006; 
Collinge et al. 2008; Goldfarb et al. 2004). 
  
The principal pathological change observed in vCJD-affected brains is the formation 
of florid plaques which can be readily identified on hematoxylin-eosin stains 
(Ironside et al. 2000). Florid plaques have an dense core with radiating fibrils in the 
periphery of the plaque which are surrounded by a rim of vacuoles (Ironside 1998; 
Will et al. 1996). Spongiform degeneration can be observed in various regions, but 
particularly severe in caudate nucleus and putamen (Ironside et al. 2000). Marked 
astrocytosis and neuronal loss in the thalamus is another diagnostic feature of vCJD 
(Ironside et al. 2000); interestingly, this region (pulvinar of the thalamus) is also 
characterized by bilateral high signal on magnetic resonance imaging (MRI) brain 
scans (Zeidler et al. 2000).  
 
In Western blot analysis,  the unglycosylated species of PrPres from vCJD-affected 
brains migrates at ~ 19 KDa with its N-terminus predominantly at serine 97 (type 2 
PrPres)(Parchi et al. 2000b). Additionally, PrPres in vCJD is characterized by the 
predominance of diglycosylated form of PrPres, which has been used as a molecular 
marker to distinguish vCJD from some forms of sCJD with type 2 PrPres (Collinge et 
al. 1996; Head et al. 2004a). Recent studies employing an antibody whose epitope 
lies between type 1 and type 2 N-termini have shown that type 1 PrPres is present at 
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low levels in vCJD brains (Yull et al. 2006; Yull et al. 2009), although technical 
validity of this kind of approach was questioned by Notari et al. (Notari et al. 2007). 
 
BSE in sheep and scrapie were found to be efficiently transmitted to sheep by blood 
transfusion even when donor sheep were in preclinical stage of infection, raising 
concerns about the potential risk of iatrogenic transmission associated with 
preclinical vCJD carriers (Houston et al. 2000; Houston et al. 2008; Hunter et al. 
2002). To date, four cases of secondary (human-to-human) infection of vCJD via 
blood transfusion have been identified. While three of the four patients with MM 
genotype at codon 129 developed clinical symptoms and died of vCJD (Health 
Protection Agency. 2007; Llewelyn et al. 2004; Wroe et al. 2006), one patient with 
MV genotype died in a preclinical phase without any evidence of a neurological 
disorder (Peden et al. 2004). Three donors developed vCJD signs after 17 months to 
three and a half years of their blood donation; two secondary vCJD patients were 
associated with a common donor (Health Protection Agency. 2007). The biological 
strain properties of the vCJD (or BSE) agent were found not to be altered in the 
secondary human-to-human transmission (Bishop et al. 2008). Similarly, 
neuropathological features and PrPres profiles in the secondary cases were 
indistinguishable from those of primary cases (Head et al. 2009b; Wroe et al. 2006).    
 
1.6.3 Other forms of acquired human prion disease: kuru and iCJD                  
Kuru is an epidemic prion disease which affected the Fore population and its 
neighbouring population in the Eastern Highlands of Papua New Guinea (Gajdusek 
and ZIGAS 1957; Gajdusek and ZIGAS 1959). More than 3,000 cases of kuru are 
thought to have occurred (Goldfarb 2002); the majority of kuru cases have been 
detected in women and children. The most probable route of spread of kuru is the 
ritual cannibalistic consumption of dead relatives (Gajdusek 1977). Kuru epidemic is 
presumably believed to be initiated by the cannibalistic consumption of an individual 
who died of sCJD (Gajdusek 1977). This proposition is strengthened by a recent 
study showing similar transmission properties between kuru and sCJD (Wadsworth 
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et al. 2008b). Since cannibalism was outlawed in the late 1950s, the occurrence has 
declined gradually and the age of onset has increased progressively (Gajdusek 1977; 
Goldfarb et al. 2004). Kuru is the first form of human prion disease whose 
transmissibility was experimentally proven (Gajdusek et al. 1967; Gajdusek et al. 
1968; Gajdusek et al. 1966), followed by success in transmitting other members of 
human prion disease (Gibbs, Jr. et al. 1968; Masters et al. 1981; Tateishi et al. 1995). 
Kuru is characterized clinically by a progressive cerebellum disease (Gajdusek and 
ZIGAS 1957; Gajdusek and ZIGAS 1959), and its incubation period may reach five 
decades given that small number of cases (mostly MV genotype) are still occurring 
(Collinge et al. 2006). 
 
Iatrogenic CJD (iCJD) is an acquired form of human prion disease which is 
accidentally transmitted during the course of medical or surgical procedures (Aguzzi 
et al. 2008). The first case of iCJD was reported in 1974 in association with 
transplantation of a cornea derived from a donor who had died of CJD (Duffy et al. 
1974). Since then more than 400 cases of iCJD have been globally identified in 
association with accidental transmission of CJD prions (Will 2003). The majority of 
iCJD cases are associated with implantation of contaminated  dura mater grafts (196 
cases) or contaminated growth hormones derived from human cadavers (194 
cases)(Brown et al. 2006). The mean incubation period is 11 years (range: 1.5 - 23 
years) in dura mater-associated cases and 15 years (range: 4 - 36 years) in growth 
hormone-associated cases (Brown et al. 2006).  
 
1.6.4 Familial (genetic) forms of human prion disease                  
About 10 - 15% of cases of human prion disease are associated with disease-specific 
mutations (Kovacs et al. 2005; Windl et al. 1996; Windl et al. 1999).  So far, more 
than 30 pathogenic mutations in the PRNP have been identified, which can be 
divided into three types: point mutations resulting in an amino-acid substitution or 
premature stop codon, and insertion of additional octapeptide repeats (Mead 2006). 
They can be inherited in an autosomal-dominant manner, many of which show high 
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penetrance (the proportion of carriers who will eventually develop the 
disease)(Gambetti et al. 2003; Kovacs et al. 2005). Although it remains uncertain 
how pathogenic mutations in the PRNP lead to the development of prion disease, one 
possible explanation is that they may make it easier for PrPC to be spontaneously 
converted into PrPSc (Wadsworth et al. 2003). It remains questionable whether all 
forms of familial prion disease are transmissible since some less frequent forms of 
GSS lack the evidence of transmissibility (Brown et al. 1994; Tateishi et al. 1996). 
Familial prion diseases present clinically with marked variability even between 
individuals carrying the same PRNP mutation (Barbanti et al. 1996; Collinge et al. 
1992; Zarranz et al. 2005; Zerr et al. 1998). It is well known that polymorphism at 
codon 129 contribute to the phenotypic diversity of familial prion disease (Gambetti 
et al. 2003). Familial prion diseases can be classified into three phenotypes according 
to their clinical and pathological features: CJD, GSS and FFI.  
 
In a sCJD-like phenotype called familial CJD (fCJD), clinical and pathological 
features are overall within the range of those of sCJD although marked variability 
between and within family groups carrying different mutations are also evident. The 
substitution of lysine (K) for glutamic acid (E) at codon 200 (E200K) in the PRNP is 
the most frequently observed pathogenic mutation in association with fCJD 
(Gambetti et al. 2003; Kovacs et al. 2005). The patients carrying the E200K 
mutation have been identified in various countries including: Chile, Italy, Slovakia 
and Jews of Israel (Chapman et al. 1994; D'Alessandro et al. 1998; Goldfarb et al. 
1991; Lee et al. 1999; Spudich et al. 1995). Other point mutations in the PRNP 
associated with fCJD include D178N, V180I, T183A and V210I (Gambetti et al. 
2003). While the patients who have the D178N mutation with valine at codon 129 on 
the mutant allele develop the disease phenotype of CJD, those who share this 
mutation but with methionine at codon 129 on the mutant allele develop the 
phenotype of FFI (Goldfarb et al. 1992b).   
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The phenotype of Gertsmann-Straussler-Scheinker Syndrome (GSS) was first 
described in 1936 in a large Austrian family, which was later found to be associated 
with proline-to-leucine substitution (P102L) in the PRNP (Kretzschmar et al. 1991). 
The disease onset occurs from the third to seventh decade of life with average 
disease duration of five to six years (Collins et al. 2001; Piccardo et al. 1998). The 
majority of patients with GSS phenotype present with slowly progressive cerebellar 
ataxia, accompanied by cognitive decline at a later stage of the disease progress 
(Collins et al. 2001); however, variation in clinical phenotype between family 
members carrying the same mutation can range from that of typical CJD to that of 
classic GSS (Goldfarb et al. 1992a; Hainfellner et al. 1995). On microscopic 
examination, GSS is characterized by the presence of multicenteric amyloid plaques 
(Kovacs and Budka 2009). Protease treatment of brain extracts from individuals 
affected with GSS yields proteolytic fragments of PrPSc of lower molecular weight 
(Parchi et al. 1998; Piccardo et al. 1998; Tagliavini et al. 2001). The P102L 
substitution is the commonest mutation associated with the GSS phenotype (Doh-ura 
et al. 1989; Hsiao et al. 1989). Other associated mutations include: P105L, A117V, 
Y145STOP, F198S (Collins et al. 2001).  
 
The phenotype of fatal familial insomnia (FFI) was first described in 1986 (Lugaresi 
et al. 1986), which was later found to be a member of prion diseases (Medori et al. 
1992). Patients with FFI present with progressive untreatable insomnia, autonomic 
dysfunction and motor signs (Almer et al. 1999; Medori et al. 1992). Thalamic 
degeneration accompanying marked neuronal loss and astrogliosis is prominent 
pathological changes in FFI (Gambetti et al. 2003). The unglycosylated species of 
PrPres from brains affected with FFI migrates at ~ 19 KDa (type 2 PrPres) in Western 
blot analysis (Monari et al. 1994). Additionally, PrPres associated with FFI is 
characterized by a marked under-representation of the unglycosylated form (Parchi et 
al. 1995; Parchi et al. 1999a). The only known PRNP mutation linked to FFI is the 
D178N with methionine at codon 129 on the mutant allele (Goldfarb et al. 1992b); as 
described above, the patients with this mutation but valine at codon 129 on the 
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mutant allele develops the phenotype of fCJD.  However, it has been questioned by 
several studies whether the phenotype determination of patients with D178N is fully 




1.7 Complicated biochemical properties of PrPSc  
1.7.1 PK-sensitive isoform of PrPSc  
Currently, the identification of PrPSc is the only unambiguous marker of prion 
infection. In the absence of a definitive PrPSc-specific antibody and given the poor 
understanding of PrPSc structure (Aguzzi and Calella 2009; Aguzzi and Polymenidou 
2004), PrPSc has been most commonly distinguished from PrPC by its partial 
resistance to proteolysis. In most forms of prion disease, PrPSc leaves an N-
terminally truncated core fragments of PrPSc (PrPres) under the condition in which 
PrPC is fully degraded by PK (Bolton et al. 1982; Meyer et al. 1986); both N-
terminally and C-terminally truncated smaller fragments of PrPSc are also detectable 
in several forms of prion disease including GSS and PSPr in humans and atypical 
scrapie in sheep (Gambetti et al. 2008; Klingeborn et al. 2006; Piccardo et al. 1998). 
For decades, the demonstration of PrPres by immunological methods has been the 
basis of diagnosis of prion diseases.  
 
However, recent studies have revealed that PK-sensitive isoform of PrPSc is present 
at substantial levels in the brains affected with prions. This unnoticed fraction of 
PrPSc was first argued for in a report describing conformation-dependent 
immunoassay (CDI)(Safar et al. 1998). It was found that the conformational 
rearrangement of PrPC into PrPSc accompanies the burial of epitopes toward the N-
terminal region of PrP (Peretz et al. 1997). It was found that the epitope of mAb 3F4 
recognizing amino acids 108-111 of hamster PrP is not accessible in native PrPSc in 
contrast to PrPC and becomes exposed after denaturation (Safar et al. 1998); Safar's 
CDI was developed in the form of direct ELISA employing this mAb as a detector 
antibody. In the CDI, time-resolved fluorescence (TRF) signals were similar between 
native and denatured samples of normal hamster brains containing only PrPC (Safar 
et al. 1998). In contrast, CDI signals greatly increased after denaturation in the 
analysis of hamster brains infected with various laboratory prion strains (Safar et al. 
1998); newly detected CDI signals after denaturation was thought to be mostly 
derived from PrPSc. Strikingly, when scrapie-infected hamster brains were assayed 
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by CDI following proteolysis, the newly detected signals after denaturation were 
greatly reduced implying the presence of PK-susceptible fraction of PrPSc (Safar et al. 
1998). Moreover, eight prion strains could be distinguished by the ratio of PK-
sensitive PrPSc to PK-resistant PrPSc (Safar et al. 1998). 
 
Subsequently, Safar's CDI was improved into a sandwich format by incorporating a 
capture antibody named Mar-1 (Bellon et al. 2003). When PrPSc in CJD brain 
homogenates were enriched by precipitation with sodium phosphotungstate (NaPTA) 
and then assayed by the sandwich CDI, its sensitivity was similar to that of 
infectivity bioassay measured in transgenic mice (Bellon et al. 2003; Safar et al. 
2005a). Furthermore, as much as 90% of PrPSc in brains affected with sCJD was 
found to be susceptible to PK digestion (Safar et al. 2005a). Similarly, a significant 
proportion of PrPSc in natural isolates of sheep scrapie was also found to be 
susceptible to PK in CDI analysis (Thackray et al. 2007a).   
 
The biological significance of this PK-susceptible fraction of PrPSc was revealed in a 
recent study (Colby et al. 2010). Synthetic prions which were generated by 
polymerizing recombinant mouse PrP into amyloid fibers were shown to transmit 
disease without generating detectable PK-resistant PrPSc when inoculated into 
transgenic mice (Colby et al. 2010); intriguingly, serial transmission of these 
synthetic prion strains did not generate PK-resistant form of PrPSc. Moreover, 
spongiform degeneration in mice infected with synthetic prions containing only PK-
susceptible PrPSc was more severe than those infected with synthetic prions 
associated with PK-resistant PrPSc (Colby et al. 2010). Nevertheless, in naturally 
occurring prion strains, it remains largely uncertain how much (or whether) PK-
sensitive fraction of PrPSc contributes to the determination of biological disease 
properties such as infectivity, strain phenomenon and neurotoxicity. In several 
laboratory prion strains, PK-susceptible fraction of PrPSc was found not to be 
required in maintaining biological strain properties and biochemical properties of 
PrPSc (Bessen and Marsh 1994; Deleault et al. 2008). Additionally, the majority of 
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PK-sensitive fraction of PrPSc in the RML prion strain was not associated with prion 
infectivity when measured by scrapie cell assay (Cronier et al. 2008). In comparison, 
the incubation period of the Chandler prion strain was prolonged to some degree 
following proteolytic removal of PK-sensitive fraction of PrPSc (Shindoh et al. 2009).  
 
1.7.2 Various sizes of PrPSc aggregates 
In contrast to monomeric or dimeric PrPC (Meyer et al. 2000; Pergami et al. 1996), 
PrPSc is present as polymers that often form amyloid plaques in the brain. A recent 
study has shown that PrPSc in scrapie-infected hamster brains constitutes a spectrum 
of aggregate sizes, ranging from small oligomers to large polymers (Tzaban et al. 
2002). When the brain homogenates from prion-infected hamsters were fractionated 
by ultracentrifugation in 10 - 60% sucrose step gradient, PrP molecules spread 
throughout the sucrose gradient (Tzaban et al. 2002); in contrast, PrP molecules from 
the brains of normal hamsters were mostly found in the top few fractions. In an 
additional analysis using size exclusion chromatography, PrPSc was shown to form a 
spectrum of aggregation sizes ranging from smaller than 600 KDa to that of prion 
rods, which are known to be composed of as many as 1,000 PrP molecules (Prusiner 
et al. 1983; Tzaban et al. 2002). Interestingly, PrPSc species of lower molecular mass 
which were recovered in the intermediate fractions of the sucrose gradient were 
found to be susceptible to protease digestion (Tzaban et al. 2002). Similarly, PrPSc 
molecules in mouse-adapted scrapie strains also dispersed throughout the 10 - 60% 
gradient after ultracentrifugation (Pan et al. 2004; Pan et al. 2005a; Pan et al. 2005c). 
A significant proportion of PrP molecules in various subtypes of sCJD was recovered 
in the bottom heavy fractions of the 10 - 60% gradient after ultracentrifugation, 
whereas the majority of PrP molecules in GSS associated with A117V mutation and 
in PSPr failed to sediment in the same condition of velocity sedimentation (Cali et al. 
2006; Gambetti et al. 2008; Yuan et al. 2006).   
 
The biological significance of size of PrPSc aggregates in prion disease was revealed 
by Caughey and colleagues in a recent study (Silveira et al. 2005). In this study, 
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highly purified PrPres molecules from scrapie-infected hamster brains was first 
sonicated to generate various sizes of PrPres and then fractionated according to their 
size. The analysis of these fractions revealed that, in respect to PrP content, prion 
infectivity and converting activity of PrPres peaked in small oligomeric species of 
PrPres of 300 - 600 KDa (Silveira et al. 2005); in comparison, these activities were 
substantially lower in smaller particles or larger aggregates of PrPres.   
 
1.7.3 Conformational stability of PrPSc  
Protein conformation can be investigated by measurements of conformational 
stability after exposure to a denaturant (such as GdnHCl) in an appropriate range of 
concentrations (Shirley 1995). Based on this concept, Prusiner and co-workers 
developed the conformation stability assay (CSA) in order to investigate the 
conformation of PrPSc from different laboratory prion strains (Peretz et al. 2001; 
Peretz et al. 2002). In CSA, aliquots of brain homogenates containing PrPSc are first 
exposed to increasing concentrations of GdnHCl and then digested with PK. A 
fraction of PrPSc which becomes susceptible to proteolytic degradation following 
incubation with GdnHCl at a particular concentration is considered to be denatured 
by the concentration of GdnHCl (Peretz et al. 2001); the relative conformational 
stability of PrPSc is expressed as the concentration of GdnHCl required to render half 
of PrPSc molecules susceptible to PK (GdnHCl1/2 value).  
 
Prion strains which were indistinguishable by electrophoretical mobility of PrPres in 
Western blot analysis could be discriminated by the conformational stability of PrPSc 
(or PrPres)(Peretz et al. 2001; Peretz et al. 2002). PrPSc in transgenic mice 
propagating synthetic prions was found to be conformationally far more stable than 
that of commonly used RML strain (Legname et al. 2005). In a subsequent study, a 
positive correlation between higher stability (as judged by GdnHCl1/2 values 
measured by CSA) and longer incubation periods was found (Legname et al. 2006). 
The hypothesis that incubation time is a function of PrPSc stability was further tested 
by artificially producing an array of synthetic PrP amyloids differing in their 
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conformational stability and then testing their biological properties (Colby et al. 
2009). The results confirmed that a more labile PrPSc conformation correlated with 
faster replication, shorter incubation periods and a degree of strain instability (Colby 









1.8 Biochemical approaches for PrPSc analysis     
In the absence of a foreign nucleic acid genome associated with prion diseases, 
efforts to provide a molecular basis for the biological diversity of prions have 
focused on the biochemical characterization of disease-associated prion protein 
(PrPSc). PrPSc has been traditionally analysed by conventional Western blot (WB) 
following limited proteolysis. The WB analysis of proteolytic fragments of PrPSc 
produces information on electrophoretic mobility and glycoform ratio of PrPres. 
Occasionally, two-dimensional (2D) gel electrophoresis in which proteins are 
separated based on their size and charge has been used to characterize PrPSc (Pan et 
al. 2005b; Pan et al. 2001; Zanusso et al. 2002). 2D gel electrophoresis was reported 
to differentiate between MM2 subtype of sCJD and sporadic form of fatal insomnia, 
which is not distinguishable based on conventional one-dimensional gel 
electrophoresis (Pan et al. 2001). However, variation between gels remains a 
problematic issue in the 2D gel electrophoresis (Huzarewich et al. 2010). The precise 
proteolytic cleavage sites of PrPSc can be determined using mass spectrometry 
(Dagdanova et al. 2010; Tagliavini et al. 2001) or by automated Edman degradation 
(Parchi et al. 2000b; Xie et al. 2006). Despite its diagnostic usefulness, however, 
protease-resistant core fragment size is at best a surrogate marker of conformation of 
PrPSc and size classes present in this polydispersed material is not taken account. 
Another important limitation in the analysis of PK-resistant PrPSc is the failure to 
take account of PK-sensitive of PrPSc.  
 
The key event that occurs in prion-affected individuals is the conversion of PrPC into 
PrPSc, which mainly accumulates in the brain of affected individuals. Conformational 
variation of PrPSc has been proposed as a main strain determinant in order to explain 
strain phenomenon in prion diseases. A conformation-based assay was first reported 
by Safar and colleagues using hamster prion strains (Safar et al. 1998). Safar's 
conformation-dependent immunoassay (CDI) was further improved by introducing a 
capture antibody and NaPTA precipitation (Bellon et al. 2003; Safar et al. 2005a). 
Similar conformation-based immunoassays have been reported by other groups 
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(McCutcheon et al. 2005; Thackray et al. 2007a). Conformational variation of PrPSc 
between different prion strains has been investigated by measuring its stability 
(Peretz et al. 2001; Peretz et al. 2002). This assay named conformational stability 
assay (CSA) is able to distinguish some prion strains which are not distinguishable 
based on gel mobility of PrPres (Peretz et al. 2001; Peretz et al. 2002). 
 
Since PrPSc is a polydispersed aggregated molecule, its sedimentation property and 
size can be exploited not only to separate PrPSc from PrPC but to understand 
biological properties of prions. Two hamster-adapted TME strains (HY and DY 
strains) showed distinct sedimentation properties after ultracentrifugation (Bessen 
and Marsh 1992a). Various traditional sizing methods such as size exclusion 
chromatography (Tzaban et al. 2002; Yuan et al. 2006), filtration (Caughey et al. 
1995), ultracentrifugation in sucrose step gradient (Pastrana et al. 2006; Tzaban et al. 
2002) have been used to investigate size class of PrPSc. Silveira and colleagues 
recently tried another kind of separation method named field flow fractionation 
(FFF) to overcome the pitfalls of these sizing methods in analysing large, insoluble 
protein aggregates (Silveira et al. 2006; Silveira et al. 2005). Given the recent 
findings regarding biological influence of PrPSc size (Kristiansen et al. 2007; Silveira 
et al. 2005; Simoneau et al. 2007; Tixador et al. 2010), it would be important to 
measure precise size classes of PrPSc in various prion strains and disease phenotypes 
 
Prion propagation in vivo can be modelled using in vitro converting assay. Successful 
cell-free formation of protease-resistant prion protein was first reported by Caughey 
and colleagues (Kocisko et al. 1994). This conversion assay employing partially 
purified PrPres and 35S-labelled recombinant PrPC has made a substantial contribution 
to our understanding of various issues including polymorphic effect in sheep scrapie 
(Bossers et al. 1997), molecular basis of prion strain (Bessen et al. 1995) and species 
barrier (Raymond et al. 1997; Raymond et al. 2000). More recently, another kind of 
in vitro converting assay named protein misfolding cyclic amplification (PMCA) was 
introduced by Soto and colleagues (Saborio et al. 2001). In PMCA, PrPSc in diseased 
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brain is diluted in normal brain homogenates and then subjected to repeated cycle of 
incubation and sonication (Castilla et al. 2006). PMCA has shown much higher 
conversion efficiency when compared to Caughey's assay and is thought to more 
closely mimic in vivo prion propagation (Jones et al. 2010). Newly generated PrPSc 
by PMCA was found to be infectious (Castilla et al. 2005a) and to retain biological 
and biochemical strain properties (Castilla et al. 2008b; Soto et al. 2005). PrPSc in 
body fluids such as blood and urine can be successfully detected using PMCA 
(Castilla et al. 2005b; Chen et al. 2010; Gonzalez-Romero et al. 2008). Furthermore, 
PMCA can spontaneously generate PrPSc from normal brains of various species 
including humans (Barria et al. 2009). PMCA technique was successfully applied to 
human prion diseases such as vCJD (Jones et al. 2007; Jones et al. 2009b). In an 
assay named quaking induced conversion (QuIC), recombinant PrP was used as 
substrate instead of normal brain material and automated shaking replaced sonication 
(Atarashi et al. 2008; Orru et al. 2009).  
 
Human prion agents are classified as Hazard Group 3 pathogen and required to be 
handled in Containment Level 3 (CL3) facility by Advisory Committee on 
Dangerous Pathogens classify (www.dh.gov.uk/ab/ACDP/index.htm). The 
requirement of CL3 can act as a substantial technical constraining factor in analysing 
human prion disease, as was the case in this study. In this study, conformational 
(CDI and CSA) and sizing (sucrose density gradient) methods in addition to 
conventional WB, which are available in CL3 laboratory within NSCJDU, were 
employed for the biochemical analysis of PrPSc.  
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1.9 Aims  
In CJD, the biochemical characterization of PrPSc is currently largely based on the 
Western blot analysis of PK-resistant core fragments of PrPSc (PrPres). Given the 
recent progress toward a better biochemical characterization of PrPSc (as described in 
section 1.7), it becomes evident that the Western blot analysis of PrPres is an 
incomplete description of biochemical diversity of PrPSc present in CJD brains.   
 
This study aims to investigate the biochemical properties of PrPSc in CJD brains by 
employing approaches that differ in principle from conventional Western blot 
analysis of PrPres, and thus to provide a more complete description of PrPSc species 
occurring in the human brains affected by prions. These biochemical assays include 
conformation-dependent immunoassay (CDI), velocity sedimentation in sucrose step 
gradients, gradual unfolding of PrPSc mediated by exposure to a wide range of 
concentration of GdnHCl.  This thesis addresses the following three specific aims:  
 
1. To compare abnormal PrP defined by a conformation change (CDI) with that 
defined by resistance to limited proteolysis (WB) (Chapter 2).  
 
2. To investigate the distribution profiles of different PrP (PrPC, PrPSc and PrPres) 
conformers after velocity sedimentation in sucrose step gradients (Chapter 3). 
 
3. To measure the conformational stability of PrPSc to GdnHCl-induced denaturation 
using conformation-sensitive mAb 3F4 in CDI (Chapter 4).  














Abnormal prion protein in CJD brains: 
comparison of a conformational change 




Prion diseases are characterized by the conversion of the host-encoded prion protein 
(PrPC) into a disease-associated isoform (PrPSc), which is thought to be the main 
component of the infectious agent or prion (Bolton et al. 1982; Prusiner 1982; 
Prusiner 1998). The conversion of α-helical PrPC into ß-sheet-rich PrPSc accompanies 
the change of biochemical properties such as protease resistance or detergent 
solubility (Caughey et al. 1991; Meyer et al. 1986; Pan et al. 1993). In the absence of 
a definitive PrPSc-specific antibody, PrPSc has been distinguished from PrPC based on 
these biochemical properties. The proteolytic treatment of PrPSc leaves N-terminally 
truncated, PK-resistant core fragments of PrPSc (PrPres)(Oesch et al. 1985). The 
presence of PrPSc in a sample has been most commonly demonstrated by detecting 
PrPres, usually in Western blot after limited proteolysis. In CJD, two distinct types of 
PrPres have been identified on the basis of the sizes of PK-resistant fragments (type 1 
and type 2); a nonglycosylated fragment of type 1 PrPres migrates at 21 KDa, whereas 
that of type 2 PrPres migrates at 19 KDa (Parchi et al. 1996). Additionally, PrPres can 
be classified into two types based on the proportion of the three possible glycoforms 
(type A and type B)(Parchi et al. 1997; Parchi et al. 2000b). All vCJD cases can be 
characterized by the type 2 PrPres with high glycosylation site occupancy (type 2B), 
which can be distinguished from type 2 PrPres in sCJD cases usually predominated by 
the monoglycosylated form (Collinge et al. 1996; Head et al. 2004a; Parchi et al. 
1999b; Parchi et al. 1996). The type of PrPres in combination with genotype at PRNP 
codon 129 have been the molecular basis in the classification of sCJD (Parchi et al. 
1999b).  
 
Another biochemical method that distinguishes PrPSc from PrPC is conformation-
dependent immunoassay (CDI), which is based on a conformational transition in the 
N-terminus of PrP during the formation of PrPSc (Peretz et al. 1997). CDI was 
initially developed in the form of direct ELISA using the mAb 3F4 that binds to 
amino acids 109 -112 of human PrP (Safar et al. 1998). The introduction of NaPTA 
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precipitation and incorporation of a capture antibody into CDI greatly increased the 
sensitivity in detecting PrPSc (Bellon et al. 2003; Safar et al. 2002; Safar et al. 2005a). 
Interestingly, CDI has revealed that a significant portion of PrPSc in the brains of 
scrapie-infected hamsters is susceptible to PK digestion (Safar et al. 1998); in a 
subsequent study, as much as 90% of PrPSc present in the brains of humans affected 
with CJD was estimated to be PK-sensitive (Safar et al. 2005a). Moreover, CDI was 
reportedly able to distinguish various prion strains propagated in hamsters based on 
the ratio of PK-resistant PrPSc to PK-sensitive PrPSc (Safar et al. 1998). 
 
In this chapter, multiple samples from various CJD phenotypes were comparatively 
examined by CDI or WB following limited proteolysis, in order to investigate the 
relation between the inaccessibility of the 3F4 binding site and resistance to limited 
proteolysis, both of which define PrPSc biochemically. Three vCJD cases and 12 
sCJD cases (three cases each from MM1, MM2, MV1 and MV2 subtypes) were 
investigated by the two biochemical methods; in each case, three samples (each of 
~100mg) were taken each from the frontal cortex, cerebellum and thalamus and 
analysed separately (i.e. nine brain specimens in individual cases). The abnormal 
form of PrP determined by the two aforementioned biochemical methods were 
compared between CJD phenotypes, cases and regions (For clarity, hereafter, 
abnormal PrP with a hidden 3F4 epitope is termed "PrPSc" and abnormal PrP leaving 
PK-resistant core fragments after limited proteolysis is referred to as "PrPres"). 
Additionally, adjacent samples of the three brain regions in individual cases were 
examined by histology to assess the correlation with the biochemical results.   
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2.2 Materials and methods  
 
2.2.1 Laboratory requirement in handling human TSE material 
The Advisory Committee on Dangerous Pathogens (ACDP) classifies TSE agents in 
various species as hazard group 3 (www.dh.gov.uk/ab/ACDP/index.htm). In prion-
infected individuals, a high titre of prion infectivity is found in central nervous 
system (brain and spinal cord) and a lower level of infectivity is also present in 
peripheral nerve and/or in lymphoid tissue such as tonsil and spleen. The prion 
agents are not inactivated by conventional chemical and physical decontamination 
methods and exhibit exceptional stability against such treatments. The effective ways 
of prion decontamination recommended by the ACDP is to incubate infective 
material with 2M sodium hydroxide (NaOH) for 1 hour or with 20,000ppm sodium 
hypochlorite (NaClO) for 1 hour.  
 
In this study, human brain material from diseased individuals of different phenotypes 
was analysed using various biochemical methods. The overall containment measures 
recommended by the ACDP when working with human prion agents are 
Containment Level 3 (CL3, with derogations). All laboratory work described in this 
thesis were performed in CL3 laboratory, which is located within the National CJD 
surveillance unit (NCJDSU). As required by the Lab code of Practice in NCJDSU, 
all laboratory procedures involving human TSE material was performed within a 
microbiological cabinet and decontamination of infective material was achieved by 
incubation with 2M NaOH for the minimum of one hour.   
 
2.2.2 Human brain materials  
2.2.2.1 Case selection criteria 
In this study, brain material was obtained by submission of a tissue request to the 
National CJD Surveillance Unit Brain & Tissue Bank under the name of the primary 
supervisor (Dr. Mark W. Head).  
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Cases of human prion disease were selected based on the following criteria: 1) 
whether half-frozen brain is available; 2) whether consent for research use of brain 
material was obtained; 3) typical clinical and neuropathological presentation of 
disease phenotype of interest; 4) excluding CJD cases with mixed PrPres type. Under 
these selection criteria, if available, priority was given to relatively recent cases 
which have presumably experienced fewer freezing/thawing cycles. When selecting 
cases, other parameters such as sex and post mortem interval were not usually 
considered due to the limited number of available cases.  
 
2.2.2.2 Case details 
Brain materials from 12 variant CJD (vCJD) cases, 22 sporadic cases (sCJD) cases 
and one GSS case with the PRNP P102L mutation were used in this chapter. Five 
non-CJD cases with other neurological disorders were used as controls. These cases 
were selected based on the availability of autopsy-collected frozen half brain 
specimens with consent for research use. Appropriate ethical approval was obtained 
for the research use of these brain materials. A definite diagnosis for these cases had 
been made by established criteria (Budka et al. 1995; Ironside et al. 2000). The 
codon 129 polymorphism of the PRNP of each case was determined by restriction 
fragment length polymorphism (Nurmi et al. 2003). The protease-resistant core 
fragments of PrPSc (PrPres) found in brains were classified as type 1, 2A or 2B 
according to the nomenclature of Parchi and colleagues (Parchi et al. 1999b). All 13 
vCJD cases were homozygous for methionine at the PRNP codon 129 genotype and 
had a type 2B PrPres isotype in brain tissue (Table 2.1). The 22 sCJD cases comprised 
of 13 sCJD cases with MM genotype at codon 129 and a type 1 PrPres, three cases 
with MM genotype and a type 2A PrPres, three cases with MV genotype and a type 1 
PrPres, and three cases with MV genotype and a type 2A PrPres (Table 2.2). One GSS 
case was homozygous for methionine at codon 129 with P102L mutation and had 
only small fragments of PrPres (Table 2.3). The five non-CJD control cases were 
referred to the National CJD surveillance Unit suspected to be CJD, but received an 
alternative diagnosis, such as vascular dementia or Alzheimer’s disease. Their final 
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diagnosis and genotype at PRNP codon 129 are described in Table 2.4. Variables 
such as sex, disease duration and post mortem interval were compared as a group 
between neurological controls, sCJD and vCJD cases (Table 2.5).  
 
2.2.2.3 Brain samples for analysis 
For CDI analysis, initially, around 100mg of frozen tissue was taken from grey 
matter-enriched frontal cortex (FC). In a group of CJD cases, triplicate samples were 
taken from frontal cortex, cerebellar cortex (Cb) and thalamus (Th). For the CJD 
cases in which multiple frozen tissues were taken from several brain regions, sections 
were taken from formalin-fixed, paraffin-embedded tissue blocks from the 

















Post mortem  
interval (days) 
vCJD1 M 25 10 MM 2B 2 
vCJD2 F 29 10 MM 2B 1 
vCJD3 F 51 13 MM 2B 2 
vCJD4
a
 M 18 13 MM 2B 2 
vCJD5 M 25 10 MM 2B 2 
vCJD6 F 28 9 MM 2B 3 
vCJD7 M 26 11 MM 2B 4 
vCJD8 M 32 17 MM 2B 2 
vCJD9 F 17 13 MM 2B 1 
vCJD10 M 19 11 MM 2B 3 
vCJD11 M 35 15 MM 2B 4 
vCJD12 M 33 12 MM 2B 5 
vCJD13 M 29 7 MM 2B 4 
   
   Note a. This case was used only for stability study (Chapter 4). 
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Post mortem  
interval (days) 
MM1-1 M 67 1 MM 1 5 
MM1-2 M 79 4 MM 1 2 
  MM1-3
a
 F 57 24 MM 1 1 
MM1-4 M 61 1 MM 1 5 
MM1-5 F 78 3 MM 1 6 
MM1-6 M 79 3 MM 1 2 
MM1-7 M 77 1 MM 1 3 
MM1-8 M 63 4 MM 1 4 
MM1-9 M 74 2 MM 1 2 
MM1-10 F 74 4 MM 1 10 
MM1-11 F 74 3 MM 1 3 
MM1-12 M 61 3 MM 1 3 
MM1-13 M 73 3 MM 1 3 
MM2-1 F 44 17 MM 2A 1 
MM2-2 M 37 23 MM 2A 2 
MM2-3 F 60 8 MM 2A 3 
MV1-1 M 77 4 MV 1 4 
MV1-2 M 74 3 MV 1 4 
MV1-3 M 38 8 MV 1 4 
MV2-1 F 60 14 MV 2A 4 
MV2-2 M 72 7 MV 2A 7 
MV2-3 M 65 9 MV 2A 4 
VV2-1
b
 M 52 6 VV 2A not available  
 
Note a. This case is classified as the panencephalopathic variant of sporadic CJD. 
          b. This case was used only for stability study (Chapter 4). 
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Neurological control  
(n=5) 
2:3 
71.2 ± 5.5  
(65 - 80) 
7.4 ± 5.6  
(2 - 14) 
3.0 ± 1.2  
(1 - 4) 
vCJD  (n=13) 9:4 
28.2 ± 8.9  
(17 - 51) 
8.9 ± 2.6  
(7 - 17) 
2.7 ± 1.3  






71.7 ± 6.9  
(61 - 79) 
2.7 ± 1.2  
(1 - 4) 
4.0 ± 2.3  
(2 - 10) 
sCJD  
All sCJD cases 
(n=23) 
16:7 
65.0 ± 12.7  
(37 - 79) 
6.7 ± 6.6  
(1 - 24) 
3.7 ± 2.1  
(1 - 10) 
 
Note a. Values are mean ± S.D. with range in parentheses.  
          b. One MM1 sCJD case (MM1-3 in Table 2.2) which is also classified as the 
panencephalopathic variant of sporadic CJD is not included. 
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2.2.3 Methods  
2.2.3.1 Conformation-dependent immunoassay (CDI) 
2.2.3.1.1 History and methodological speculation  
Conformation-dependent immunoassay (CDI) was first described by Safar and 
colleagues in 1998 (Safar et al. 1998). Based on the conformational rearrangement 
that occurs in the N-terminus of PrP during the conversion of PrPC into PrPSc, Safar's 
CDI was in the form of direct ELISA using dissociation-enhanced time-resolved 
fluorescence (TRF) system (Safar et al. 1998). This CDI measured the 
immunoreactivity of an antibody named 3F4 whose epitope is accessible in PrPC, but 
masked in native PrPSc; after denaturation PrPSc becomes accessible by mAb 3F4. 
While normal hamster brains containing only PrPC showed similar level of TRF 
signals before and after denaturation, diseased brains exhibited great increase of 
fluorescence signals after denaturation (Safar et al. 1998); newly detected CDI 
signals after denaturation were thought to be mostly derived from PrPSc. Safar's CDI 
revealed that a proteinase K (PK)-sensitive isoform of PrPSc is present at a substantial 
level in scrapie-affected hamster brains. Interestingly, various hamster prion strains 
were distinguishable based on the ratio of PK-sensitive PrPSc to PK-resistant PrPSc 
(Safar et al. 1998). In addition, Safar and colleagues also identified selective 
precipitation of PrPSc by NaPTA, which increased the diagnostic sensitivity of CDI 
by being incorporated into the sample processing procedure (Safar et al. 1998).  
 
Since the first description of CDI using hamster prion strains in 1998, various groups 
have reported improved versions of CDI with a similar format as follows: sandwich 
formatted ELISA, semi-purification of PrPSc using NaPTA precipitation and time-
resolved fluorescence (TRF) detection system. In 2002, CDI was successfully 
applied as a diagnostic test for BSE with sensitivity being similar to that of animal 
bioassay measured in transgenic mice (Safar et al. 2002); since the mAb 3F4 
recognizes only human and hamster prion protein (PrP), Safar et al. employed high-
affinity recombinant antibody fragments reacting with bovine PrP. In the following 
year, human PrPSc in vCJD and sCJD brains were successfully detected by CDI 
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incorporating NaPTA precipitation in sample treatment (Bellon et al. 2003). 
Subsequently, using the same format of CDI as Bellon's, Safar et al. reported that as 
much as 90% of PrPSc in sCJD brain was susceptible to proteolysis (Safar et al. 
2005a). More recently, CDI successfully detected vCJD PrPSc newly generated by 
PMCA (Jones et al. 2007). The existence of a substantial level of PK-sensitive PrPSc 
in natural sheep scrapie was also revealed by CDI (Thackray et al. 2007a).        
 
Because CDI does not require proteolytic treatment to differentiate between PrPC and 
PrPSc, a major advantage of this kind of assay is that both PK-sensitive and PK-
resistant species of PrPSc can be measured. Given that the ratio of PK-sensitive PrPSc 
to PK-resistant PrPSc was found to be distinct between hamster prion strains and that 
PK-sensitive isoform of PrPSc may constitute as much as ~ 90% of PrPSc in sCJD, it 
would seem to be imperative to investigate both isoforms of PrPSc for a fuller 
understanding of prion disease. Another potential advantage that CDI has is that this 
assay allows the separate investigation of PrPC from PrPSc in diseased brain. 
Although PrPC has received relatively less attention when compared to PrPSc, its 
possible contribution to the pathologic effect of PrPSc raises the necessity for the 
investigation of PrPC (Brandner et al. 1996; Mallucci et al. 2003; Rambold et al. 
2008). One limitation of CDI is that this assay does not produce information on PrPres 
such as its size or glycoform ratio. This limitation may be more pronounced in 
human prion disease given the importance of PrPres type in distinguishing various 
disease phenotypes (Collinge et al. 1996; Hill et al. 2003; Parchi et al. 1999b)  
 
Although CDI was initially developed based on the conformational difference 
between PrPC and PrPSc, the selective precipitation of PrPSc using NaPTA has been 
widely employed in CDI as a sample treatment step in order to increase its diagnostic 
sensitivity. For the same reason, this semi-purification step of PrPSc has been 
occasionally performed in diagnostic Western blot, particularly in the test using 
peripheral tissue (Peden et al. 2010; Peden et al. 2006; Peden et al. 2007; Wadsworth 
et al. 2001). In this study, CDI was performed without NaPTA semi-purification step 
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for the following reasons: 1) this study is not designed for diagnostic purpose; 2) this 
study is intended to look at both PrPC and PrPSc simultaneously; 3) only a small 
proportion of PrPC is reported to be recovered by NaPTA precipitation (Wadsworth 
et al. 2001); 4) it is questionable whether NaPTA can precipitate all species of PrPSc, 
for example oligomeric species (Sasaki et al. 2009). Despite close similarity in CDI 
format between this study and previous studies (Bellon et al. 2003; Safar et al. 
2005a), direct comparison of results (for example, the proportion of PK-sensitive 
PrPSc) between them may be limited given the above-stated points. Nonetheless, the 
composition of two PrP conformers present in CJD brains is believed to be more 
accurately measured using brain homogenates rather than using a particular fraction 
such as a NaPTA-precipitated one.  
 
2.2.3.1.2 CDI procedures 
Preparation of brain tissue 
Brain homogenates were prepared in nine volumes (w/v) of phosphate-buffered 
saline (PBS), pH 7.4, containing 2% Sarcosyl by two cycles of homogenization in 
the FastPrep instrument (Qbiogene). Each cycle was run for 45 seconds at the speed 
of 6.5ms-1 with the interval of 10 minutes between the runs. The 10% brain 
homogenates were further diluted to 5% (w/v) using PBS containing 2% Sarcosyl 
(w/v) and were incubated for 10 minutes at room temperature on a shaking platform. 
The samples were then cleared by centrifugation at 500 × g for 5 minutes at 20°C 
and the supernatants were collected. The cleared samples were aliquoted and stored 
at -80°C until use. In some cases, the 5% brain homogenates were serially diluted by 
a factor of two before analysis.  
 
Preparation of microtitre plate 
A 96-well black microtitre plate (Fisher, DIS-942-010H) was incubated overnight at 
room temperature with 200µl/well 10µg/ml anti-PrP antibody MAR-1 (CSL Behring, 
Marburg, Germany) in bicarbonate-carbonate coating buffer. MAR-1 recognizes 
specifically human PrP with a correctly formed disulphide bridge. After overnight 
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incubation, the plate was washed four times with wash buffer (PerkinElmer) and then 
saturated with 0.5% (w/v) bovine serum albumin (BSA) and 6% Sorbitol (w/v) in 
wash buffer for 1 hour at room temperature on a plate shaker. Plates were washed 
four times with wash buffer immediately before loading samples.   
 
Conformation-dependent immunoassay (CDI)  
The conformation-dependent immunoassay (CDI) was performed as described 
previously with a few modifications (Bellon et al. 2003; Safar et al. 2005a). The 5% 
brain homogenates prepared in 2% Sarcosyl in PBS were split into two parts for CDI 
application. One part was mixed with the same volume of PBS containing Complete 
EDTA-free® protease inhibitors (native sample, N) and the other part was mixed with 
the same volume of 8M GdnHCl and incubated for 6 minutes at 81°C (denatured 
sample, D). Both N and D samples were adjusted using distilled water containing 
EDTA-free protease inhibitors to a final concentration of GdnHCl of 0.35M in 435µl 
final volume. Samples were then loaded in duplicate into the plate (200µl/well) 
coated with MAR-1. After incubating the plate for 2 hours at room temperature with 
shaking, the plate was washed four times with wash buffer. The detection of bound 
PrP was achieved by the europium (Eu)3+ -labelled mAb 3F4 recognizing amino 
acids 109-112 of human PrP. The detector antibody diluted in assay buffer 
(PerkinElmer) at 50ng/ml was added to each well, followed by incubation for 2 hours 
at room temperature on a plate shaker. The plate was developed after six times 
washes followed by 5 minutes incubation in enhancement solution (PerkinElmer) at 
room temperature. The low pH of enhancement solution allows Eu3+ to become free 
from its chelation with the mAb 3F4. Subsequently, a highly fluorescent chelation is 
formed between the free Eu3+ and ligand in enhancement solution. The time-resolved 
fluorescent (TRF) signals, measured as cps (counts per seconds), were counted using 
a Victor 2 fluorometer (PerkinElmer). The flowchart of CDI is illustrated in Figure 
2.1. 
 
CDI D/N ratio and [D-N] value  
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TRF counts obtained from CDI were used to generate a D/N ratio and a [D-N] value 
(Safar et al. 1998; Safar et al. 2005a). The D/N ratios were obtained by dividing TRF 
counts of denatured samples (D) by the counts of the corresponding native samples 
(N). For the generation of [D-N] values, TRF counts measured in the native state 
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2.2.3.2 Other methods 
Western blot (WB) analysis of PrPres  
The analysis of PrPres in brain tissue was conducted as described previously (Yull et 
al. 2009). The cleared 5% brain homogenates was digested with 50µg/ml PK for 1 
hour at 37°C unless specified. PK activity was terminated by the addition of Pefabloc 
SC (Roche) to a final concentration of 1mM. Samples were mixed with NuPAGE 
LDS 4X sample buffer to a final concentration of 1X and then incubated for 10 
minutes at 100°C. For the pellets obtained after methanol precipitation or 
centrifugation at 20,800 × g for 1 hour, proteins were resuspended with 25µl of 2X 
LDS sample buffer and boiled for 10 minutes. Samples were loaded onto a 10% Bis-
Tris NuPAGE gel (Invitrogen) and then electrophoresed in MES buffer (Invitrogen) 
for 50 minutes at 200 volts. The separated proteins on the gel were transferred to 
polyvinylidene difluoride (PVDF) membrane (Hybond-P; Amersham) for 1 hour at 
30 volts. The membrane was then blocked for 1 hour with 5% (w/v) non-fat dry milk 
in TBST (20mM Tris/HCl, pH 7.4, 150mM NaCl and 0.1% Tween 20). After three 
washes with TBST, the membrane was incubated with anti-PrP antibody 3F4 (Dako) 
at a final concentration of 75ng/ml IgG for 1 hour. The membrane was again washed 
three times with TBST and then incubated with horseradish peroxidase-conjugated 
anti-mouse IgG F(ab’)2 fragment (Amersham) at a dilution of 1 in 40,000 for 1 hour. 
Following five washes in TBST, blots were developed with ECL plus reagent 
(Amersham) and then exposed to X-ray film (Hyperfilm ECL; Amersham) for the 
periods of 30 seconds to 30 minutes. The molecular weight of PrP was determined by 
reference to IgG-binding MagicMark XP Western protein standards (Invitrogen). 
Films showing suitable exposures were scanned using a Bio-Rad GS-800 
densitometer and quantitative analysis of the blots was performed using Quantity 
One Software (Bio-Rad Laboratories).  
 
Protein precipitation by methanol  
Samples left undigested or digested with various concentrations of PK were mixed 
with nine volumes of pre-chilled methanol followed by overnight incubation at          
 58
-80°C. Samples were then centrifuged at 16,000 × g for 30 minutes and the 
supernatants were carefully aspirated. Proteins in the pellet fractions were 
resuspended in sample buffer and analysed by Western blot as described above.  
 
Enrichment of PrPres by centrifugation  
For the enrichment of PK-resistant fragments of PrPSc, samples of various volumes 
digested with 50µg/ml were centrifuged at 20,800 × g for 1 hour at 4°C as described 
previously (Head et al. 2004b). After careful aspiration of the supernatants, pellets 
were analysed by Western blot as described above.   
 
Neuropathology 
Serial sections were cut at 5m from formalin-fixed, paraffin-embedded tissue 
blocks and then mounted onto Superfrost glass slides (Thermo Scientific). The 
sections were dried overnight in a 56°C incubator and then deparaffinised and were 
taken down to water followed by immersion into picric acid to remove formalin 
pigment. For routine staining, sections were stained with hematoxylin and eosin.  
 
For PrP immunohistochemistry, sections treated with picric acid were blocked with 
3% hydrogen peroxide in methanol for 30 minutes to prevent endogenous peroxidase 
from acting. Sections were then autoclaved at 121°C in distilled water for 10 minutes, 
followed by immersion in 96% formic acid for 5 minutes and then digestion with 
10µg/ml PK for 5 minutes at room temperature. For PrP labelling, duplicate sections 
were incubated for 1 hour with the mAbs 3F4 (Dako) or KG9 (TSE Resource Center, 
Roslin institute) diluted in Novocastra IHC Diluent (Novocastra Laboratories Ltd). 
The mAb 3F4 was used at a dilution of 1:15 (final concentration: 5 µg/ml) and the 
mAb KG9 was used at a dilution of 1:1,000 (The mAb KG9 is not a commercial 
antibody and was obtained in the form of culture fluid. The dilution factors of both 
mAbs were in-house titrations in NSCJDU). The detection system used was the 
NovolinkTM polymer kit from Leica Microsystems. Sections were incubated for 30 
minutes with Post Primary Block, followed by incubation with Polymer Link for 30 
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minutes. PrP immunolabelling on the section was visualized using diaminobenzidine 
(DAB) followed by light counterstaining with hematoxylin.    












2.3 Results  
 
2.3.1 Analysis of brain homogenates by CDI without additional pre-
treatment 
The CDI in this study employed the mAb 3F4 recognizing amino acids 109-112 of 
human PrP as a detector. The epitope of the mAb 3F4, which is exposed in PrPC, is 
hidden in PrPSc and becomes accessible upon denaturation (Kascsak et al. 1987; 
Peretz et al. 1997; Safar et al. 1998). Therefore, CDI signals obtained from native 
samples represent PrPC and those obtained from denatured samples represent total 
PrP irrespective of their conformations (Safar et al. 1998). Since the newly detected 
PrP signals after denaturation are thought to be mainly derived from PrPSc, the 
difference of CDI signals between native and denatured aliquots (D-N) and/or the 
ratio of CDI signals between the two folding states (D/N) have been used as 
indicators for the presence of PrPSc (Bellon et al. 2003; Safar et al. 1998; Safar et al. 
2005a). In this section, samples from CJD and control brains were assayed by CDI 
without additional treatment like NaPTA precipitation, and [D-N] values and D/N 
ratios were compared between CJD and non-CJD groups.     
 
2.3.1.1 Non-CJD (neurological control) cases 
Tissues of frontal cortex from five non-CJD control cases were investigated by CDI 
in the native and denatured states. The 5% brain homogenate was prepared as 
described in section 2.2.3 and split into two parts. While one part was mixed with 
same volume of PBS containing protease inhibitors and left without further treatment 
(native sample), the other part was heated at 81°C for 6 minutes after mixing with 
same volume of 8M GdnHCl (denatured sample). Both aliquots were diluted and 
adjusted to a final concentration of 0.35M GdnHCl and assayed by CDI.  
 
The TRF counts obtained in the native state from neurological control brains were 
variable between cases, implying variable amounts of PrPC between them (white bars 
in Figure 2.2a); after denaturation, slight increase of fluorescence signals was 
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observed in all cases (black bars in Figure 2.2a). The difference of TRF counts 
between the two different folding states ([D-N] value) was in the range of 13,000 ~ 
46,000 with the average of 25,900 (Figure 2.1b). When the ratios of the TRF counts 
between native and denatured aliquots were generated (D/N ratios), they were in the 
range of 1.2 ~ 1.5 and were similar between cases (Figure 2.1c). The higher [D-N] 
values do not always mean higher D/N ratios because the levels of PrPC were 
variable between cases. The D/N ratio was highest in non-CJD1(1) sample among 
those investigated in this study, whereas the [D-N] value was highest in the non-


















































Figure 2.2 Comparison of CDI results between native and denatured states in 
non-CJD brains. Five cases of neurological controls were analysed by CDI using 
brain homogenates from tissues of frontal cortex. (a) Comparison of TRF counts 
measured in the native (white bars) and the denatured states (black bars) (b) [D-N] 
values in non-CJD brains. TRF counts of native samples were subtracted from those 
of corresponding denatured samples to give [D-N] values. (c) D/N ratios in non-CJD 
brains. TRF counts of denatured samples were divided by those of corresponding 







































































2.3.1.2 vCJD cases 
Tissues of frontal cortex from 12 vCJD cases were assayed by CDI in the native and 
denatured states. When the vCJD samples were analysed by CDI in the native state, 
the fluorescence signals were readily detectable in all vCJD cases and were broadly 
similar between cases (white bars in Figure 2.3a). Given that CDI fluorescence 
counts obtained from native samples represent PrPC (Safar et al. 1998), readily 
detectable amounts of PrPC were present in the vCJD-affected brains. The amounts 
of PrPC were roughly similar between cases, accounting for a significant portion of 
total PrP. The levels of PrPC in vCJD cases were largely within the range of those of 
neurological controls (Figure 2.2), despite great difference in the age of disease onset 
between the two groups (Table 2.5). Individuals that differ in other factors such as 
sex, disease duration and/or post mortem interval did not show any readily 
recognizable distinction in PrPC levels.     
 
Upon denaturation, significant increase of CDI TRF counts was observed in all 12 
cases (black bars in Figure 2.3a). Although the differences of CDI signals between 
the native and denatured states were variable between cases, they can be easily 
distinguishable from those of non-CJD brains (Figure 2.3b). The [D-N] values were 
in the range of 100,000 ~ 260,000, except for two cases whose values were 62,000 
(vCJD13) and 74,000 (vCJD10), respectively; even [D-N] values from these two 
cases were much higher than the average of those of neurological controls (average: 
25,900). Since the increase of CDI TRF counts after denaturation in CJD brains was 
considered to be mainly derived from PrPSc, the variation in the [D-N] values 
between these vCJD samples appeared to reflect differences in the levels of PrPSc.     
 
When the ratios of the TRF counts between native and denatured aliquots were 
generated (D/N ratios), they were in the range of 2.0 ~ 5.0, except for two cases 
whose ratios were 1.6 (vCJD13) and 1.9 (vCJD3), respectively (Figure 2.4c). The 
D/N ratios in all 12 cases including the two cases with low values were higher than 
those of control brains (average: 1.3). The samples with higher [D-N] values had 
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usually higher D/N ratios, but the difference in the D/N ratios between vCJD and 





















Figure 2.3 Comparison of CDI results between native and denatured states in 
vCJD brains. Twelve vCJD cases were analysed by CDI using brain homogenates 
from tissues of frontal cortex. (a) Comparison of TRF counts measured in the native 
(white bars) and the denatured states (black bars). (b) [D-N] values in vCJD brains, 
which were generated by subtracting TRF counts of native aliquots from those of 
corresponding denatured aliquots. (c) D/N ratios in vCJD brains, which were 
generated by dividing TRF counts of denatured aliquots by those of corresponding 
native aliquots. Solid lines in (b) and (c) represent the average [D-N] values and D/N 
ratios of non-CJD brains, respectively. Data shown represent the average for 



















































































































































































































2.3.1.3 sCJD cases  
For further analysis, tissues of frontal cortex from 13 MM1 sCJD cases were assayed 
by CDI. When the MM1 sCJD samples were analysed by CDI in the native state, the 
fluorescence signals were readily detectable in all cases despite significant variation 
between cases (white bars in Figure 2.4a). The levels of CDI signal in some cases 
(for example, MM1-4) were more than five times higher than those in others (for 
example, MM1-10). Since CDI fluorescence counts obtained from native samples 
represent PrPC, this kind of variation was thought to reflect variable amounts of PrPC 
between MM1 sCJD cases. While the level of PrPC in four MM1 sCJD cases (MM1-
2, 3, 6, 10) was recognizably lower than that of control even with lowest level, that 
of other MM1 cases was overall within the range of controls. The relatively low level 
of PrPC in some MM1 cases did not appear to be directly associated with factors such 
as post mortem interval. For example, MM1-10 case with longest post mortem 
interval (10 days) among cases examined in this study showed PrPC amount similar 
to MM1-2 or MM1-3 cases with one to two day post mortem interval. Moreover, 
MM1-6 was greatly shorter in disease duration than MM1-3 (3 months versus 24 
months), but PrPC level was not greatly different between the two cases. In 
comparison, PrPC level in frontal cortex of one MM2 case (MM2-2) was 
approximately five times higher than MM1-3, despite their similarity in disease 
duration (23 months versus 24 months) (Figure 2.5c).    
 
In denatured aliquots of those samples, significant increase of CDI signals was 
observed in most cases except for MM1-7 (black bars in Figure 2.4a). The [D-N] 
values were quite variable between cases and were in the range of 52,000 ~ 272,000, 
except for one case whose value was 34,000 (MM1-7) (Figure 2.4b). In case of 
MM1-7, the [D-N] value was higher than the average of non-CJD controls, but lower 
than that of non-CJD2 (average: 25,900, non-CJD2: 46,000). Similar to the vCJD-
affected samples, the variation in the [D-N] values was thought to reflect difference 
in the level of PrPSc.     
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The D/N ratios of MM1 sCJD cases were in the range of 2.0 ~ 14.0, except for two 
cases whose ratios were 1.4 (MM1-7) and 1.9 (MM1-12) (Figure 2.4c). In case of 
MM1-7, the ratio was higher than the average of the non-CJD cases, but lower than 
that of non-CJD1(1) (average: 1.3, non-CJD1(1):1.5). In four MM1 cases, the D/N 
ratios were remarkably higher than those of other remaining MM1 cases or those of 
vCJD cases with the ratios around or over than 10 (MM1-2, 3, 6, 10 in Figure 2.4c). 
When compared to other MM1 cases, the CDI signals obtained in the native state 
from these four cases were quite low and their [D-N] values were relatively high 
(Figures 2.4a and 2.4b). In a similar context, the CDI signals of native aliquots from 
these four MM1 cases were much lower than vCJD cases showing similar levels of 
[D-N] values (for example, vCJD1 or vCJD5 in Figure 2.3b), resulting in 
significantly higher D/N rations than those vCJD cases. The samples with higher [D-
N] values overall displayed higher D/N ratios, but the difference in the D/N ratios 
























Figure 2.4 Comparison of CDI results between native and denatured states 
in MM1 sCJD brains. Thirteen MM1 sCJD cases were analysed by CDI using brain 
homogenates from tissues of frontal cortex. (a) Comparison of TRF counts measured 
in the native (white bars) and the denatured states (black bars). (b) [D-N] values in 
MM1 sCJD brains, which were generated by subtracting TRF counts of native aliquots 
from those of corresponding denatured aliquots. (c) D/N ratios in MM1 sCJD brains, 
which were generated by dividing TRF counts of denatured aliquots by those of 
corresponding native aliquots. Solid lines in (b) and (c) represent the average [D-N] 
values and D/N ratios of non-CJD brains, respectively. Data shown represent the 































































































































































































































2.3.2 PrPC and PrPSc in CJD brains with different disease phenotypes 
For further investigation of PrPC and PrPSc in CJD brains, multiple samples from 
vCJD and sCJD (MM1, MM2, MV1 and MV2 subtypes) were investigated by CDI 
without any pre-treatment such as NaPTA precipitation or PK digestion. In each CJD 
phenotype, three cases were analysed using tissues of frontal cortex (FC), cerebellum 
(Cb) and thalamus (Th). Three samples (~ 100mg in each sample) were taken each 
from the three brain regions in individual cases (i.e. nine brain specimens per case), 
except for MM2 cases where six samples were taken in each region (i.e. 18 brain 
specimens per case). Thus, 27 samples (nine samples per case multiplied by three 
cases) were examined in each phenotype, except for MM2 sCJD in which 54 samples 
were assayed. In total, 162 brain samples from different CJD phenotypes were 
assayed by CDI, without pre-treatment such as NaPTA precipitation.  
 
CDI fluorescent counts obtained from native samples were considered to represent 
PrPC. In this section, CDI [D-N] value was used as a main indicator to estimate the 
amount of PrPSc in a sample, given that the level of PrPC was variable between 
regions within individual brains or between cases and that CDI D/N ratios were 
significantly influenced by the amounts of PrPC (see sections 2.3.1.3 and 2.3.2.1). 
CDI D/N ratios were mentioned occasionally where necessary. In order to compare 
the amount of PrPSc inferred from CDI [D-N] value with PrPres, the same brain 
homogenates used for CDI analysis were examined by Western blot after limited 
proteolysis (For clarity, the abnormal form of PrP with buried 3F4 epitope is 
designated as “PrPSc” and abnormal PrP leaving PK-resistant core fragments after 
limited proteolysis is referred to as “PrPres”).  
 
It is well known that direct comparison of PrPres amounts between samples run on 
different gels is not valid due to the variations in the Western blotting process, 
antibody binding efficiencies, and/or differences in visualization reactions (Schoch et 
al. 2006; Yuan et al. 2006). In this study, nine samples from each case (three samples 
per region multiplied by three regions) were run on same gels and the comparison of 
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PrPres amounts was considered only between the nine samples. Additionally, the 
quantitative analysis of PrPres signals obtained in Western blot is further limited by 
narrow linear range in densitometry (for more details, see section 2.3.5.2).  
 
2.3.2.1 PrPC in CJD brains with different disease phenotypes 
In sections 2.3.1.2 and 2.3.1.3, it was shown that PrPC was readily detectable in FC 
tissues from vCJD and MM1 sCJD brains. For further analysis of PrPC in CJD brains, 
multiple samples from vCJD and sCJD (MM1, MM2, MV1 and MV2 subtypes) were 
investigated by CDI. CDI fluorescent counts obtained from native aliquots were 
considered to represent PrPC. Consistent with the results in sections 2.3.1.2 and 
2.3.1.3, PrPC was readily detectable in all examined CJD samples, but its amounts 
were variable between cases and regions (Figures 2.5 and 2.6). In vCJD, the levels of 
PrPC in the frontal cortex were similar between the three cases (white bars in Figure 
2.5a) and those in Cb or Th tissues were similar to or two-fold larger than FC (grey 
and black bars in Figure 2.5a). In sCJD brains, the levels of PrPC were more variable 
between regions and/or cases (Figures 2.5b, 2.5c and 2.6) and it appeared to be 
difficult to find any consistent pattern reflecting distinct sCJD subtypes. While the 
levels of PrPC in vCJD samples were overall within the range of PrPC amounts 
identified in control samples, those from some sCJD samples were significantly 






























Figure 2.5 PrPC in CJD brains with MM genotype at codon 129. Three cases each 
from vCJD (a), MM1 sCJD (b) and MM2 sCJD (c) were analysed using multiple 
tissues of frontal cortex (white bars), cerebellum (grey bars) and thalamus (black 
bars). The amount of PrPC in each sample was investigated by CDI in the native state. 
In vCJD and MM1 sCJD, data shown represent the average ± S.D. of three samples. 
Data for MM2 cases were based on six samples in each region. The result in each 

























































































Figure 2.6 PrPC in CJD brains with MV genotype at codon 129. Three cases each 
from MV1 sCJD (a) and MV2 sCJD (b) were analysed using triplicate tissues of 
frontal cortex (white bars), cerebellum (grey bars) and thalamus (black bars). The 
amount of PrPC in each sample was investigated by CDI in the native state. Data 
shown represent the average ± S.D. of three samples. The result in each sample was 





















































2.3.2.2 PrPSc in CJD brains: comparison of conformational change (CDI) 
with resistance to limited proteolysis (WB)  
  
2.3.2.2.1 vCJD 
In each region, [D-N] values were presented as an average of three samples. CDI [D-
N] values in vCJD samples were usually significantly higher than the average of five 
controls shown as solid line (Figure 2.7a). In each case, the [D-N] value in 
cerebellum (Cb) was higher than those in frontal cortex (FC) or thalamus (Th), 
despite overlaps of standard deviations between cerebellum and thalamus (Figure 
2.7a). In the cerebellum and thalamus, the levels of [D-N] value were roughly similar 
between the three vCJD cases (grey and black bars in Figure 2.7a). In comparison, 
the level of [D-N] value in the frontal cortex was highly variable between the cases 
(white bars in Figure 2.7a); the value of vCJD1 FC was almost as high as that of 
vCJD1 Th, whereas the value of vCJD3 FC was about 20% of that of vCJD3 Th. A 
direct comparison of TRF counts between the two different folding states from nine 
individual samples of vCJD3 was shown in Figure 2.7b.    
 
In order to compare the amount of PrPSc inferred from CDI [D-N] value with PrPres, 
the same brain homogenates used for CDI analysis were digested with PK at 
50µg/ml for 1 hour at 37°C and assayed by Western blot. The results from individual 
samples (nine samples per case [three samples per region multiplied by three 
regions]) were shown in Figure 2.8. In most vCJD samples, PrPres was readily 
detectable in a short exposure (30 seconds); PrPres signals in the two FC samples 
(FC2 and FC3) from vCJD3 were detected after extended exposures. In each case, 
PrPres signals from Th samples were stronger than those of frontal cortex or 
cerebellum; exceptionally, in vCJD1, the level of PrPres in Th3 sample was similar to 
those of FC (1 and 2) or Cb samples. This pattern of PrPres distribution was in 
contrast to that of PrPSc inferred from CDI [D-N] value, because the levels of PrPSc 
from Cb samples were overall higher than or similar to those from Th samples of the 
corresponding cases. Similarly, PrPres signals in Cb2 and Cb3 samples of vCJD3 
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were much weaker than those in the Th samples of the same brain, although [D-N] 
values in the two Cb samples were similar to or slightly higher than those in the Th 
samples (compare bottom row in Figure 2.8 with Figure 2.7b); densitometric analysis 
revealed that PrPres amounts in the two Cb samples were only 10 ~ 15% of those in 
the Th samples. Additionally, high variation in the intensity of PrPres signals was 
occasionally observed between samples of same regional origin (FC region of vCJD1 
or Cb region of vCJD3). For example, PrPres signal in FC3 sample of vCJD1 was less 
than 30% of FC1 or FC2 samples in densitometry, although [D-N] value in FC3 was 
more than 80% of the two other FC samples.   
 
Collectively, abnormal forms of PrP which were determined by its conformation or 
partial resistance to limited proteolysis were readily detectable in most of the vCJD 
samples, but their abundance was variable between regions and/or cases; while the 
amounts of PrPSc inferred from CDI [D-N] value were most abundant in cerebellum, 




















Figure 2.7 CDI [D-N] values for tissues of FC, Cb and Th from vCJD brains. (a) 
Samples of FC (white bars), Cb (grey bars) and Th (black bars) from three vCJD 
brains were analysed by CDI in the native and denatured states. CDI [D-N] values 
were generated by subtracting TRF counts measured in the native state from those 
measured in the denatured state. The solid line shows the average of [D-N] values of 
five controls. Data shown represent the average ± S.D. of three samples and the 
result in each sample was an average for duplicate wells. (b) The TRF counts from 
nine individual samples of vCJD3 were directly compared between the native (white 













































































Figure 2.8 Distribution of PrPres in three regions of vCJD brains. The brain 
homogenates used for CDI analysis were digested with PK at 50µg/ml for 1 hour at 
37°C and then analysed by Western blot using mAb 3F4. In each row, the results 
from nine samples of each case (three samples per region multiplied by three 
regions) were shown. Molecular weight expressed in KDa is shown to the left. 
 












2.3.2.2.2 MM1 sCJD  
In each region, [D-N] values were presented as an average of three samples. In the 
three cases of MM1 sCJD, [D-N] values in frontal cortex were higher than or similar 
to those in the two other regions (Figure 2.9a). In MM1-1, the [D-N] values in FC 
samples was significantly higher than those of cerebellum or thalamus; additionally, 
the [D-N] values in the Th samples were not greatly different from that of non-CJD 
controls expressed as solid line (Figure 2.9a). However, the levels of PrPC in the Th 
samples of MM1-1 were very low, which resulted in the generation of D/N ratios 
higher than 1.8 (range: 2.9 ~ 3.3). Therefore, a low level of abnormal PrP appeared 
to be present in this region. In MM1-2, overall distribution pattern of [D-N] values 
between regions was similar to that of MM1-1, although [D-N] values from three Th 
samples were highly variable ([D-N] value in Th1: 259,198; Th2: 31,168; and Th3: 
23,454). In MM1-6, the levels of [D-N] value were relatively similar between the 
three regions; as in MM1-2, the values between the three Th samples were 
significantly variable (Figure 2.9b). A direct comparison of TRF counts between the 
two different folding states from individual nine samples of MM1-6 was shown in 
Figure 2.9b.  
 
In order to compare the amount of PrPSc inferred from CDI [D-N] value with PrPres, 
the same brain homogenates used for CDI analysis were digested with PK and 
immunoblotted with mAb 3F4. The results from individual samples (nine samples 
per case [three samples per region multiplied by three regions]) were shown in 
Figure 2.10. In MM1-1, PrPres was detectable only in three FC samples although 
trace of PrPres-like signals was seen in samples of the two other regions (upper row in 
Figure 2.10). In MM1-2, PrPres immunoreactivity was detected in all three regions 
with FC samples having highest levels of signals (middle row in Figure 2.10); in 
thalamus, PrPres was detectable only in one of the three samples which showed the 
highest [D-N] value. In MM1-6, PrPres signals were detected in all three regions 
showing roughly similar intensity between them (except for Th3 sample with little 
PrPres) (bottom row in Figure 2.10).  
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Collectively, in MM1 sCJD brains, PrPSc was more consistently detectable in 
samples of frontal cortex and cerebellum when compared to those of thalamus. When 
the distribution patterns of PrPSc determined by CDI [D-N] value were compared 
with those of PK-resistant fragments of PrPSc, there was an overall correlation 
between the two (compare Figures 2.9a and 2.9b with Figure 2.10); exceptionally, 
PrPSc was detectable at low levels by CDI in the cerebellum and thalamus of MM1-1, 





































Figure 2.9 CDI [D-N] values for tissues of FC, Cb and Th from MM1 sCJD brains. 
(a) Samples of FC (white bars), Cb (grey bars) and Th (black bars) from three MM1 
sCJD brains were analysed by CDI in the native and denatured states. CDI [D-N] 
values were generated by subtracting TRF counts measured in the native state from 
those measured in the denatured state. The solid line shows the average of [D-N] 
values of five controls. Data shown represent the average ± S.D. of three samples and 
the result in each sample was an average for duplicate wells. (b) The TRF counts 
from nine individual samples of MM1-6 were directly compared between the native 



















































































Figure 2.10 Distribution of PrPres in three regions of MM1 sCJD brains. The brain 
homogenates used for CDI analysis were digested with PK at 50µg/ml for 1 hour at 
37°C and then analysed by Western blot using mAb 3F4. In each row, the results 
from nine samples of each case (three samples per region multiplied by three 



















2.3.2.2.3 MM2 sCJD  
Initially, as in vCJD or MM1 sCJD, nine samples from each case (i.e. three samples 
in each region multiplied by three regions) were examined. [D-N] values were 
presented as an average of three samples in each region (Figure 2.11a). In all three 
cases, [D-N] values were quite low when compared to the results from vCJD or 
MM1 sCJD and only those from FC tissues were barely distinguishable from the 
solid line representing the average of [D-N] values of five controls (Figure 2.11a). 
When additional nine samples in each case were examined for a more thorough 
analysis, the results were overall similar to those from initial group of samples except 
for the slight increase of the [D-N] values in the cerebellum (Figure 2.11b). A direct 
comparison of TRF counts between the two different folding states from individual 
samples of MM2-1 (additional group) was shown in Figure 2.11c.  
 
In the MM2-3 case, D/N ratios in some of Th samples were slightly higher than 1.8 
despite their very low [D-N] values; one of the three Th samples of the initial group 
and all three samples of the additional group had D/N ratios slightly higher than 1.8 
(range: 1.9 ~ 2.1). In the thalamus of MM2-3, the levels of PrPC in all examined 
samples were very low (see Figure 2.5c) and thus the [D-N] values in these samples 
with D/N ratios slightly higher than 1.8 were also clearly lower than controls.  
 
The proteolytic fragments of PrPSc obtained after limited proteolysis were analysed 
by Western blot and the results from individual samples were shown in Figures 2.12a 
(initial group) and 2.12b (additional group). In consistent with the results based on 
CDI [D-N] value, PrPres was reliably detectable from FC samples despite occasional 
sample-to-sample variation. Intriguingly, weak but reliable three-band PrP 
immunoreactivity was detected in several Th samples from the additional group 
despite their negligible [D-N] values (for example, Th3 sample of MM2-1 in the 
additional group). Among Th samples showing faint PrPres signals, only one sample 
had a D/N ratio higher than 1.8 (Th3 sample of MM2-3; D/N ratio: 2.0). The gel 
migration of nonglycosylated fragment of PrPres from Th samples appeared to be 
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slightly slower than that of FC samples. It should be noted that, in the analysis of 
samples from the additional group, two times more brain lysates were loaded onto 



































Figure 2.11 CDI [D-N] values for tissues of FC, Cb and Th from MM2 sCJD 
brains. (a) Samples of FC (white bars), Cb (grey bars) and Th (black bars) from 
three MM2 sCJD brains were analysed by CDI in the native and denatured states. 
CDI [D-N] values were generated by subtracting TRF counts measured in the native 
state from those measured in the denatured state. (b) Additional group of samples 
were taken from the regions of FC (white bars), Cb (grey bars) and Th (black bars) 
and were analysed in the same way. Solid lines in (a) and (b) show the average of 
[D-N] values of five controls. In both (a) and (b), data shown represent the average ± 
S.D. of three samples and the result in each sample was an average for duplicate 
wells. (c) The TRF counts from nine individual samples of MM2-1 (additional 
group) were directly compared between the native (white bars) and denatured (black 






















































































































Figure 2.12 Distribution of PrPres in three regions of MM2 sCJD brains. The brain 
homogenates from initial group of samples (a) or from additional group of samples 
(b) digested with PK at 50µg/ml for 1 hour at 37°C and then analysed by Western 
blot using mAb 3F4. In each row, the results from nine samples of each case (three 
samples per region multiplied by three regions) were shown. All blots shown here 
were given a maximal exposure (30 minutes). Molecular weight expressed in KDa is 
























2.3.2.2.4 MV1 sCJD  
As in CJD with the MM genotype at codon 129, nine samples (i.e. three samples in 
each region multiplied by three regions per case) each from three cases were 
examined by CDI. The [D-N] values were presented as an average of three samples 
in each region. In cases of MV1-1 and MV1-3, [D-N] values in the three regions 
were readily distinguishable from the solid line showing the average of [D-N] values 
of five control cases. In both cases, the [D-N] values in the cerebellum and thalamus 
were similar to each other, but higher than that in the frontal cortex (Figure 2.13a). In 
MV1-2, [D-N] values were noticeably lower than the two other cases and its level in 
the cerebellum was lower than the average of controls (Figure 2.13a). A direct 
comparison of TRF counts between the two different folding states from individual 
nine samples of MV1-2 was shown in Figure 2.13b.  
 
For further analysis of abnormal PrP present in MV1 sCJD brains, the same brain 
homogenates used for CDI analysis were digested with PK and immunoblotted with 
mAb 3F4. The results from individual samples (nine samples per case) were shown 
in Figure 2.14. In MV1-1, PrPres signals were detected in all three regions with the 
frontal cortex having relatively lower PrP immunoreactivity (upper row in Figure 
2.14). In MV1-2, PrPres was detected in the frontal cortex and thalamus with the 
cerebellum being spared from PrPres accumulation; PrPres signals in FC samples were 
quite weak and barely detectable in two of three FC samples after a maximal 
exposure (30 minutes) (middle row in Figure 2.14). In MV1-3, PrPres signals were 
detected in all three regions showing roughly similar intensity between samples of 
different regional origins (bottom row in Figure 2.14).  
 
When the distribution patterns of PrPres were compared with those of PrPSc inferred 
from CDI [D-N] values, a good correlation was observed between the two; 
exceptionally, PrPres signals from FC samples of MV1-3 was overall similar to those 
from Cb or Th samples, although PrPSc levels inferred from CDI [D-N] values were a 
bit lower in FC samples than Cb or Th samples. Given that MV1 subtype of sCJD is 
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considered one uniform disease phenotype (Parchi 1999), distinct PrPSc distribution 
profile seen in case MV1-2 was a somewhat unexpected. Mechanism underlying this 
kind of heterogeneity between MV1 cases remains to be determined, but this distinct 
topology of PrPSc accumulation does not appear to be explicable in terms of clinical 
factors such as sex and disease duration or post mortem interval considering the 





















Figure 2.13 CDI [D-N] values for tissues of FC, Cb and Th from MV1 sCJD 
brains. (a) Samples of FC (white bars), Cb (grey bars) and Th (black bars) from 
three MV1 sCJD brains were analysed by CDI in the native and denatured states. 
CDI [D-N] values were generated by subtracting TRF counts measured in the native 
state from those measured in the denatured state. The solid line shows the average of 
[D-N] values of five controls. Data shown represent the average ± S.D. of three 
samples and the result in each sample was an average for duplicate wells. (b) The 
TRF counts from nine individual samples of MV1-2 were directly compared between 
the native (white bars) and denatured (black bars) states. Data shown represent the 













































































Figure 2.14 Distribution of PrPres in three regions of MV1 sCJD brains. The brain 
homogenates used for CDI analysis were digested with PK at 50µg/ml for 1 hour at 
37°C and then analysed by Western blot using mAb 3F4. In each row, the results 
from nine samples of each case (three samples per region multiplied by three 





















2.3.2.2.5 MV2 sCJD  
As in other CJD phenotypes, nine brain samples from individual brains were 
analysed by CDI. When the [D-N] values were presented as an average of three 
samples in each region, their profiles were distinct between the three cases as shown 
in Figure 2.15a. In MV2-1, [D-N] values in every three region were greatly higher 
than the solid line representing the average of five control cases. In MV2-2, [D-N] 
values were recognizably lower than the two other MV2 cases and its level in the 
cerebellum region was lower than the average of controls. In MV2-3, although the 
levels of [D-N] value in the cerebellum and thalamus were similar to those of 
corresponding regions of MV2-1, its level in the frontal cortex region did not seem 
significantly distinguishable from that of non-CJD controls. A direct comparison of 
TRF counts between the two different folding states from individual nine samples of 
MV2-3 was shown in Figure 2.15b.  
 
For further analysis of abnormal PrP present in MV2 sCJD brains, the same brain 
homogenates used for CDI analysis were analysed by Western blot following 
proteolysis at 50µg/ml PK for 1 hour at 37°C. The results from individual samples 
(nine samples per case) were shown in Figure 2.15a. In MV2-1, PrPres was readily 
detectable in a short exposure (30s) from all samples; PrP immunoreactivity was 
strongest in the cerebellum, followed by the thalamus and frontal cortex (upper row 
in Figure 2.16a). In MV2-2, PrPres was detected in the frontal cortex and thalamus 
with much stronger immunoreactivity in the former region; the cerebellar region in 
this case was spared from PrPres accumulation (middle row in Figure 2.16a). 
Intriguingly, while PrPres detected in the frontal cortex showed typical type 2 
migration pattern with a nonglycosylated fragment migrating at ~19 KDa, PrPres 
detected in the thalamus appeared to have type 1 pattern with a nonglycosylated 
fragment migrating at ~21 KDa (Th1 or Th2 samples) or to have a mixture of both 
types (Th3 sample). Similar results were obtained in the repeated examination of 
MV2-2 samples (Figure 2.16b). In MV2-3, PrPres was readily detectable in the 
cerebellum and thalamus with the frontal cortex being spared from PrPres 
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accumulation (bottom row in Figure 2.16a). In this case, although PrPSc level in Cb3 
sample (inferred from [D-N] value) was higher than those of Th2 and Th3 samples, 
PrPres signal in the Cb sample was much weaker than the two Th samples (compare 
bottom row in Figure 2.16a with Figure 2.15b); densitometric analysis showed that 
PrPres amount in the Cb3 sample was about 15 ~ 20% of those of the two Th samples. 
Additionally, in this MV2-3 case, the intensity of PrPres signals was significantly 
variable between samples of same regional origins when compared to the CDI [D-N] 
values. In the Cb3 sample, PrPres amount was 10 ~ 15% of those of Cb1 or Cb2 
samples in densitometry, whereas [D-N] value in the Cb3 was around 90% of the two 
other Cb samples (compare bottom row in Figure 2.16a with Figure 2.15b). Similarly, 
PrPres signal in Th1 sample was less than 30% of Th1 or Th2 samples in 
densitometry, whereas [D-N] value in Th3 sample was around 70 ~ 80% of those of 
two other Th samples.  
 
Overall, on a region-to-region comparison basis, the distribution patterns of PrPSc 
inferred from CDI [D-N] value were overall correlated with those of PrPres; however, 
disagreement between the results of the two biochemical methods was also present in 
some samples of MV2-3. Interestingly, the distribution patterns of PrPSc/PrPres were 
recognizably variable between cases.  
 
The topography of PrPres accumulation in the MV2 subtype of sCJD is known to be 
influenced by disease duration (Parchi et al. 1996; Parchi et al. 2000a). While the 
patients with a short clinical duration of illness accumulate large amounts of PrPres in 
the subcortical regions, but less in the neocortex, those with a longer duration 
accumulate relatively larger amounts of PrPres in the neocortex (Parchi et al. 1996). 
Therefore, in comparison with MV2-1 (duration: 14 months), the scant accumulation 
of abnormal PrP in the frontal cortex of MV2-3 (duration: 9 months) may be 
explained from this viewpoint. In comparison, despite its short disease duration of 7 
months, case MV2-2 harboured much more amount of PrPSc/PrPres in the frontal 
cortex than the thalamus with the cerebellum being spared from the accumulation of 
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abnormal PrP; this PrPres distribution pattern was rather similar to that of MM2 cases 
(Figure 2.12). Post mortem interval in MV2-2 was rather longer than other two MV2 
cases (7 days versus 4 days), but this "moderate" difference in post mortem interval 
did not appear to be associated with the distinct topology of PrPSc/PrPres 



















Figure 2.15 CDI [D-N] values for tissues of FC, Cb and Th from MV2 sCJD 
brains. (a) Samples of FC (white bars), Cb (grey bars) and Th (black bars) from 
three MV1 sCJD brains were analysed by CDI in the native and denatured states. 
CDI [D-N] values were generated by subtracting TRF counts measured in the native 
state from those measured in the denatured state. The solid line shows the average of 
[D-N] values of five controls. Data shown represent the average ± S.D. of three 
samples and the result in each sample was an average for duplicate wells. (b) The 
TRF counts from nine individual samples of MV2-3 were directly compared between 
the native (white bars) and denatured (black bars) states. Data shown represent the 



















































































Figure 2.16 Distribution of PrPres in three regions of MV2 sCJD brains. (a) The 
brain homogenates used for CDI analysis were digested with PK at 50µg/ml for 1 
hour at 37°C and then analysed by Western blot using mAb 3F4. In each row, the 
results from nine samples of each case (three samples per region multiplied by three 
regions) were shown. (b) The nine samples of MV2-2 were repeatedly examined by 
Western blotting using mAb 3F4 after the limited proteolysis. In both (a) and (b), 
molecular weight expressed in KDa is shown to the left.  
 

















2.3.3 Further analysis of CJD brains by CDI: comparison before and after 
proteolysis 
In the initial study describing CDI, it was reported that a substantial proportion of 
PrPSc was PK-sensitive and different hamster prion strains were distinguishable 
based on the ratio of PK-resistant PrPSc to PK-sensitive PrPSc (Safar et al. 1998). A 
recent study based on CDI argued that as much as 90% of PrPSc in sCJD brains was 
PK-sensitive (Safar et al. 2005a). In this context, in order to examine the degree of 
loss of CDI signals after proteolysis, three CJD cases (one case each from vCJD, 
MM1 sCJD and MM2 sCJD) were analysed by CDI before and after proteolysis. In 
each case, three samples from FC region were examined. As control, FC samples 
from two non-CJD brains were also contained in this study.   
  
2.3.3.1 Non-CJD brains 
The 5% homogenates were prepared from frontal cortex of two non-CJD cases in 
PBS containing 2% Sarcosyl and then digested by various concentrations of PK 
starting at the concentration of 2.5µg/ml for 1 hour at 37°C. After PK digestion, 
proteins were precipitated by overnight incubation with methanol and then assayed 
by CDI in the denatured state or by Western blot. Unexpectedly, PrP was 
undetectable in the non-CJD brains by either detection method after proteolysis with 
as little as 2.5µg/ml PK (Figure 2.17); as shown in Figure 2.17a, the fluorescence 
counts obtained after proteolysis with 2.5µg/ml PK was similar to those obtained 
after proteolysis with 50µg/ml PK. Therefore, it appeared that PrPC in non-CJD 
brains was highly susceptible to the proteolytic treatment even at the concentration of 






















Figure 2.17 High susceptibility of PrPC to proteolytic treatment in non-CJD 
brains. Brain homogenates prepared from frontal cortex of non-CJD brains remained 
undigested or digested with varying concentrations of PK (range: 2.5µg/ml ~ 
50µg/ml) followed by methanol precipitation of proteins. (a) Samples were analysed 
by CDI in the denatured state. Data shown represent the average for duplicate wells 
and error bars showing S.D. were omitted (Grey bars: non-CJD1; black bars: non-
CJD2). (b) Samples from the non-CJD2 case were assayed by Western blot using 
mAb 3F4.  
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2.3.3.2 CJD brains 
In order to compare the CDI signals before and after proteolysis, triplicate samples 
were taken from FC region of CJD brains (one vCJD, one MM1 sCJD and one MM2 
cases). The 5% brain homogenates were prepared in PBS containing 2% Sarcosyl 
and then digested with 2.5µg/ml PK or 50µg/ml PK for 1 hour at 37°C.  
 
Figure 2.18 shows a direct comparison of fluorescence counts between the two 
different folding states in a representative sample of each case. When the samples 
were assayed by CDI in the native state, the fluorescence signals obtained from 
undigested samples were no longer present following proteolysis with 2.5µg/ml PK 
(grey bars in Figure 2.18); however, the CDI signals were readily detectable 
following denaturation of samples digested with 2.5µg/ml PK (black bars in Figure 
2.18). Thus, similar to the results from non-CJD brains, the application of mild 
proteolysis at 2.5µg/ml PK appears to be quite efficient in digesting PrPC present in 
the frontal cortex of CJD brains. After digestion with 50µg/ml PK, more than a half 
of total PrP signal was lost when compared to the results of corresponding samples 
digested with 2.5µg/ml PK (black bars in Figure 2.18).  
 
When the ratios of the TRF counts between native and denatured aliquots were 
generated (D/N ratios), they were in the range of 2 ~ 5 in undigested samples (white 
bars in Figure 2.19). After proteolysis with 2.5µg/ml, a dramatic increase in the D/N 
ratios was observed in all the samples (grey bars in Figure 2.19); the ratios increased 
from 50 times up to 200 times, reaching the range of 100 ~ 400. After proteolysis in 
the diagnostic standard condition (50µg/ml PK, 1 hour, 37°C), the D/N ratios in 
every sample dropped “moderately” to the range of 70 ~ 200 showing some variation 
between the three samples of each case (black bars in Figure 2.19). The three CJD 
phenotypes were broadly similar in their patterns of changes of CDI D/N ratio 
following the proteolysis at the two different conditions.    
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When the [D-N] values found in undigested samples were compared with those of 
corresponding samples digested with 50µg/ml PK, only 30 ~ 60% of [D-N] values 
were detectable after the standard proteolysis (Figure 2.20a). When compared to 
those digested with 2.5µg/ml PK, there remained about 30 ~ 50% of [D-N] values in 
samples digested with 50µg/ml PK (Figure 2.20b). In both comparisons, some 
variation between the three samples of each case was observed. The distinction 
between the three CJD phenotypes did not seem possible based on the change of [D-




























Figure 2.18 Comparison of CDI results before and after proteolysis. Brain 
homogenates were prepared from frontal cortex of vCJD3 (a), MM1-6 (b) and MM2-
2 (c). The homogenates left undigested or digested with two different concentrations 
of PK (2.5µg/ml PK or 50µg/ml PK) and were then analysed by CDI. Grey bars: 
TRF counts obtained in the native state; Black bars: TRF counts obtained in the 







































































































Figure 2.19 Comparison of CDI D/N ratios before and after proteolysis. Brain 
homogenates were prepared from triplicate FC samples of vCJD3 (a), MM1-6 (b) 
and MM2-2 (c). The brain homogenates left undigested (white bars) or digested with 
2.5µg/ml PK (grey bars) or 50µg/ml PK (black bars) and were then analysed by CDI. 
D/N ratios were generated by dividing TRF counts of denatured aliquots by those of 























































Figure 2.20 Comparison of CDI [D-N] values before and after proteolysis. Brain 
homogenates were prepared from triplicate FC samples of vCJD3, MM1-6 and 
MM2-2. The brain homogenates left undigested or digested with 2.5µg/ml PK or 
50µg/ml PK and were then analysed by CDI. [D-N] values were generated by 
subtracting TRF counts measured in the native state from those measured in the 
denatured state. (a) [D-N] values obtained from samples digested with 50µg/ml PK 
were expressed as relative values (%) to those obtained from corresponding 
undigested samples. (b) [D-N] values obtained from samples digested with 50µg/ml 
PK were expressed as relative values (%) to those obtained from corresponding 
samples digested with 2.5µg/ml PK. Each bar represents individual samples (white 

















































2.3.4 Further characterization of proteolytic fragments of PrPSc in Western 
blot 
2.3.4.1 PrPres type analysis 
In some of the CJD cases analysed in section 2.3.2.2, PrPres appeared to be slightly 
different in its gel migration between regions. For further analysis, samples from 
these cases were digested with PK and run on the gel between PrPres type 1 and type 
2B standards (which are used as PrPres type standards for routine diagnostic Western 
blot analysis in NCJDSU). The standard sample with type 1 PrPres was from cerebral 
cortex of a case of MM1 sCJD and the standard sample with type 2B PrPres was from 
cerebral cortex of a case of vCJD; both samples were used after enzymatic hydrolysis 
with 50µg/ml PK. 
 
In the three cases of MM2 sCJD, the gel mobility of PrPres from Th samples appeared 
to be slightly slower than that of FC samples (see Figure 2.12b). In order to examine 
PrPres type more precisely, one FC sample and one Th sample in each case were run 
on the gel between PrPres type standards following limited proteolysis. While equal 
amount of brain lysate was analysed in all FC samples and a Th sample from MM2-2, 
Th samples from MM2-1 and MM2-3 were analysed using pellet fraction obtained 
after centrifuging brain homogenate (250µl) at 20,800 × g for 1 hour. As shown in 
Figure 2.21, in all three cases, gel mobility of PrPres was similar between FC and Th 
samples; the migration of an unglycosylated PrPres band was clearly faster than type 
1 standard, showing type 2 electrophoretic mobility.   
 
In MV2-2, while FC samples had type 2 PrPres, Th samples appeared to have type 1 
PrPres (Th1 and Th2 samples) or both types (Th3 sample) (see Figure 2.16). To 
examine PrPres type more precisely in this MV2 case, one sample each from frontal 
cortex and thalamus were run on the gel between PrPres type standards following 
limited proteolysis. In order to obtain PrPres signals similar to the type controls, two 
times more brain lysate in the Th sample was loaded onto the well of the gel when 
compared to FC sample. For comparison, samples from MV2-1 (one sample each 
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from the three regions) were also analysed in the same way. In MV2-1, PrPres in the 
FC and Cb samples had a type 2 migration pattern; interestingly, a nonglycosylated 
fragment of PrPres in the Th sample migrated faster than that of type 1 standard but 
slower than that of type 2 standard (Figure 2.22a). In MV2-2, PrPres in the FC sample 
had a type 2 migration pattern, whereas PrPres in the Th sample had a type 1 























Figure 2.21 Analysis of PrPres type in MM2 sCJD brains. Brain homogenates were 
prepared from frontal cortex (FC) and thalamus (Th) of the MM2 cases as described 
in section 2.2.3. The homogenates were digested with 50µg/ml PK for 1 hour at 37°C 
and then analysed by Western blot using mAb 3F4. For precise determination of 
PrPres type, these samples were run between in-house standard samples with type 1 
(T1) PrPres or type 2B (T2B) PrPres. While Th samples from MM2-1 and MM2-3 
were analysed using pellet fraction obtained after centrifuging 250µl of sample at 
20,800 × g for 1 hour, the other MM2 samples were analysed using equal volume of 
brain lysates (24µl). 
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Figure 2.22 Analysis of PrPres type in MV2 sCJD brains. Brain homogenates were 
prepared from frontal cortex (FC), cerebellum (Cb; [a] only) and thalamus (Th) of 
the MV2 cases as described in section 2.2.3. The homogenates were digested with 
100µg/ml (a) or 50µg/ml PK (b) for 1 hour at 37°C and then analysed by Western 
blot using mAb 3F4. For precise determination of PrPres type, these samples were run 
between in-house standard samples with type 1 (T1) PrPres or type 2B (T2B) PrPres. 
In MV2-1(a), the amount of brain lysate loaded onto the well was equal between the 
three regions. In MV2-2 (b), the amount of brain lysate examined was two times 
more in the Th sample than that in the FC sample.  
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2.3.4.2 A small proteolytic fragment of PrPSc in MV2-2 
When the blot in Figure 2.22b was given a maximal exposure (30 minutes), a PK-
resistant fragment with lower molecular weight was detected (Figure 2.23a). For 
further analysis of this small-size proteolytic fragment of PrPSc, brain homogenates 
prepared from frontal cortex and thalamus of the MV2 case (MV2-2) were digested 
with PK at 50µg/ml PK for 1 hour at 37°C; brain homogenate from a GSS case with 
small-size proteolytic fragments of PrPSc was also digested at the same time under 
the same condition. For Western blot analysis, equal amount of sample was loaded 
onto each lane, except for G2 lane in which pellet fraction obtained after centrifuging 
brain homogenate (100µl) at 20,800 × g for 1 hour was analysed. As shown in Figure 
2.23b, a proteolytic fragment with low molecular weight was clearly detectable in the 
duplicate lanes of the Th sample and its molecular weight was similar to that from 
the GSS case. It did not seem clear whether a proteolytic fragment with low 



























                                   
 
Figure 2.23 A proteolytic fragment of PrPSc with low molecular weight in a case 
of MV2 sCJD. (a) A maximal exposure (30 minutes) of the blot shown in Figure 
2.21b. A lower-molecular-weight band (a small fragment marked as arrow) was seen 
in the tissue of thalamus (Th lane). For more details, refer to Figure 2.21b. (b) Brain 
homogenates were prepared from frontal cortex (FC) and thalamus (Th) of MV2-2 
case or from frontal cortex of a GSS case (G1 and G2). The homogenates were 
digested with 50µg/ml PK at the same time and analysed by Western blot using mAb 
3F4. A lower-molecular-weight band (marked as arrow) was seen in the duplicate 
lanes of the Th sample as well as in both GSS lanes. In each lane, equal amount of 
sample was loaded, except for G2 lane in which pellet fraction obtained after 
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2.3.5 Supplementary data  
2.3.5.1 Linear range investigation in CDI 
To examine the linear range of the conformation-dependent immunoassay (CDI) 
under the experimental condition adopted in this study, the 5% brain homogenates 
were prepared in PBS containing 2% Sarcosyl from tissues of CJD brains. The brain 
homogenates were serially diluted by a factor of two using the homogenization 
buffer and assayed by CDI in the native and denatured states without any additional 
treatment like NaPTA precipitation or PK digestion. The homogenization buffer was 
contained in each CDI plate to show background levels.   
 
The TRF counts obtained from the native 5% samples were lower than 200,000 in all 
the three CJD brain samples (Figure 2.24). When the CDI results obtained in the 
native state from serially diluted samples were plotted against the concentration of 
brain homogenate, they decreased in a linear form until they reached a solid line 
represent background level (open symbols in Figure 2.24). Given that the recognition 
site of the mAb 3F4 is hidden in PrPSc (Kascsak et al. 1987; Safar et al. 1998), the 
fluorescence signals observed from the native CJD samples are believed to represent 
PrPC present in those CJD brain samples.   
 
After denaturation, the TRF counts increased significantly when compared to their 
native corresponding samples; the increase of CDI signals was more outstanding in 
FC tissue of a vCJD brain or in Th tissue of another vCJD brain in comparison with 
FC tissue of a sCJD MM1 brain (Figure 2.24). These newly detected PrP signals 
after unfolding are thought be mainly derived from PrPSc (Safar et al. 1998). In the 
sCJD brain sample, the TRF counts of 5% brain homogenate were around 300,000; 
the CDI signals decreased in a liner form despite few minor fluctuations as the 5% 
sample was serially diluted (filled symbols in Figure 2.24a). In cases of the two 
vCJD brain samples, the TRF counts were around 700,000 (FC of vCJD4) and 
600,000 (Th of vCJD2) in the concentration of 5%. When serially diluted samples 
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were assayed by CDI, the TRF counts began to decrease in a linear way from the 
points of few steps serial dilution (filled symbols in Figures 2.24b and 2.24c).  
  
Collectively, these results have shown that the CDI assay in this study has a 103-fold 
linear range (roughly from the value of 500 to 500,000) under the experimental 
condition in this study. It is of note that the same format of CDI as one in this study 
was reported to be linear over a 104-fold range when NaPTA precipitation step was 


































Figure 2.24 Investigation of linear range in CDI. Brain homogenates were prepared 
from frontal cortex of a case of MM1 sCJD (a) or a case of vCJD (b) or from 
thalamus of another case of vCJD (c) as described in section 2.2.3. The 5% brain 
homogenates were serially diluted by a factor of two using homogenization buffer 
and then assayed by CDI. Empty symbols represent the results obtained from native 
samples and filled symbols represent the results from corresponding denatured 
samples. Background level obtained from homogenization buffer was shown as a 
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2.3.5.2 Linear range investigation in Western blot analysis of PrPres  
To examine the linear range of Western blot analysis of PrPres combined with 
densitometry, the 5% brain homogenates were prepared from thalamus of two vCJD 
cases and they were digested with PK at 50µg/ml PK for 1 hour at 37°C. 
Subsequently, the PK-digested samples were serially diluted by a factor of two using 
the homogenization buffer (PBS containing 2% Sarcosyl) and analysed by Western 
blotting.  
 
As shown in Figure 2.25a, PrPres signals gradually declined according as the PK-
treated brain samples were serially diluted. Densitometry was performed using 
Quantity One Software (Bio-Rad Laboratories) and values of optical density (OD) 
were determined by measuring the three PrPres bands as a whole (i.e. not adding up 
the OD values of individual PrPres bands). In case of the Th sample of vCJD2, the 
PrPres signals declined in a linear range from the concentration of 1.25% (OD value: 
50) to the concentration of 0.08% (OD value: 2.4) (left blot in Figure 2.25a and 
Figure 2.25b). In another vCJD Th sample, a linear range was observed from the 
concentration of 1.25% (OD value: 38.6) to the concentration of 0.16% (OD value: 
3.2); in this sample, the linear range may extend further at the higher end (toward the 
concentration of 2.5%) (right blot in Figure 2.25a and Figure 2.25c). In summary, the 
liner range under the experimental condition in this study seems to extend at least 
from the OD value of 2.5 to 40. The linear range for WB analysis was found to lie 
between OD values of 0.8 and 8.0 when the three PrPres bands were measured 



























Figure 2.25 Investigation of linear range in Western blot analysis of PrPres. (a) 
Brain homogenates were prepared from thalamus of two cases of vCJD as described 
in section 2.2.3. The 5% brain homogenates were digested with 50µg/ml PK for one 
hour at 37°C and then serially diluted by a factor of two using homogenization buffer. 
PrPres in the serially diluted samples was investigated by Western blot using mAb 
3F4. The concentration of brain lysate in each lane was shown on the top of the blots. 
(b) and (c) The two blots in (a) were quantified by densitometry; (b) represents the 
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2.3.5.3 Analytical precision 
To examine the analytical precision of CDI, a 5% brain homogenate was prepared 
from frontal cortex of a case of vCJD and was denatured as described in section 2.2.3. 
After diluting and adjusting the concentration of GdnHCl to 0.35M, two hundred 
microliters of the vCJD sample was loaded into each of the 96 wells of two plates 
and then assayed by CDI. In plate 1, the mean TRF counts of 96 wells were 400,000 
with standard deviation of 20,000; in plate 2, the mean was 420,000 with standard 
deviation of 15,000 (Figure 2.26). The coefficient of variation (CV; %) was obtained 
by dividing the standard deviation by the mean and then multiplying the value by 
100. The intra-assay CV was 5.1% (plate 1) and 3.5% (plate 2), respectively.  
 
The analytical precision of CDI was further assessed by analysing CDI results 
obtained from eight CJD samples tested repeatedly on three to four separate 
occasions. These samples were examined by CDI for the conformation stability 
analysis (Chapter 4). The analytical precision between assays (inter-assay variation) 
expressed as the (CV; %) for these samples ranged from 6.6% to 16.1%, except for 


































Figure 2.26 Intra-assay variation in CDI. The 5% brain homogenates prepared from 
frontal cortex of a case of vCJD were applied to two CDI plates after denaturation. 
(a) Scatter diagram of TRF counts of individual wells in the two plates. (b) The 




















































2.4.1 PrPC in CJD brains 
Since the epitope of mAb 3F4 employed as a detector in CDI is not accessible in 
PrPSc and becomes exposed only after denaturation, the CDI fluorescence signals 
obtained from native samples represent PrPC. When brain samples from different 
forms of CJD were analysed by CDI in the native state, PrPC was readily detectable 
in all examined CJD samples. The level of PrPC was variable between regions and/or 
cases (particularly in sCJD brains). This PrPC variation may be partly associated with 
variations in sampling and difference in age, post-mortem intervals, etc. between 
individual cases. While the levels of PrPC in vCJD samples were overall within the 
range of PrPC amounts identified in the controls, those in some sCJD samples were 
significantly lower than the controls. However, since only tissues of frontal cortex 
from non-CJD controls were analysed by CDI in this study, the direct comparison of 
PrPC levels between non-CJD and CJD samples (from Cb and Th regions) may not 
be accurate. Moreover, given that the non-CJD controls were initially referred to the 
Unit for a consideration of CJD but received an alternative diagnosis (see Table 2.4) 
and that the upregulation of PrPC was observed in various neurodegenerative diseases 
(Kovacs et al. 2002b; Voigtlander et al. 2001), the levels of PrPC in these 
neurological controls do not necessarily represent those in "normal" brains.  
 
To the best of my knowledge, this is the first description of PrPC present in human 
brains infected with prions. The presence of PrPC in diseased brains, however, was 
previously described in the brains of scrapie-infected hamsters (Meyer et al. 1986; 
Safar et al. 1998). Meyer and colleagues reported that the level of PrPC was similar 
between the brains of scrapie-infected and control hamsters when the two isoforms 
of PrP were separated based on their difference in detergent solubility (Meyer et al. 
1986). In another study based on CDI employing the mAb 3F4 as a detector, Safar 
and colleagues have shown that PrPC is present in the hamster brains infected with 
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various prion strains with some variation in its level between strains (Safar et al. 
1998).  
 
The presence of PrPC in CJD brains appears to be natural because PrPC serves as a 
precursor protein of PrPSc and thus its presence is a prerequisite for the replication of 
PrPSc (Bueler et al. 1993; Caughey and Raymond 1991). More interestingly, a 
growing body of evidence suggests that PrPC is quite possibly linked to neurotoxicity 
in prion-infected brains. The first experimental evidence supporting this concept was 
provided by grafting brain tissue overexpressing PrPC into the brain of PrP knockout 
mice, in which PrPSc is not toxic to PrP-deficient neurons (Brandner et al. 1996). 
This finding was further supported by Mallucci and colleagues, who has shown that 
the depletion of neuronal PrPC expression in mice infected with scrapie reversed the 
early spongiform degeneration and prevented the development of neurological 
symptoms despite further accumulation of PrPSc in astrocytes (Mallucci et al. 2003). 
It was then reported that the accumulation of PrPSc amyloids did not accompany 
clinical disease in GPI-negative transgenic mice (Chesebro et al. 2005). A more 
recent observation from Rambold and colleagues that PrPC was required for the 
pathologic effects of PrPSc also supports this notion (Rambold et al. 2008). In 
different studies, minor populations of PrPC molecules with topological variants have 
been reported to be toxic species of PrP. A small population of newly synthesized 
PrP molecules can be localized in the cytosol (cyPrP) as a result of inefficient 
translocation into the endoplasmic reticulum (ER)(Rane et al. 2004). The stress in 
the ER which can be triggered by the accumulation of PrPSc was reported to lead to 
the increase of cyPrP (Rane et al. 2008), which could possibly contribute to the 
neurotoxicity during prion infection (Hetz et al. 2005; Kang et al. 2006; Orsi et al. 
2006). Expression of cyPrP in transgenic mice with a deleted N-terminal ER 
targeting signal sequence caused severe cerebellar degeneration (Ma and Lindquist 
2002). Another minor isoform of PrP that is claimed to be linked to neurotoxicity is a 
transmembrane form of PrP in which central hydrophobic domain spans the 
membrane with its N-terminus exposed to the cytosol (Hegde et al. 1998). 
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Transgenic mice expressing this variant of PrP (termed ctmPrP) developed a fatal 
neurodegenerative disease (Hegde et al. 1998; Stewart et al. 2005). Interestingly, a 
very recent study has shown that both cyPrP and ctmPrP can interact with and disrupt 
the function of Mahogunin, a cytosolic ubiquitin ligase whose loss causes 
spongiform degeneration in mice (Chakrabarti and Hegde 2009). Taken together, 
PrPC molecules detected by CDI in this study may contribute to the disease 
pathogenesis in CJD. 
 
It has been known that several genetic forms of human prion diseases, especially FFI, 
do not accumulate substantial amounts of PrPSc in the brain, despite fatal clinical 
diseases (Almer et al. 1999; Brown et al. 1995; Tateishi et al. 1990; Tateishi et al. 
1995). Moreover, the distribution and severity of pathological changes do not always 
correlate with the amounts and distribution of PrPSc deposition (Almer et al. 1999; 
Budka 2003; Schoch et al. 2006). In particular, neuronal loss and gliosis in prion-
infected human brains were reported not to be directly related to the amount of PrPSc 
deposition (Parchi et al. 2000a). In this context, the region of thalamus in MM2-2 is 
of interest because abnormal PrP was not demonstrable by PrP immunostaining and 
barely detectable by the biochemical methods despite the presence of severe neuronal 
loss and marked gliosis along with mild vacuolation; interestingly, PrPC molecules 
were easily identifiable by CDI in this region. Since CDI-based detection of PrPC 
cannot distinguish secreted form of PrPC from cyPrP and ctmPrP, it would be 
interesting to investigate the level of those topological variants in these regions using 
an antibody that selectively recognizes them by virtue of their uncleaved ER-
targeting signal peptide (Stewart and Harris 2003; Stewart and Harris 2005). 
Additionally, it would be also interesting to analyse PrPC molecules (both secreted 
and topologically variant forms) present in cases of FFI or other inherited diseases in 
which little PrPSc is detectable despite fatal clinical disease. 
 
2.4.2 CDI-based distinction between non-CJD and CJD brains: FC tissue 
analysis  
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In contrast to PrPC, the binding site of the mAb 3F4 is hidden in the native form of 
PrPSc but become exposed after denaturation (Peretz et al. 1997). Thus, in the CDI 
employing the mAb 3F4 as a detector, newly detected fluorescence signals after 
denaturation in PrPSc-containing samples are considered to be mainly derived from 
PrPSc (Safar et al. 1998). In the CDI analysis frequently combined with NaPTA 
precipitation, the difference of fluorescence signals between native and denatured 
aliquots (D-N) and/or the ratio of CDI signals between the two folding states (D/N) 
have been used as indicators for PrPSc (Bellon et al. 2003; Jones et al. 2009a; Jones 
et al. 2008; Safar et al. 2002; Safar et al. 2005a; Thackray et al. 2007a).  
 
In the analysis of non-CJD brains containing only PrPC, CDI fluorescence signals 
increased slightly after denaturation when compared those measured from native 
aliquots and the D/N ratios were in the range of 1.2 ~ 1.5. Similar to the observation 
in this study, the D/N ratios observed in normal hamster brains were reported to be 
less than or equal to 1.8 (Safar et al. 1998). The [D-N] values were in the range of 
13,000 ~ 46,000 with the average of 25,900. However, the increases of CDI signals 
after denaturation were much more significant in the CJD brains and most of them 
were easily distinguishable from the non-CJD controls on the basis of [D-N] values 
and/or D/N ratios. Among the 25 CJD cases (12 vCJD and 13 MM1 sCJD cases), 
only one MM1 case was not distinguishable from the non-CJD controls by both 
indicators. The D/N ratios in vCJD brains were in the range of 1.8 ~ 5.0 except for 
one case. In comparison, the ratios in MM1 sCJD brains were more widely spread 
with values in the range of 1.8 ~ 14.0 except for one case. While the vCJD case with 
the D/N ratio lower than 1.8 were easily distinguishable from controls by its [D-N] 
value, the MM1 case showing low D/N ratio was also indistinguishable from controls 
by its [D-N] value. When compared to the D/N ratios obtained from various 
laboratory prion strains propagated in hamsters (Safar et al. 1998), the ratios 
obtained from vCJD cases are in a similar range to those of DY or 139H strains; in 
contrast, no hamster prion strains have shown such a wide variability of D/N ratios as 
those seen between cases of MM1 sCJD.  
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Among the two CDI indicators, [D-N] values are thought to more properly reflect the 
amounts of PrPSc in CJD samples, although fluorescence counts of PrPC molecules 
were shown to increase up to 50% after denaturation in this study (non-CJD control 
brains) or reported to increase up to 80% in a previous study (normal hamster 
brains)(Safar et al. 1998). In comparison, low D/N ratios do not necessarily mean 
low levels of PrPSc and high ratios do not necessarily mean high levels of PrPSc, 
because the ratios are influenced by amounts of PrPC as well as those of PrPSc. For 
example, when some of the vCJD and MM1 cases which were similar in their [D-N] 
values were compared, the ratios in the former were significantly lower than the 
latter due to their difference in the amounts of PrPC. Nonetheless, when compared 
within each phenotype, the CJD samples with higher D/N ratios showed overall 
higher [D-N] values.  
 
2.4.3 PrPSc in CJD brains determined by CDI or resistance to limited 
proteolysis (WB) 
2.4.3.1 Analysis of multiple samples from different brain regions  
In each CJD case, three brain regions (frontal cortex, cerebellum and thalamus) were 
examined by the two biochemical methods. The frontal cortex was selected because 
this area has been most commonly used for diagnostic purpose, i.e. for the detection 
of PrPres and biochemical PrP typing (Parchi et al. 2009b). The cerebellum was 
selected because clinical and neuropathological features in this region are important 
in classifying some forms of sCJD (Parchi et al. 1999b; Parchi et al. 1996; Schulz-
Schaeffer et al. 1996). The thalamus was selected as a representative region of 
subcortical structure mainly because its pathological features in vCJD patients were 
strikingly different from those of cerebral and cerebellar cortex (Ironside et al. 2000; 
Ironside et al. 2002). Interestingly, the regions of cerebellum and thalamus were 
recently reported to be important for a reliable classification of sCJD (Cali et al. 
2009; Parchi et al. 2009b). Considering the complexity of PrPres types between the 
samples from the same anatomical area of a patient (Cali et al. 2009; Head et al. 
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2004a; Parchi et al. 2009b), triplicate samples (six samples in MM2 cases) were 
examined in each brain region.  
 
2.4.3.2 A conformational change (CDI) versus resistance to limited proteolysis 
(WB)  
In this study, multiple brain specimens with different regional origins from various 
CJD phenotypes were analysed by CDI without NaPTA precipitation and Western 
blot after limited proteolysis. PrPSc present in the CJD brain samples were 
determined by the two biochemical criteria: a conformational change in N-terminal 
region (CDI) or resistance to limited proteolysis (WB).  
  
When the distribution patterns of PrPSc inferred from CDI [D-N] value were 
compared with those of PK-resistant fragments of PrPSc (PrPres), there was an overall 
correlation between the two biochemical criteria to define disease-associated isoform 
of PrP, despite their differences in the principle and platform. The samples and/or 
regions in which CDI [D-N] values were negligible or not significantly 
distinguishable from those of controls were usually spared from PrPres accumulation. 
The distribution patterns of abnormal PrP in individual brains were generally similar 
between the two biochemical measurements; in each case, generally speaking, a 
brain region with highest level of PrPSc showed strongest PrPres immunoreactivity 
and another region with lowest level of PrPSc had least abundant PrPres.  
 
However, occasional disagreement was also evident between the two biochemical 
measurements of PrPSc. For example, in all three vCJD cases, PrPres was more 
abundant in the thalamus despite similar or higher levels of PrPSc in the cerebellum. 
In the Cb samples from the MM1-1 case, little PrPres was detectable despite 
significant levels of PrPSc inferred from [D-N] values. In MM2 cases, faint but 
reliable three-band PrPres signals were detectable in few Th samples despite their 
negligible [D-N] values. In the MV2-3 case, PrPres signal in a Cb sample was greatly 
weaker than two Th samples, although PrPSc level in the Cb sample was slightly 
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higher than the two Th samples. In addition, significant variation in PrPres 
immunoreactivity was occasionally seen between samples from the same region 
despite relative similarity in the level of PrPSc. This discordance between PrPSc and 
PrPres may be related to non-uniform distribution of PK-sensitive PrPSc to total PrPSc 
between samples from the same region or between regions within the same brain. In 
a previous study, PK-sensitive fraction of PrPSc was reported to comprise as much as 
90% of PrPSc in the frontal cortex and white matter of sCJD-infected brains (Safar et 
al. 2005a). However, it has been unclear whether the PK-sensitive isoform PrPSc is 
uniformly distributed within the same brain. The results in this study suggest that the 
ratio of PK-sensitive PrPSc to total PrPSc is not always uniform in individual CJD 
brains. 
 
2.4.3.3 CDI analysis following limited proteolysis 
PrPC molecules present in non-CJD brains as well as CJD brains were shown to be 
highly susceptible to the digestion with 2.5µg/ml PK. This condition of mild 
proteolysis resulted in the great increase in CDI D/N ratios in all CJD samples 
examined. The proteolytic treatment of CJD samples under diagnostic standard 
condition (50µg/ml PK, 1 hour, 37°C) led to “moderate” decrease both in [D-N] 
values and in the D/N ratios (when compared to those measured following digestion 
with 2.5µg/ml PK).  
 
The high susceptibility of PrPC molecules present in non-CJD brains to PK was also 
observed in a recent study reporting "protease-sensitive prionpathy" cases (Gambetti 
et al. 2008), in which PrPC molecules became undetectable following treatment even 
with 1µg/ml PK for 1 hour at 37°C. In a similar context, PrPC molecules became 
fully digested with 50µg/ml PK even after 5 minute incubation (Yull et al. 2009). In 
this study and other studies described above, the immunodetection of PrPC following 
proteolysis was performed by the mAbs recognizing the N-terminus of PrP. Since 
PrPC is first degraded by PK to an intermediate fragment of 25 - 28 KDa prior to the 
complete degradation and its initial cleavage site is known to lie between residues 
 121
113 and 144 (Buschmann et al. 1998), it appears quite possible that a partially 
degraded form of PrPC which is not detectable by 3F4 is present following the 
proteolysis with 2.5µg/ml PK in this study or in those above-described studies.  
 
The significant loss of CDI signals observed in the CJD samples following limited 
proteolysis with 50µg/ml PK is consistent with the previous studies (Safar et al. 
1998; Safar et al. 2005a). The three CJD phenotypes (vCJD, MM1 and MM2 sCJD) 
are broadly similar in the degree of loss of fluorescence signals following the 
proteolysis, which makes it difficult to distinguish the three CJD phenotypes with 
MM genotype at codon 129, unlike the hamster prion strains (Safar et al. 1998). In 
this study, it is difficult to determine exactly what the proportion of PK-sensitive 
fraction of PrPSc is for the following reasons: first, CDI [D-N] values obtained from 
in undigested CJD samples would not to be fully attributed to PrPSc molecules 
because fluorescence signals of PrPC molecules also increase slightly after 
denaturation (see section 2.3.1.1); second, it remains unknown whether a subset of 
PK-sensitive isoform of PrPSc is susceptible to the enzymatic hydrolysis even with 
2.5µg/ml PK. Although it seems unlikely, this kind of possibility cannot be fully 
excluded because a fraction of PK-sensitive PrPSc with converting activity in PMCA 
was shown to be highly sensitive to the proteolysis even with 5µg/ml PK (Pastrana et 
al. 2006). Even when taking these limitations into account, the estimated proportion 
of PK-susceptible PrPSc in this study does not appear as high as the level (~90% of 
total PrPSc) reported by Safar et al. (Safar et al. 2005a). For example, the level of 
CDI [D-N] values in the CJD samples treated with 50µg/ml PK lies in the range of 
30 ~ 60% of those of undigested corresponding samples; moreover, given the above-
mentioned limitation on CDI [D-N] values obtained from undigested CJD samples, a 
minor portion of loss of CDI signals following the standard proteolysis is thought to 
be related with the enzymatic hydrolysis of PrPC molecules. Despite the close 
similarity in the CDI format and procedures, the main difference between the two 
studies is whether NaPTA precipitation is incorporated in sample processing 
procedures. While pellet fraction recovered by NaPTA precipitation is used for CDI 
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analysis in Safar's study (Safar et al. 2005a), cleared brain homogenate is directly 
applied to CDI in this study. It remains to be determined whether NaPTA 
precipitation is related with the discrepancy between the two studies, however it 
should be noted that a significant portion of PrP molecules recovered by NaPTA 
precipitation was shown to be PK-resistant in WB analysis (Gambetti et al. 2008; 
Wadsworth et al. 2001) 
 
2.4.3.4 Speculation on the distribution profiles of PrPSc/PrPres in CJD brains 
The distribution patterns of abnormal PrP in the three brain regions appeared to be 
different between vCJD and two MM sCJD subtypes. In the vCJD brains, abnormal 
PrP was more abundant in the cerebellum (based on CDI) or in the thalamus (based 
on PK-resistance). In contrast, both types of MM sCJD harboured more abundant 
amounts of abnormal PrP in the frontal cortex, except for one MM1 case showing 
similar levels of abnormal PrP between the three regions. In both MV subtypes of 
sCJD, regional distribution patterns of abnormal PrP were more variable between 
cases. While abnormal PrP was detectable in all the three regions in two MV1 cases, 
abnormal PrP was not detectable in the cerebellum in the remaining case. In two 
MV2 cases, abnormal PrP was more abundant in the cerebellum and thalamus than 
the frontal cortex, whereas the distribution profile of abnormal PrP in the remaining 
case was rather similar to the MM2 case with cerebellum being spared from 
accumulation of abnormal PrP.  
 
The distribution profiles of abnormal PrP obtained from sCJD cases appears to be in 
agreement with previous studies in which distribution profiles of PrPres were 
investigated in wider brain areas from more sCJD cases. Previous studies have 
shown that both MM1 and MM2 subtypes of sCJD harbour more amounts of PrPres 
in the cerebral cortex than the thalamus or cerebellum (Parchi et al. 1996; Schoch et 
al. 2006). In both MV subtypes of sCJD, regional profiles of PrPres were reported to 
be more variable between cases (Schoch et al. 2006); in this study, MV cases 
containing very low or undetectable levels of PrPres in various regions including FC, 
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Cb and Th were readily identifiable when only limited numbers of cases were 
investigated. 
    
The distribution pattern of abnormal PrP in the MV2-2 case deserves further 
comment. In contrast to these two MV2 cases, the MV2-2 case (disease duration: 7 
months) harboured much more amount of PrPSc/PrPres in the frontal cortex than the 
thalamus, with the cerebellum being spared from the accumulation of abnormal PrP. 
This topography of abnormal PrP obtained from MV2-2 looks overall more similar 
to those described from MM2 cases. Consistent with this biochemical observation, 
the MV2-2 case has features of MM2 pathology without showing any detectable 
kuru plaques in the cerebellum. The atypical biochemical and neuropathological 
features of the MV2-2 which look close to those of MM2 subtype may be associated 
with the propagation of different prion strains, given that MV2 and MM2 subtypes of 
sCJD showed different biological properties on transmission into the bank voles 
(Nonno et al. 2006). Alternatively, the phenotypic variation between the MV2-2 case 
and other MV2 cases may be related with where prion replication initiates 
(peripheral versus central initiation) rather than the propagation of different prion 
strain (Wadsworth et al. 2008a; Will 2003). It would be interesting to compare 
clinical symptoms of the MV2-2 case with other MV2 or MM2 cases.   
 
In vCJD, to the best of my knowledge, there is no published paper with which to 
compare the distribution profiles of abnormal PrP identified in this study; 
additionally, it does not appear to be possible to generalize this study's results due to 
the small number of cases. Nonetheless, the regional distribution of PrPSc/PrPres 
obtained from the three vCJD cases suggests that the accumulation of abnormal PrP 
in vCJD brains may start earlier in the cerebellum and subcortical area than in the 
neocortex. It is of note that a recent vCJD transmission study has shown that 
incubation periods with inocula prepared from cerebellum were consistently shorter 
than inocula from frontal cortex, suggesting higher titres of infectivity in the former 
tissue (Ritchie et al. 2009). The accumulation of abnormal PrP in MV2 and VV2 
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subtypes of sCJD appears to happen in a similar way as discussed above or as shown 
in the previous studies (Parchi et al. 1996; Schoch et al. 2006).  
 
2.4.4 PK-resistant fragments of PrPSc (PrPres)   
2.4.4.1 Mixed PrPres types 
Although this study was designed to investigate abnormal PrP defined by the two 
biochemical criteria (a conformational change [CDI] and limited proteolysis [WB]), 
it is also necessary to discuss the coexistence of PrPres types in sCJD cases 
considering the current significance of this issue in sCJD classification (Cali et al. 
2009; Parchi et al. 2009b). 
  
The original PrPres type determined previously from routine examination of frontal 
cortex was confirmed in most of the sCJD cases examined in this study, although 
multiple samples which originated from three different brain regions were analysed. 
Exceptionally, the existence of both PrPres types was seen in the MV2-2 case. In this 
case, the frontal cortex had only type 2 PrPres, whereas the thalamus showed both 
types of PrPres. Among the three samples of the thalamus from this case, two samples 
had only type 1 PrPres and the remaining one sample had both types of PrPres.      
  
The occurrence of both types of PrPres in the brains of individual patients has been 
addressed extensively in previous studies (Collins et al. 2006; Haik et al. 2004; Head 
et al. 2004a; Head et al. 2001; Lewis et al. 2005; Puoti et al. 1999; Schoch et al. 
2006; Uro-Coste et al. 2008). Since the initial report that about 5% of sCJD cases 
had both types of PrPres (Parchi et al. 1999b), the concurrence of both PrPres types in 
the brains of individual patients has been detected in a substantial proportion of sCJD 
cases (Head et al. 2004a; Puoti et al. 1999; Schoch et al. 2006; Uro-Coste et al. 
2008). The use of mAbs that specifically recognize type 1 PrPres led to the suggestion 
that all CJD cases associated with type 2 PrPres could contain type 1 PrPres 
(Polymenidou et al. 2005; Yull et al. 2006), which was questioned in a later study in 
relation to partially cleaved PrPSc fragments (Notari et al. 2007). Two recent studies 
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that examined extensive samples of different brain areas from larger scale of cases 
have shown that there are sCJD cases associated with only type 1 PrPres or type 2 
PrPres; the sCJD cases with mixed PrPres types account for 30 ~ 40% in both studies 
(Cali et al. 2009; Parchi et al. 2009b), which is broadly consistent with the 
prevalence reported from some of previous studies (Head et al. 2004a; Puoti et al. 
1999; Uro-Coste et al. 2008).  
 
Although only one of the 12 sCJD cases examined in this study was shown to contain 
both types of PrPres, the coexistence of PrPres types may be found in more cases. 
When the mAb 3F4 that binds to both types of PrPres is used, the conventional 
western blot system has been shown to have limited analytical sensitivity in detecting 
the concurrence of PrPres types in individual samples (Polymenidou et al. 2005; Yull 
et al. 2006); the two studies performed independently failed to distinguish type 1 
PrPres representing up to 20~40% of total PrPres in artificial mixtures of both PrPres 
types. A more refined method employing a high resolution gel electrophoresis 
system or the use of more discriminatory antibodies may help detect the coexistence 
of PrPres types more accurately (Notari et al. 2007; Yuan et al. 2008). Furthermore, 
in many of the sCJD cases showing type coexistence, one minor PrPres type was 
found focally in very limited brain areas in contrast to the other predominant PrPres 
type found in most affected areas (Cali et al. 2009; Head et al. 2004a; Parchi et al. 
2009b). Although the brain region of thalamus contained in this study is one of the 
areas showing type co-occurrence most frequently (Cali et al. 2009; Parchi et al. 
2009b), the analysis of more brain areas may reveal the presence of type concurrence 
in additional cases.   
 
2.4.4.2 PrPres migrating between type 1 and type 2 standards 
The Western blot analysis of PK-treated brain homogenate from the thalamus of 
MV2-1 (a typical MV2 case with kuru plaques) revealed the presence of PK-resistant 
fragments migrating faster than type 1, but slower than type 2 standards. The band 
representing the unglycosylated fragment of this PrPres species appears to migrate at 
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~20 KDa. In MV2 subtype of sCJD, the existence of a PK-resistant core fragment 
migrating at 20 KDa in addition to typical type 2 PrPres was described previously 
(Notari et al. 2007). While the 20 KDa fragment has been always found as a doublet 
in association with type 2 PrPres in the previous studies (Notari et al. 2007; Parchi et 
al. 2009b), the 20 KDa fragment found in this study is present independently from 
type 2 PrPres. 
 
2.4.4.3 PK-resistant fragment of PrPSc with low molecular mass comparable to 
that of GSS 
In the thalamus from the MV2-2 case, a low molecular weight PK-resistant fragment 
is observed in addition to the typical three PrPres bands. The gel mobility of this small 
proteolytic fragment is similar to that seen in a P102L GSS case, indicating that the 
molecular weight of this small PrP fragment is presumably of ~8 KDa (Parchi et al. 
1998; Piccardo et al. 1998). The PrPres profile seen in the MV2-2 case is closely 
similar to those seen in P102L GSS cases which have typical three PrPres bands in 
addition to a small fragment of ~8 KDa (Parchi et al. 1998; Piccardo et al. 1998). 
Although the proteolytic fragment of PrPSc of 7 - 8 KDa is well known to be 
characteristic of GSS, PrPres species of similar molecular weight has been 
occasionally detected in other phenotypes of human prion disease (Piccardo 1998, 
Kascsak 1993, Krebs 2007). Interestingly, previous studies which extensively 
examined PK-resistant fragments of PrPSc in sCJD brains have not detected this 
PrPres species (Cali et al. 2009; Notari et al. 2008; Parchi et al. 1999b; Parchi et al. 
2009b); C-terminal fragments of PrPSc migrating to 12 - 13 KDa which are not 
detectable by mAb 3F4 due to the cleavage of its epitope were the smallest form of 
PrPres identified in these studies. The prevalence of the PrPSc fragment of  ~8 KDa in 
sCJD brains remains to be determined. Since the full genotyping of PrP could not be 
performed due to the absence of consent in this MV patient with low molecular 
weigh fragment of PrP, the possibility of a pathogenic mutation in the PRNP gene 
can not be fully excluded.  
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2.4.5 Speculation on potential limitation associated case selection 
CJD cases examined in this study were mainly selected based on the availability of 
half-frozen brain, consent for research use of brain material, typical cases of a 
particular disease phenotype of interest. Since clinical details such as age at onset 
and disease duration are important parameters distinguishing vCJD from sCJD or 
between various subtypes of sCJD (Brandel et al. 2009; Parchi et al. 1999b; Will et 
al. 1996) and clinically typical cases in each  phenotype were selected, difference in 
age at clinical onset and/or disease duration between vCJD and sCJD is inevitable. 
Additionally, the proportion of male and female cases was not equivalent with male 
patients occupying ~ 70% of cases in both vCJD and sCJD. Age at clinical onset may 
influence disease duration in both vCJD and sCJD (Pocchiari et al. 2004); patients 
who developed clinical signs at a younger age resulted in longer survival time in both 
CJD phenotypes. Similarly, gender can also have influence on disease progress and 
female patients were found to survive longer than male patients (Pocchiari et al. 
2004). Although there are no studies showing that these clinical parameters influence 
PrPSc biochemistry (conventionally represented by PrPres type), their possible 
influence on topography of PrPSc accumulation in the brain or on the amount of PK-
sensitive PrPSc cannot be fully excluded given their influence on disease progression.  
 
Another parameter which was difficult to control during case selection is post 
mortem interval (PMI). PMI was in the range of 1 - 5 days except for three sCJD 
cases and one GSS cases whose PMI was 6 days or longer. PMI in one sCJD was 10 
days. Considering that PrPSc is a highly robust molecule showing strong resistance to 
conventional chemical and physical treatments, the results on PrPSc biochemistry are 
not thought to be substantially influenced by variation in PMI. This view is 
supported by studies showing that the intensity of PrPres signals from BSE-affected 
cattle brains remained unchanged after controlled autolysis at 37°C up to 7 days 
(Chaplin et al. 2002; Hayashi et al. 2004). In comparison, PrPC is a labile molecule 
and thus it appears possible long delay in post mortem may influence the abundance 
of PrPC. However, any direct correlation between PMI and PrPC abundance was not 
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observed in this study. For example, the level of PrPC was similar between MM1 
cases that greatly differ in PMI (1 - 2 days versus 10 days). Accordingly, it remains 
to be determined how exactly PrPC level in brain samples might be influenced by 
different PMI.   
 
 
2.4.6 Analytical sensitivity of CDI 
In this study, 34 CJD cases (12 vCJD and 22 sCJD cases) were examined by CDI 
without using NaPTA precipitation. Although this study was not designed for 
diagnostic applications, all CJD cases except for one MM1 case were found to be 
distinguishable from control cases even without the use of a NaPTA precipitation 
step. The analytical sensitivity was 97% (33/34 cases). Western blot analysis for the 
detection of PrPres for this MM1 case (or sample) was not performed, but its PrPres 
level is believed to be quite low given the overall correlation between the two 
biochemical criteria that define disease-associated PrP.   
 
CDI assay variability that is expressed as the coefficient of variation (CV) was less 
than 5.2% (intra-assay) or ranged from 6.6% to 20.4% (inter-assay), which is largely 
within the acceptable range of less than 20% (Maple et al. 2004; Pombo et al. 2004). 
Additionally, the nature of this chapter is to compare the two biochemical criteria as 
discussed before. Nine brain samples from each CJD case were examined by CDI in 
the same plate or were run on the same gel, and then the results of the two methods 
were directly compared on a case-to-case basis. Therefore, inter-plate variation of 
CDI is thought to be less important when compared to intra-plate variation. Similarly, 
CDI results in other chapters were also presented in normalized forms (D/N ratio in 
Chapter 3 or fractional denaturation in Chapter 4), which would serve to minimize 
the effect of inter-plate variation.    
 
2.4.7 Mixed phenotypes in neuropathology: implication for sCJD 
classification 
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Among the 6 sCJD cases (3 MM and 3 MV) in which only type 1 PrPres was 
detectable, three cases (1 MM and 2 MV) have shown focally confluent type of 
vacuoles along with perivacuolar PrP deposition, in addition to the predominant 
phenotype composed of fine spongiform degeneration and synaptic immunostaining. 
Although only type 2 PrPres was detectable in the three MM2 cases, the mixture of 
both phenotypes of neuropathology is easily identifiable in all three cases. While two 
of the three MV2 cases have typical pathological features of this subtype 
characterized by the presence of kuru plaques in the cerebellum, the remaining MV2 
case (MV2-2) with mixed PrPres types and a small proteolytic fragment of ~ 8 KDa 
does not have any detectable kuru plaques and has neuropathological features more 
similar to the MM2 subtype of sCJD (Parchi et al. 1999b; Parchi et al. 1996).   
 
Although the coexistence of PrPres types was not detected in any of the sCJD cases 
showing a mixture of synaptic and perivacuolar pattern of staining, the lack of 
detection of mixed PrPres types can be associated with analytical sensitivity or 
sampling issue as discussed in this study (see section 2.4.4.1) or in previous studies 
(Cali et al. 2009; Head et al. 2004a; Parchi et al. 2009b; Yull et al. 2006).  In a 
recent study, Parchi et al. proposed that sCJD cases showing a mixed synaptic and 
perivacuolar pattern of immunostaining could be classified into "mixed subtypes" 
even without the detection of co-occurrence of PrPres types in Western blot (Parchi et 
al. 2009b). Therefore, some of cases examined in this study (one of the three MM1, 
two of three MV1 and all MM2 cases) could be classified into "mixed" subtypes, as 
described in the recent studies (Cali et al. 2009; Parchi et al. 2009b).  
 
The MV2-2 case showing pathological features resembling the MM2 subtype of 
sCJD deserves further comment. Although the large, confluent vacuoles and 
perivacuolar immunostaining are observable in a subgroup of MV2 cases with kuru 
plaques (Parchi et al. 1999b; Parchi et al. 2009b), to the best of my knowledge, a 
MV2 case that shows typical MM2 pathology without any kuru plaque has not yet 
been reported. Given the biochemical and neuropathological profiles identified in 
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this case, it is questionable whether this case can fit in with even an updated version 
of the molecular classification system of sCJD (Parchi et al. 2009b). 
 
2.4.8 Summary 
In summary, this chapter has addressed the relation of the two biochemical criteria 
(CDI versus WB following limited proteolysis) using multiple brain samples from 
various forms of CJD brains. Despite overall agreement between the two 
biochemical measurements, occasional disagreement between PrPSc (inferred from 
CDI [D-N] value) and PrPres (WB following limited proteolysis) was also evident. 
The analysis of CJD brain samples by CDI following proteolysis has shown that a 
significant proportion of PrPSc is susceptible to this treatment. Therefore, the 
occasional discordance between PrPSc and PrPres could be explained by non-uniform 
distribution of PK-sensitive PrPSc to total PrPSc in individual brains. Additionally, 
one MV2 sCJD case which showed the topography of abnormal PrP similar to those 
seen MM2 cases displayed pathological features resembling MM2 subtype of sCJD. 
These results indicate that Western blot analysis of PK-resistant fragments of PrPSc is 
an incomplete description of PrPSc present in CJD brains and that further complexity 











Distribution profiles of different        
PrP conformers after fractionation    




The hallmark of prion disease is the accumulation of pathogenic disease-associated 
isoform of PrP (PrPSc), which is thought to be the main component of prions 
(Prusiner 1998). PrPSc can be distinguished from cellular isoform of PrP (PrPC) by its 
biochemical properties. While α-helix-rich PrPC is detergent-soluble and sensitive to 
PK, ß-sheet-rich PrPSc is detergent-insoluble and partially resistant to PK (Caughey 
et al. 1991; Meyer et al. 1986; Pan et al. 1993).  
 
In contrast to monomeric or dimeric PrPC (Meyer et al. 2000; Pergami et al. 1996), 
PrPSc is an assembled multimer that often forms amyloid plaques in the brain. The 
size of PrPSc can range from small oligomers to large aggregates (Tzaban et al. 2002; 
Yuan et al. 2006) and may vary between different disease phenotypes (Gambetti et al. 
2008). When separated in 10 - 60% sucrose step gradients, PrP molecules from 
prion-infected brains were dispersed throughout the gradients; in contrast, PrPC 
molecules from normal brains were observed only in the top few fractions of the 
gradients (Pan et al. 2004; Pan et al. 2005a; Pan et al. 2005c; Tzaban et al. 2002). In 
diseased brains, PrP species which migrated to heavy bottom fractions of the 10 - 
60% gradient were partially resistant to proteolysis, whereas those recovered in the 
other fractions were susceptible to PK (Tzaban et al. 2002). Although the separation 
of protein in the velocity sedimentation in sucrose gradients is known to be a 
function of distinct molecular densities, sizes and shapes, the sedimentation property 
of PrP molecules in the 10 - 60% sucrose gradient was shown to reflect their sizes, as 
determined by size exclusion chromatography (Tzaban et al. 2002; Yuan et al. 2006). 
In another study performed by Pastrana et al., a PK-sensitive fraction of PrPSc was 
first obtained based on its detergent-insolubility and then subject to the 10 - 60% 
sucrose gradient (Pastrana et al. 2006). This PK-sensitive fraction of PrPSc was 
mainly present in the light upper fractions of the gradient, whereas PK-resistant PrPSc 
mostly migrated to the denser bottom fractions (Pastrana et al. 2006); moreover, the 
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PK-sensitive fraction of PrPSc was shown to have the ability to convert PrPC into 
PrPSc in PMCA.  
 
In this study, the homogenates from neurological control brains and CJD brains were 
subject to 10 - 60% sucrose step gradients in order to examine the distribution 
profiles of different PrP conformers in the gradients. For the analysis of CJD brains, 
tissues of frontal cortex from vCJD and MM1 sCJD were compared. Additionally, in 
vCJD, tissues from two other brain regions (cerebellum and thalamus) were also 
examined. Following fractionation in the sucrose gradients, the distribution profiles 
of PrPC in control and CJD brains were determined by CDI using native aliquots of 
individual fractions. The distribution of PrPSc in the sucrose gradients was inferred 
from CDI D/N ratios. In some cases, the fractionated samples from CJD samples 
were examined by CDI following mild proteolysis with 2.5µg/ml PK. The existence 
of PrPres in individual fractions was displayed by Western blotting following 
treatment with 50µg/ml PK.  
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3.2 Materials and methods  
 
3.2.1 Human brain materials  
Seven variant CJD (vCJD) cases, six cases of MM1 subtype of sporadic cases (MM1 
sCJD) and five control (non-CJD) cases with neurological symptoms were examined. 
All of these CJD and control cases were also analysed in Chapter 2. Their clinical, 
genetic and biochemical details were shown in Tables 2.1, 2.2 and 2.4 in Chapter 2. 
In all instances the tissues used were grey matter-enriched frontal cortex (FC) and, 
additionally, cerebellar cortex (Cb) and thalamus (Th) in vCJD, dissected from 
frozen half-brain specimens. 
 
3.2.2 Methods  
 
Preparation of brain tissue 
Brain homogenates were prepared in nine volumes (w/v) of phosphate-buffered 
saline (PBS), pH 7.4 by two cycles of homogenization in the FastPrep instrument 
(Qbiogene). Each cycle was run for 45 seconds at the speed of 6.5ms-1 with the 
interval of 10 minutes between the runs. The samples were aliquoted and stored at -
80°C until use.  
 
Velocity sedimentation in sucrose step gradient 
Fractionation in sucrose step gradient was performed as described previously 
(Tzaban et al. 2002) with minor modifications. The 10% brain homogenate in PBS 
was mixed with equal volume of lysis buffer (4% n-octyl-β-D-glucopyranoside 
[NOG] in PBS) and then incubated for 30 minutes in ice. After clarifying the sample 
for 1 minute at 3,800 × g to remove insoluble material, the supernatant was incubated 
for 30 minutes on ice in the presence of 1% Sarcosyl, followed by carefully loading 
on top of a 10 - 60% sucrose step gradient. Gradient was prepared in a 5ml 
ultracentrifuge tube (Beckman Coulter) from 745µl of each of the following sucrose 
concentration: 10, 15, 20, 25, 30, 60% in TNS buffer (20mM Tris-HCl, pH 7.5, 
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150mM NaCl, 1% Sarcosyl). The samples were centrifuged for 1 hour at 4°C at 
50,000 rpm (gaverage = 200,000 × g) in a MLS-50 rotor in the Optima MAX 
ultracentrifuge (Beckman Coulter). Eleven fractions of 450µl were then collected 
from the top of the tube and were stored at -80°C. In some cases, aliquots of 
collected fractions were stored at -80°C  
 
Conformation-dependent immunoassay (CDI)  
Each fraction from the sucrose gradient was prepared in two parts for CDI 
application. On some occasions, samples were assayed by CDI after digestion with 
2.5µg/ml or 50µg/ml PK for 1 hour at 37°C. One part was mixed with same volume 
of PBS containing Complete EDTA-free® protease inhibitors (native sample, N) and 
the other part was mixed with the same volume of 4M GdnHCl and incubated for 6 
minutes at 81°C (denatured sample, D). Both D and N samples were adjusted using 
distilled water containing EDTA-free protease inhibitors to a final concentration of 
GdnHCl of 0.35M in 435µl final volume. Subsequently, CDI was performed as 
described in section 2.2.3 without any modification.  
 
CDI D/N ratio  
TRF counts obtained from CDI were used to generate D/N ratios (Safar et al. 1998; 
Safar et al. 2005a). The D/N ratios were obtained by dividing time-resolved 
fluorescence counts (TRF) counts of denatured samples (D) by the TRF counts of the 
corresponding native samples (N).  
 
Western blot (WB) analysis  
Polyacrylamide gel electrophoresis was carried out using NuPAGE Novex gel 
system (Invitrogen) as described in section 2.2.3. Each fraction from the sucrose 
gradient was analysed before or after digestion with 2.5µg/ml or 50µg/ml PK for 1 
hour at 37°C. Undigested or digested samples were mixed with NuPAGE LDS 4X 
sample buffer to a final concentration of 1X. The samples were incubated for 10 
minutes at 100°C and then separated on a 10% Bis-Tris NuPAGE gel. The separated 
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proteins were transferred to polyvinylidene difluoride (PVDF) membrane. 
Subsequent immunodetection of PrP and quantitative analysis of the blots were 
performed as described in section 2.2.3 without any modification. 
 
Coomassie blue staining 
Samples from each fraction were incubated for 10 minutes at 100°C in the presence 
of 1X sample buffer and electrophoresed on a 10% Bis-Tris NuPAGE gel 
(Invitrogen). After electrophoresis, separated proteins in the gel were stained with 
0.1% Coomassie blue in 10% acetic acid and 45% methanol for 2 hours and then 




Total protein concentration in the fractionated samples was determined by using the 
Bio-Rad DC Protein Assay according to the manufacturer’s instruction. Aliquots 
from individual fractions were analysed by the protein assay and then read at 750nm 
on a spectrometer. Total protein concentration in individual fractions was calculated 
using a standard curve which was generated using Bovine Serum Albumin (BSA) 




Statistical analysis was performed with the student's t-test or one-way ANOVA in 
Microsoft® Office Excel. 
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3.3 Results  
 
3.3.1 Distribution profiles of PrPC, total PrP and PrPSc in sucrose gradient 
The distribution profiles of different PrP conformers in sucrose step gradients were 
investigated using frontal cortex (FC) tissue from CJD brains and neurological 
controls. In vCJD, additional cerebellum (Cb) and thalamus (Th) tissues were also 
analysed in order to compare the sedimentation profiles of PrP from different regions 
of vCJD-affected brains. Brain lysates prepared from non-CJD, vCJD and MM1 
sCJD brains were loaded on a 10 – 60% sucrose gradient and separated by 
ultracentrifugation at 200,000 × g for 60 minutes. Eleven fractions of 450µl were 
collected from top to bottom after velocity sedimentation and analysed by 
conformation-dependent immunoassay (CDI). CDI fluorescence counts obtained 
from an aliquot in the native state represent cellular isoform of PrP (PrPC), whereas 
CDI results obtained from denatured aliquots represent total PrP present in a sample 
irrespective of their conformations (Safar et al. 1998). The distribution of disease-
associated PrP conformer (PrPSc) in the sucrose gradient was inferred from the ratio 
of the time-resolved fluorescence (TRF) counts between native and denatured 
aliquots (D/N ratio) (Bellon et al. 2003; Safar et al. 1998). 
 
3.3.1.1 Distribution profiles of PrPC in sucrose gradient 
FC samples from five non-CJD brains were analysed to investigate the distribution of 
PrPC after fractionation in the sucrose gradients. The distribution of PrPC in each 
fraction was measured by CDI in the native state. Although considerable variations 
in the level of PrPC were present between cases, PrPC was mostly detected in top few 
fractions (Figure 3.1a). When the relative distribution of PrPC between fractions was 
expressed as a percentage of the total in all fractions, it became clearer that PrPC was 
mostly present in the light fractions (fraction 1 ~ fraction 3) in each case (Figure 
3.1b). The amount of PrP recovered in the top three fractions was around 90% of 
total PrP, irrespective of case when determined by CDI using native aliquots. In the 
intermediate and bottom fractions of the gradient, however, trace of CDI signals was 
 138
also detectable. These results indicate that cellular isoform of PrP present in non-CJD 
brains mostly failed to sediment and stayed in the light top fractions after 
ultracentrifugation in the sucrose gradient.  
 
In order to examine the sedimentation profiles of PrPC present in CJD brains, FC 
tissues from seven vCJD cases and six MM1 sCJD cases were fractionated by 
centrifugation in the 10 – 60% sucrose step gradient. For the three of the seven vCJD 
cases, Cb and Th were also analysed for comparison with FC. When fractions from 
vCJD FC samples were assayed by CDI in the native state, most fluorescence counts 
were detected in the top few fractions indicating that PrPC from vCJD FC also failed 
to sediment after centrifugation in the sucrose gradients (Figure 3.2a). Despite the 
variation in the level of PrPC, the normalized distribution profiles of PrPC were 
similar between vCJD cases and were not distinguishable from those of non-CJD 
controls (Figure 3.2b; compare it with Figure 3.1b). When samples from Cb and Th 
of vCJD brains were separated in the gradients and analysed in the same way, the 
distribution profiles of PrPC were similar to those of vCJD FC, although a minor 
fraction of PrPC from Th samples was recovered in the intermediate and bottom 
fractions (black and striped bars in Figure 3.4a). PrPC from FC of MM1 sCJD brains 
was also predominantly recovered in the light, top fractions of the gradients, 
although normalization also revealed the presence of a small proportion of PrPC in 
the intermediate and bottom fractions (Figure 3.3). It is of note that, except for one 
case, the levels of PrPC from MM1 sCJD brains were lower than those of non-CJD 
brains and vCJD brains (compare Figure 3.3a with Figures 3.1a and 3.2a). 
 
For further analysis, the eleven fractions from the gradient were categorized into 
three groups. The fractions 1 to 3 (in which most of PrPC was found) was grouped as 
“top fractions” and fractions 9 to 11 were grouped into “bottom fractions.” The 
remaining fractions (fractions 4 - 8) were grouped as “intermediate fractions.”  As 
described above, the distribution profiles of vCJD FC or Cb were similar to that of 
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non-CJD FC, with ~90% of PrPC being recovered in the top fractions (P in the top 
fraction = 0.135) (white, grey and black bars in Figure 3.4b).  
 
In contrast, in vCJD Th, only 60% of PrPC molecules were present in the top 
fractions, with ~20% of PrPC being recovered in the intermediate and bottom 
fractions (striped bars in Figure 3.4b). The distribution profile of vCJD Th was 
significantly different when compared to those of the two other vCJD regions (P < 
0.0001 in top and intermediate fractions; P = 0.001 in bottom fractions). The results 
from FC of MM1 sCJD were similar to that of vCJD Th (P > 0.05 in all three 
grouped fractions) (dotted bars in Figure 3.4b).      
 
Collectively, the analysis of fractionated samples by CDI in the native state showed 
that cellular isoform of PrP from both non-CJD and CJD brains remains mainly in 
the top fractions of the sucrose gradients, although small amounts of PrPC were also 
identifiable in the intermediate or bottom fractions from Th samples of vCJD and FC 



















Figure 3.1 Distribution profiles of PrPC from FC of non-CJD brains after 
fractionation in sucrose step gradient. Brain lysates from the frontal cortex of 
neurological control (non-CJD) brains were fractionated in 10 – 60% sucrose step 
gradients and eleven fractions were collected from top to bottom. Each fraction was 
analysed by CDI in the native state to measure the amount of PrPC (a) and the 
relative distribution of PrPC between fractions was expressed as a percentage (%) of 
the total in all fractions (b). Each bar represents individual cases (white bars: non-
CJD1; grey bars: non-CJD2; black bars: non-CJD3; striped bars: non-CJD4; dotted 

































































Figure 3.2 Distribution profiles of PrPC from FC of vCJD brains after 
fractionation in sucrose step gradient. Brain lysates from the frontal cortex of 
vCJD-affected brains were fractionated in 10 – 60% sucrose step gradients and 
eleven fractions were collected from top to bottom. Each fraction was analysed by 
CDI in the native state to measure the amount of PrPC (a) and the relative distribution 
of PrPC between fractions was expressed as a percentage (%) of the total in all 
fractions (b). Each bar represents individual cases (white bars: vCJD1; light grey 
bars: vCJD2; black bars: vCJD3; dark grey bars: vCJD4; striped bars: vCJD5, dotted 


































































Figure 3.3 Distribution profiles of PrPC from FC of MM1 sCJD brains after 
fractionation in sucrose step gradient. Brain lysates from the frontal cortex of 
MM1 sCJD brains were fractionated in 10 – 60% sucrose step gradients and eleven 
fractions were collected from top to bottom. Each fraction was analysed by CDI in 
the native state to measure the amount of PrPC (a) and the relative distribution of 
PrPC between fractions was expressed as a percentage (%) of the total in all fractions. 
Each bar represents individual cases (white bar: MM1-1; light grey bar: MM1-2; 
black bar: MM1-6; dark grey bark: MM1-8; striped bar: MM1-10; dotted bar: MM1-




































































Figure 3.4 Comparison of PrPC distribution in sucrose step gradient between 
non-CJD and CJD brains. Eleven fractions were obtained after ultracentrifugation 
of brain lysates in the sucrose step gradients. (a) The amount of PrPC in each fraction 
investigated by CDI in the native state was expressed as a percentage (%) to the sum 
of eleven fractions. (b) Eleven fractions were categorized into three groups (top 
fractions: fractions 1 ~ 3; intermediate fractions: fractions 4 ~ 8; bottom fractions: 
fractions 9 ~ 11) and the distribution of PrP between groups was expressed as a 
percentage (%) to the sum of the three groups. Data shown represent the average ± 
S.D. obtained from five cases of FC of control (white bars), from seven cases of 
vCJD FC (grey bars) or from six cases of FC of MM1 sCJD (dotted bars). In vCJD 
Cb (black bars) and vCJD Th (striped bars), data shown represent the average ± S.D. 





















































3.3.1.2 Distribution profiles of total PrP in sucrose gradient  
In order to examine the distribution of total PrP in the sucrose gradient after velocity 
sedimentation, aliquots of fractionated samples were assayed by CDI after 
denaturation by incubation at 81° for 6 minutes in the presence of 4M GdnHCl. In 
non-CJD brains, similar to the results obtained from native aliquots, more than 90% 
of total PrP was recovered in light factions of the gradients (fractions 1 ~ 3) and trace 
of CDI signals was also dispersed in the intermediate and bottom fractions (Figure 
3.5a). Thus, in case of the neurological control brains without prion involvement in 
their pathogenesis, the distribution profiles of PrP obtained in the two different 
folding states were very similar to each other (compare Figure 3.5a with Figure 3.1b).  
 
In contrast, samples from FC of vCJD brains showed clearly distinct results in CDI 
measurement between native and denatured states. While fluorescence counts 
obtained from native samples were mostly present in the top three fractions (Figure 
3.2b), CDI signals detected in those top fractions after denaturation were reduced to 
less than 50% of the total recovered in all fractions; the remainder was mostly 
recovered in the bottom fractions (fractions 9 ~ 11) in which only a trace CDI signal 
was detected in the native state (Figure 3.5b). Thus, the distribution of total PrP in 
the sucrose gradient emerged in a bipolar pattern when fractionated samples from 
vCJD FC were investigated by CDI in the denatured state. An exception to this 
“bipolar pattern” was observed in a sample from vCJD3 FC; more than 80% of total 
PrP signals were recovered in the top few fractions when measured by CDI in the 
denatured state, which was similar to the results obtained from native aliquots (black 
bars of figure 3.5b; compare them with black bars of Figure 3.2b). 
 
In order to further examine the distribution of total PrP in the gradients, fractionated 
samples from additional regions of vCJD brains and FC of MM1 sCJD brains were 
assayed by CDI in the denatured state. In vCJD Cb, the distribution profiles of total 
PrP emerged in a “bipolar” pattern in the gradients (black bars in Figure 3.6a), which 
was similar to that found in FC of vCJD brains. In comparison, relatively higher 
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proportion of PrP signal was detected in the intermediate fractions of the gradients 
when samples from vCJD Th or from FC of MM1 sCJD were analysed in the same 
way (striped and dotted bars in Figure 3.6a).  To compare the level of PrP 
sedimentation to intermediate fractions more generally, the eleven fractions from the 
gradients were categorized into three groups. The fractions 1 to 3 in which most of 
PrPC remained were grouped as “top fractions” and the fractions 9 to 11 in which PrP 
molecules were mostly detected by CDI only after denaturation were grouped as 
“bottom fractions.” The remaining fractions (fractions 4 ~ 8) were grouped as 
“intermediate fractions.” The comparison of levels of PrP in these three groups 
showed more clearly the relative abundance of PrP molecules in the intermediate 
fractions of vCJD Th and of FC of MM1 sCJD (Figure 3.6b). While the levels of PrP 
molecules detected in the intermediate fractions from FC and Cb of vCJD brains 
were less than 10%, they were higher than 20% in the intermediate fractions from Th 
of vCJD brains and FC of MM1 sCJD brains. Statistical analysis confirmed that this 
difference in the intermediate fractions was significant with P values of <0.001 
(vCJD Th versus vCJD FC/Cb) and of <0.01 (FC of MM1 sCJD versus vCJD 
FC/Cb), respectively.  
 
In summary, in the non-CJD control brains containing only PrPC, distribution profiles 
of PrP were similar when measured in the native or denatured states. When 
fractionated samples from CJD brains were assayed by CDI, significant differences 
were observed between the two different folding states; newly detected PrP species 
after denaturation was mainly present in the bottom fractions of the gradient. Given 
that the recognition site of mAb 3F4 employed as a detector in the CDI is hidden in 
native PrPSc but becomes accessible after denaturation, newly detected CDI signals 
after denaturation (mainly in bottom fractions) were thought to be mostly attributed 
to PrPSc present in those bottom fractions. In this context, the similarity of 
sedimentation profiles between PrPC and total PrP observed in the vCJD3 FC sample 




























Figure 3.5 Distribution of total PrP in sucrose step gradient. Brain lysates from 
frontal cortex of non-CJD brains (a) or vCJD brains (b) were fractionated in 10 – 
60% sucrose step gradients and eleven fractions were collected from top to bottom. 
The amounts of total PrP present in individual fractions were determined by CDI in 
the denatured state and their relative distribution between fractions was expressed as 
a percentage (%) to the total recovered in all fractions. Each bar represents individual 
cases and their details are described in Figure 3.1 (for [a]) or Figure 3.2 (for [b]). 











































































Figure 3.6 Comparison of the distribution profiles of total PrP in sucrose step 
gradient. Eleven fractions were obtained after ultracentrifugation of brain lysates in 
the sucrose step gradients. The amount of total PrP present in each fraction was 
determined by CDI in the denatured state. (a) The amount of total PrP present in each 
fraction was expressed as a percentage (%) to the sum of eleven fractions. (b) Eleven 
fractions were categorized into three groups (top fractions: fractions 1 ~ 3; 
intermediate fractions: fractions 4 ~ 8; bottom fractions: fractions 9 ~ 11) and the 
distribution of PrP between groups was expressed as a percentage (%) to the sum of 
the three groups. Data shown represent the average ± S.D. obtained from five cases 
of FC of control (white bars), from seven cases of vCJD FC (grey bars) or from six 
cases of FC of MM1 sCJD (dotted bars). In vCJD Cb (black bars) and vCJD Th 
(striped bars), data shown represent the average ± S.D. obtained from three cases. 




















































3.3.1.3 Distribution profiles of PrPSc in sucrose gradient 
The ratio of mAb 3F4 binding to denatured/native PrP was used as an indicator in a 
direct ELISA-formatted CDI for the presence of PrPSc in hamster brains (Safar et al. 
1998). This D/N ratio was also successfully used to detect PrPSc when serially diluted 
human CJD brain samples were semi-purified by NaPTA precipitation and assayed 
by the sandwich format CDI with the mAb Mar-1 as a capture antibody and the 3F4 
as a detector (Bellon et al. 2003). Based on these previous studies, the distribution of 
PrPSc in the sucrose gradient was inferred from CDI D/N ratios which were generated 
by dividing the TRF counts of the denatured aliquots by those of corresponding 
native aliquots. 
 
As shown in figure 3.7a, D/N ratios from FC of the non-CJD brains were similar in 
all fractions of the gradients. The D/N ratios in the top three fractions in which PrPC 
was mostly present were indistinguishable from those in the intermediate or the 
bottom fractions. The ratios were usually lower than 1.5 except for three fractions 
each from three different cases (fraction 10 of non-CJD2, fraction 10 of non-CJD3 
and fraction 2 of non-CJD4). D/N ratios in those three fractions were in the range of 
1.5 ~ 1.8. It is of note that the D/N ratios in normal hamster brains were lower or 
equal to 1.8 and the D/N ratios higher than 1.8 were considered to indicate the 
presence of PrPSc in hamster brains (Safar et al. 1998). A direct comparison of TRF 
counts between the two different folding states from fractions of a non-CJD control 
sample was shown in Figure 3.7b.  
 
To examine the distribution of PrPSc in the sucrose step gradient, D/N ratios of 
fractionated samples from vCJD FC were generated and compared with those of non-
CJD brains. The D/N ratios of top three fractions in all investigated vCJD FC 
samples were in the range of 1.0 to 1.7, which were indistinguishable from the non-
CJD counterparts (Figures 3.8a). The D/N ratios in the intermediate fractions 
(fractions 4 ~ 8) increased slowly as the fractions became heavier and increased 
dramatically in the bottom fractions (fractions 9 ~ 11). Although the D/N ratios in the 
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intermediate fractions were slightly higher than the non-CJD counterparts, the high 
D/N ratios in the bottom fractions compared to the non-CJD counterparts or other 
fractions of vCJD FC were much more obvious (Figures 3.8a). A direct comparison 
of CDI results in the two different folding states from fractions of a vCJD FC sample 
was shown in Figure 3.8b. In case of the vCJD3 sample which showed similarity 
between PrPC distribution and total PrP distribution in the sucrose gradient, the D/N 
ratios in the intermediate fractions were indistinguishable from those of controls; the 
ratios in the bottom fractions were higher than those of non-CJD brains but greatly 
lower than those of the other vCJD cases (black bars in Figure 3.8a). Overall, the 
analysis of fractionated samples by CDI D/N ratio showed that a majority of PrPSc 
from FC of vCJD brains migrated to the bottom fractions of the sucrose gradients 
after ultracentrifugation.    
 
In order to compare the distribution profiles of PrPSc in the gradient between 
different regions of vCJD brains, the CDI D/N ratios were generated from 
fractionated samples of vCJD Cb and vCJD Th. In the fractions from vCJD Cb, the 
pattern of D/N ratios was overall similar to vCJD FC; while the ratios in the top 
fractions were indistinguishable from those of non-CJD counterparts, the ratios in the 
bottom fractions were noticeably higher than those in intermediate fractions (black 
bars in Figures 3.9a and 3.11). In comparison, the pattern of D/N ratios from 
fractions of vCJD Th appeared distinct from those of vCJD FC or Cb. Although the 
D/N ratios in bottom fractions were higher than intermediate fractions, the difference 
between intermediate and bottom fractions appeared less distinct in vCJD Th when 
compared to vCJD FC or Cb (striped bars in Figures 3.9a and 3.11). In addition, the 
D/N ratios from the top fractions of vCJD Th were slightly but measurably higher 
than those of the corresponding fractions from the control brains or from the two 
other regions of vCJD brains (striped bars in Figures 3.9a and 3.11). In two of the 
three vCJD cases in which Th samples were analysed, the D/N ratios were higher 
than 2 in fraction 1 (vCJD1 and vCJD3) and reached to 4.6 and 6.1 in fraction 3, 
respectively. In the remaining case (vCJD2), the ratio was 1.8 in fractions 1 and 2 but 
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increases to 3.1 in fraction 3. Therefore, at least a small portion of PrPSc molecules 
from vCJD Th samples was found to remain in the light fractions after 
ultracentrifugation in the sucrose gradient. A direct comparison of CDI results in the 
two different folding states from fractions of a vCJD Th sample was shown in Figure 
3.9b. Overall, the analysis based on CDI D/N ratios suggests that PrPSc molecules 
from vCJD Th distributed more evenly throughout the sucrose gradient compared to 
those from vCJD FC or Cb.  
 
In order to address the phenotypic influence on the sedimentation profiles of PrPSc, 
the CDI D/N ratios were generated from fractions of FC of MM1 sCJD and 
compared with those of vCJD FC. In the top fractions, the D/N ratios were 
undistinguishable from those of non-CJD FC without showing any indication of the 
presence of PrPSc (Figures 3.10a). The ratios began to increase gradually from 
fraction 4 and then increased dramatically in the bottom fractions, which were 
similar to the pattern of D/N ratios of vCJD FC (dotted bars in Figure 3.11). A direct 
comparison of CDI results in the two different folding states from fractions of a FC 
sample of MM1 sCJD was shown in Figure 3.10b. However, despite this overall 
pattern of the D/N ratios, variations were also easily recognizable between cases of 
MM1 sCJD. For example, the D/N ratios were relatively similar between 
intermediate and bottom fractions in MM1-1 in which the D/N ratios were low in the 
bottom fractions compared to others (white bars of Figure 3.10a). Therefore, it 
appears that the relative distribution of PrPSc between fractions varied between cases 
and the predominant abundance of PrPSc in the heavy bottom fractions may not be 
the rule in FC of MM1 sCJD.  
 
In summary, when brain lysates from CJD brains were subjected to sedimentation in 
the 10 – 60% sucrose gradients, a majority of PrPSc migrated to the bottom heavy 
fractions (fractions 9 ~11) judging from CDI D/N ratios. A minor fraction of PrPSc 
was also present in the intermediate fractions (fractions 4 ~ 8). In the top fractions, 
the presence of PrPSc was also identified only in vCJD Th; it is not clear, however, 
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whether or not PrPSc is present in a low level in the top fractions from other regions 
of vCJD or from FC of MM1 sCJD because the presence of high levels of PrPC in 


















Figure 3.7 CDI D/N ratios for fractions from FC of non-CJD brains. (a) The CDI 
results on fractionated samples from FC of non-CJD brains were described in 3.3.1.1 
(for native samples) and in 3.3.1.2 (for denatured samples). The CDI D/N ratios were 
calculated by dividing TRF counts of denatured samples by the counts of the 
corresponding native samples. Each bar represents individual cases and their details 
were described in Figure 3.1. (b) The CDI TRF counts from fractions of a control 
brain (non-CJD3) were directly compared between the native (white bars) and 

























































Figure 3.8 CDI D/N ratios for fractions from FC of vCJD brains. (a) The CDI 
results on fractionated samples from FC of vCJD brains were described in 3.3.1.1 
(for native samples) and in 3.3.1.2 (for denatured samples). The CDI D/N ratios were 
calculated by dividing TRF counts of denatured samples by the counts of the 
corresponding native samples. Each bar represents individual cases and their details 
were described in Figures 3.2. (b) The CDI TRF counts from fractions of FC tissue 
of a vCJD brain (vCJD9) were directly compared between the native (white bars) and 























































Figure 3.9 Comparison CDI D/N ratios between fractions derived from different 
regions of a vCJD brain. (a) The D/N ratios for eleven fractions from different 
regions of a vCJD brain (vCJD1) were generated by dividing TRF counts of 
denatured samples by the counts of the corresponding native samples. Grey bars: 
vCJD FC; Black bars: vCJD Cb; Striped bars: vCJD Th. (b) The CDI TRF counts 
from fractions of Th tissue of vCJD1 were directly compared between the native 























































Figure 3.10 CDI D/N ratios for fractions from FC of MM1 sCJD brains. (a) The 
D/N ratios for eleven fractions from FC of MM1 sCJD brains were generated by 
dividing TRF counts of denatured samples by the counts of the corresponding native 
samples. Each bar represents individual cases and their details were described in 
Figure 3.3. (b) The CDI TRF counts from fractions of FC tissue of a MM1 sCJD case 
(MM1-8) were directly compared between the native (white bars) and denatured 






















































Figure 3.11 Comparison of CDI D/N ratios for fractions derived from different 
regions of vCJD brains and FC of MM1 sCJD brains. The CDI D/N ratios were 
calculated by dividing TRF counts of denatured samples by the counts of the 
corresponding native samples. Data shown represent the average ± S.D. obtained 
from five cases of FC of control (white bars), from seven cases of vCJD FC (grey 
bars) or from six cases of FC of MM1 sCJD (dotted bars). In vCJD Cb (black bars) 
and vCJD Th (striped bars), data shown represent the average ± S.D. obtained from 




























3.3.2 Distribution profiles of PrPSc in sucrose gradient after mild proteolysis 
As shown in 3.3.1.1, PrPC in both non-CJD and CJD brains stays mostly in light top 
fractions of the sucrose gradient. If low levels of PrPSc are present in the top fractions, 
the increase of CDI TRF counts after denaturation may not be sufficient for the D/N 
ratio to be distinguishable from those of non-CJD brains. In this context, the presence 
of PrPSc in the top fractions of the gradient was further investigated after digesting 
PrPC in the fractionated samples with mild proteolysis.  
 
3.3.2.1 Effect of PK treatment to PrP conformers in fractionated samples 
For the analysis of the effect of PK treatment, first, the fractionated samples from 
two neurological control brains were digested with 2.5µg/ml PK for 1 hour at 37°C 
and then assayed by CDI. When the CDI signals in the denatured state were 
compared before and after the proteolysis, only background levels of signals were 
detected after proteolysis indicating that the PrPC present in the non-CJD fractions 
was fully susceptible to this proteolysis under these conditions (Figure 3.12).  
 
Next, the fractionated samples from different areas of a vCJD brain were digested 
with 2.5µg/ml PK or 50µg/ml PK for 1 hour at 37°C and then assayed by CDI. The 
fluorescence signals from native samples which were mainly present in the top few 
fractions largely disappeared after PK digestion at 2.5µg/ml, reflecting the high 
susceptibility of PrPC to this condition of proteolysis (upper row in Figure 3.13). 
When the samples digested with 2.5µg/ml PK were analysed after denaturation, PrP 
immunoreactivity was not detectable in the top three fractions from vCJD FC or 
vCJD Cb; in comparison, PrP signals were readily detectable in those top fractions 
from vCJD Th at a third to a quarter of the level detected prior to digestion (grey bars 
in bottom row of Figure 3.13). In the intermediate and bottom fractions digested with 
2.5µg/ml PK, about a third to a half of PrP signals remained, irrespective of brain 
regions (grey bars in bottom row of Figure 3.13). Following the treatment with 
50µg/ml PK, PrP signals were further reduced to a great extent. In vCJD FC and Cb, 
PrP signals were barely detectable only in bottom few fractions; in vCJD Th, PrP 
 158
signals were present in all fractions but their levels were only 10 ~ 30% of those 
treated with 2.5 µg/ml PK except for fraction 10 (black bars in bottom row of Figure 
3.13).  
 
Collectively, the results in this section showed that PrPC is highly susceptible to the 
digestion with 2.5µg/ml PK and that the presence of PrPSc in the top fractions can be 
revealed by this mild condition of proteolysis. However, the treatment of sucrose 
fractions with 2.5µg/ml PK also appears to digest a subset of PrPSc, given that PrP 
signals in the intermediate or bottom fractions were mostly derived from abnormal 
form of PrP and that they were reduced to levels lower than a half of the undigested 




























Figure 3.12 Absence of detectable PrP in the fractionated samples from FC of 
non-CJD1 (a) or non-CJD3 (b) after digestion with 2.5µg/ml PK. Brain lysates 
from FC of non-CJD brains were centrifuged in 10 – 60% sucrose step gradient and 
eleven fractions were collected from top of the gradients. Samples from individual 
fractions left undigested or were digested with 2.5µg/ml PK and then assayed by CDI 
in the denatured state for the measurement of total PrP. Grey bars represent 
fluorescence signals obtained from undigested samples and black bars represent 
those obtained from samples digested with 2.5μg/ml PK. Data shown represent the 

























































Figure 3.13 Effects of PK treatment to different PrP conformers in fractionated samples from different regions of a vCJD brain. 
Brain lysates prepared from FC (a), Cb (b) or Th (c) of a vCJD brain were fractionated in 10 – 60% sucrose step gradients and eleven 
fractions were collected from top of the gradients. Three aliquots from individual fractions left undigested (white bars) or were digested 
with two different concentrations of PK (2.5µg/ml [grey bars] or 50µg/ml [black bars]). Then, the fractionated samples undigested or 
digested with PK were analysed by CDI. The fluorescence signals obtained from native aliquots are shown in the upper row and those 

































































































































3.3.2.2 Distribution of PrPSc after digestion with 2.5µg/ml PK 
Based on the results in section 3.3.2.1, the fractionated samples from more CJD 
brains were first treated with 2.5µg/ml PK for 1 hour at 37°C and then assayed by 
CDI. In vCJD FC, the high D/N ratios in the bottom fractions were quite outstanding 
when compared to the intermediate fractions with the ratios usually lower than 5 or 
to the top fractions with the ratios lower than 1.5 (white bars in Figure 3.14; also 
refer to Figure 3.13a). Therefore, in vCJD FC, the application of the mild proteolysis 
prior to the CDI measurement did not cause any meaningful change in the overall 
pattern of D/N ratios, showing once more the absence of detectable PrPSc in the top 
fractions and the migration of a major fraction of PrPSc to the bottom fractions. When 
eleven fractions from Cb of a vCJD case were analysed by CDI after the mild 
proteolysis, as in vCJD FC, there was no detectable PrPSc in the top fractions and a 
major fraction of PrPSc was present in the bottom fractions (refer to Figure 3.13b). 
Also in FC of MM1 sCJD, the prior treatment of fractions with low level of PK did 
neither cause any change in the profile of D/N ratios nor reveal any sign of PrPSc in 
the top fractions; the D/N ratios were noticeably high in the bottom fractions 
(fractions 9 ~ 11), indicating the predominant abundance of PrPSc in those fractions 
(black bars in Figure 3.14).  
 
In contrast to the two other regions of vCJD brains or FC of MM1 sCJD, the 
application of mild proteolysis to the fractions of vCJD Th caused a great change in 
the CDI results in the top fractions. While the overall profiles of the D/N ratios in the 
intermediate and bottom fractions were similar before and after the proteolysis, the 
D/N ratios in the top fractions were greatly increased (grey bars in Figures 3.14; also 
refer to Figure 3.13c). The increase of the D/N ratios was particularly remarkable in 
fraction 1 from all three vCJD cases investigated (including the case described in 
3.3.2.1); the ratios of fraction 1 were in range of 1.8 to 3 before the proteolysis, but 
they reached the range of 20 to 57 after the PK treatment. Thus, the introduction of 
the mild proteolysis to the fractions of vCJD Th prior to the CDI measurement has 
revealed the presence of readily detectable amounts of PrPSc in the light fractions of 
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the sucrose gradient. Overall, PrPSc from vCJD Th was relatively evenly distributed 
throughout the gradient, when compared to vCJD FC or Cb in which a major fraction 















Figure 3.14 Comparison of CDI D/N ratios for PK-treated fractions between 
vCJD FC, vCJD Th and MM1 sCJD FC. Eleven fractions each from vCJD FC, 
vCJD Th or FC of MM1sCJD were digested with 2.5µg/ml PK for 1 hour at 37°C 
and then analysed by CDI. The D/N ratios for individual fractions were calculated by 
dividing TRF counts of denatured samples by the counts of the corresponding native 
samples. Data shown represent the average ± S.D. obtained from six cases of vCJD 
FC (white bars), three cases of vCJD Th (grey bars) and five cases of MM1 sCJD FC 

















3.3.3 Distribution of PrPres in sucrose gradient 
Partial resistance to protease digestion is commonly used as an operational definition 
of PrPSc. In addition to digestion of PrPC, proteolytic treatment results in N-terminal 
truncation of PrPSc, leaving PK-resistant core fragments of PrPSc (termed PrPres). In 
order to compare the distribution profiles of PrPres in the sucrose gradient with those 
of CDI-based PrPSc, the eleven fractions each from one case of vCJD (FC and Th 
samples) or from one case of MM1 sCJD (FC sample) were analysed by Western 
blot before and after proteolysis.  
 
Firstly, the eleven fractions from a non-CJD brain left undigested or were digested 
with 2.5µg/ml PK, and were analysed by Western blot. In undigested samples, PrPC 
immunoreactivity was mostly found in top two fractions as in the CDI analysis 
(upper row in Figure 3.15). Additionally, very faint, ambiguous signals which were 
similar to the molecular mass of PrP were just detectable in the bottom three 
fractions. PrP signals were no longer detectable after digesting each fraction with 
2.5µg/ml PK (bottom row in Figure 3.15).  
 
Next, the eleven fractions from CJD brain samples were analysed similarly. When 
each fraction from tissue of vCJD1 FC was immunoblotted with mAb 3F4, PrP 
signals were mainly detected in top two fractions and in bottom three fractions with 
weak immunoreactivity being present in some of the intermediate fractions (upper 
row in Figure 3.16a). In densitometric analysis, the amount of PrP in the top three 
fractions was 33% of the total and that in the bottom three fractions was 57% of the 
total. After digestion of individual fractions with 2.5µg/ml PK, PrP molecules found 
in the top fractions were no longer detectable and the amount of PrP detected in the 
bottom fractions accounted for 84% of the total PrP remaining (middle row in Figure 
3.16a). Following PK digestion at 50µg/ml, PrP species were mostly detectable in 
the bottom three fractions (bottom row in Figure 3.16a), accounting for ~98% of the 
total PrP remaining. Thus, similar to the results shown by CDI, total PrP in vCJD FC 
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was detected in a “bipolar” pattern in the gradient and PrPres was mostly detected in 
the bottom fractions of the gradient.  
 
In contrast to vCJD FC, PrP immunoreactivity from fractions of vCJD1 Th was 
dispersed throughout the gradient (upper row in Figure 3.16b). After proteolysis of 
individual fractions with 2.5µg/ml PK, PrP immunoreactivity was still present in all 
fractions including the top three fractions (middle row in Figure 3.16b). In the 
densitometric analysis, the amount of PrP was 16% of the total in the top three 
fractions, 47% in the intermediate five fractions and 37% in the bottom three 
fractions. Following PK digestion at 50µg/ml, PrP signals were still detectable in all 
fractions, although PrP species present in fractions 2 ~ 3 were severely reduced 
(bottom row in Figure 3.16b). In the densitometric analysis, the amount of PrP was 
6% of the total in the top three fractions, 29% in the intermediate five fractions and 
65% in the bottom three fractions.  
 
In FC of MM1 sCJD, PrP was detected throughout the gradients (upper row in Figure 
3.16c). After PK treatment at 2.5µg/ml, PrP in the top three fractions was completely 
digested and PrP immunoreactivity was detected in the intermediate and bottom 
fractions (middle row in Figure 3.16c). The amount of PrP signals detected in the 
bottom three fractions was about 65% of the total and the remaining 35% was 
present in the intermediate fractions. Following PK digestion at 50µg/ml, PrPres was 
mainly detectable in the bottom few fractions leaving faint three-band signals in 
some of the intermediate fractions (bottom row in Figure 3.16c). The amount of 
PrPres detected in the bottom three fractions was about 90% of the total PrPres signal 

















Figure 3.15 PrP distribution after fractionation in sucrose step gradient. Brain 
lysates from FC of a neurological control brain (non-CJD3) were centrifuged in 10 – 
60% sucrose step gradient and eleven fractions were collected from top of the 
gradient. Samples from each fraction left untreated (upper row) or treated with 
2.5µg/ml PK (bottom row) for 1 hour at 37°C. The distribution of PrP before and 







































Figure 3.16 PrP distribution after fractionation in sucrose step gradient. Brain lysates from vCJD1 FC (a), vCJD1 Th (b) and MM1-
1 FC (c) were fractionated in 10 – 60% sucrose step gradients and eleven fractions from top to bottom were collected. Three aliquots 
from individual fractions remained untreated (upper row) or were digested with PK at 2.5µg/ml (middle row) or at 50µg/ml (bottom 
row) for 1 hour at 37°C. The distribution of PrP before and after the proteolysis was investigated by Western blot using mAb 3F4. MM1 























(c) MM1 sCJD FC








3.3.4 Supplementary data: total protein distribution in sucrose gradient  
To investigate the distribution of total protein in the sucrose gradient, first, the 
fractionated samples from non-CJD control brains or vCJD brains were run on a gel 
and then separated proteins on the gel were stained with Coomassie blue. As shown 
in Figure 3.17, a majority of total protein stayed in the light top fractions of the 
gradient and low levels of protein were recovered in the bottom fractions.  
 
In order to measure the levels of total protein in each fraction more precisely, the 
Bio-Rad DC protein assay was performed as described in section 3.2.2. A standard 
curve generated using BSA (range: 0mg ~ 2mg in the increment of 0.25mg) was 
shown in Figure 3.18 and a trend line for this standard curve was determined using 
Excel as follows: y = 6.9358x – 0.1113 (y = protein amount; x = absorbance at 750 
nm). When the amount of total protein in each fraction was determined by this 
equation after the Bio-Rad DC protein assay, in both non-CJD control and vCJD 
brains, protein was predominantly present in the top two fractions with a minority of 
protein in the bottom few fractions (Figure 3.19).  
 
Collectively, these results have shown that the distribution of total protein in the 
sucrose gradient after ultracentrifugation was highly variable between fractions with 








































Figure 3.17 Total protein distribution after fractionation in sucrose step 
gradient. Brain lysates from FC of non-CJD3 (a), vCJD1 FC (b) and vCJD1 Th (c) 
were fractionated in 10 – 60% sucrose step gradients. Eleven fractions collected from 
top to bottom were separated by electrophoresis and the gels were stained with 
Coomassie blue.  
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Figure 3.18 A standard curve generated using BSA. Bovine Serum Albumin 
(BSA) prepared in various concentrations was assayed as described in section 3.2.2 
and read at 750nm on a spectrometer (solid line). A trend line for this standard curve 
was generated using Excel (dashed line). The equation for this trend line was 
















Figure 3.19 Total protein distribution after fractionation in sucrose step 
gradient. Brain lysates from FC of non-CJD3 (white bars), vCJD1 FC (grey bars) 
and vCJD1 Th (black bars) were fractionated in 10 – 60% sucrose step gradients and 
eleven fractions were collected from top to bottom. The amounts of total protein in 
individual fractions were determined by the standard reference curve described in 






































3.4.1 PrPC: sedimentation profiles in sucrose gradient   
3.4.1.1. Non-CJD control brains 
When brain lysates from frontal cortex of the neurological controls containing only 
PrPC were fractionated by ultracentrifugation in the sucrose gradient, PrP molecules 
mostly stayed in the light, top few fractions despite the presence of trace of signals in 
the intermediate and bottom fractions. The PrP distribution profiles obtained from 
native and denatured aliquots were indistinguishable and the D/N ratios were similar 
between the eleven fractions. In WB analysis, PrP signals were present mostly in top 
few fractions, although faint immunoreactivity migrating to similar position of PrP in 
the gel was barely seen in the bottom fractions.   
 
The PrPC distribution profiles observed in this study were in good agreement with 
those reported from previous studies employing the 10 - 60% sucrose step gradient. 
PrPC molecules from normal mice brains were recovered mostly in the top three 
fractions after fractionation in the same sucrose gradient (Pan et al. 2004; Pan et al. 
2005a; Pan et al. 2005c). Identical results were also seen in the normal hamster 
brains (Tzaban et al. 2002). The results from normal human brains were in line with 
the observation in this study in that the major proportion of PrP was distributed 
throughout the upper fractions and that low levels of PrP were also detectable in the 
remaining fractions (Gambetti et al. 2008; Yuan et al. 2006). Based on additional 
biochemical analysis, small amounts of PrP aggregates found in the heavier fractions 
were interpreted to suggest that abnormal, PrPSc-like species was present in normal 
human brains (Yuan et al. 2006). The presence of detergent-insoluble aggregates of 
PrPC was also described in uninfected cells under some metabolic insults (Lehmann 
and Harris 1997; Yedidia et al. 2001). However, CDI analysis in this study did not 
display any indication of abnormal PrP in the intermediate or bottom fractions of the 
gradient. Thus, it remains unclear whether PrP species recovered in the heavier 
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fractions have really "PrPSc-like" properties and more studies will be required to 
clarify this issue.  
 
3.4.1.2 CJD brains   
The conformation-dependent immunoassay (CDI) makes it possible to separately 
measure the cellular isoform of PrP (PrPC) from disease-associated PrP (PrPSc) in 
CJD brains. In this study, the distribution of PrPC in the sucrose gradient after 
ultracentrifugation was determined by analysing aliquots of native fractions in CDI. 
The distribution profiles of PrPC from various CJD samples were basically similar to 
that of non-CJD brains in that PrPC was predominantly present in the top few 
fractions. However, recognizable difference was also evident between regions of 
vCJD brains or between FC regions of the two CJD phenotypes. PrPC distribution 
profiles obtained from vCJD FC and Cb tissues were almost identical to that of FC of 
non-CJD. In contrast, when tissues of vCJD Th or FC of MM1 sCJD were 
fractionated in the gradient, relatively higher levels of PrPC molecules migrated to 
the intermediate and bottom fractions.  
 
The relative abundance of PrPC in the intermediate and bottom fractions of the 
gradient may indicate that PrPC forms aggregates in some of prion-infected tissues. 
The accumulation of PrPSc during prion infection was reported to cause ER stress 
(Hetz et al. 2005; Hetz and Soto 2006; Rane et al. 2008), which would favour the 
accumulation of newly synthesized PrP in the cytosol (Kang et al. 2006; Orsi et al. 
2006). Cytosolic PrP is known to form aggregates (Ma and Lindquist 2001). 
Furthermore, the accumulation of oligomeric forms of PrPSc could inhibit proteasome 
activity (Kristiansen et al. 2007), which would accelerate cytosolic accumulation of 
nascent PrP (Ma and Lindquist 2002; Yedidia et al. 2001). Of note, the relative levels 
of PrPSc in the intermediate fractions were higher in vCJD Th than in vCJD FC. 
Taken together, PrPC species observed in the heavier fractions of the gradient appear 
to be aggregates of PrPC present in CJD brains. Alternatively, PrPC molecules 
observed in heavier fractions may represent partly those recruited by PrPSc 
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aggregates but not yet converted into pathogenic isoform, given that the formation 
PrPC/PrPSc complex occurs in the propagation of PrPSc (Meier et al. 2003; Prusiner et 
al. 1990) and the formation of PrPSc in cultured cells happens slowly (Borchelt et al. 
1990). 
 
3.4.2 Total PrP in CJD brains: sedimentation profiles in sucrose gradient   
In non-CJD brains containing only PrPC, the distribution profiles of PrP measured 
using native aliquots were similar to those measured using denatured aliquots. In 
contrast, when fractions obtained from CJD brains were assayed by CDI in the native 
and denatured states, significant levels of fluorescence signals were newly detectable 
after denaturation. In tissues of vCJD FC and Cb, the distribution profiles of total PrP 
appeared as a bipolar pattern in the gradient; i.e., PrP signals were mostly detected in 
the top three fractions and bottom three fractions. In vCJD Th or FC of MM1 sCJD, 
PrP molecules distributed throughout the gradient more evenly with significant PrP 
immunoreactivity detected in the intermediate fractions. The Western blot analysis 
also showed similar results. 
 
In previous studies describing the fractionation of brain samples in sucrose step 
gradients, the distribution of PrP species in the gradient has usually been shown by 
Western blot. Therefore, their results have shown the sedimentation profiles of total 
PrP (containing both PrPC and PrPSc) in the gradients, as in the results from CDI in 
the denatured state. In a study comparatively analysing two groups of MM1 sCJD in 
which differ in their disease durations (Cali et al. 2006), prominent PrP was observed 
in the bottom fractions of the gradient with relatively weak PrP immunoreactivity 
present in the intermediate fractions. Interestingly, in Cali's study, the levels of PrP 
staying in the top fractions were overall lower than those of MM1 sCJD cases in this 
study. In another study describing a novel human prion disease designated "protease-
sensitive prionpathy" (or PSPr), the sedimentation profile of PrP from this novel 
prion disease was different from any of this study's in that quite low levels of PrP 
were distributed in the intermediate and bottom fractions (Gambetti et al. 2008); 
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interestingly, the result from GSS with A117V mutation was similar to that of PSPr. 
In laboratory prion strains such as ME7, 22L in mice or Sc237 in hamsters, PrP 
dispersed throughout the 10 - 60% gradient after ultracentrifugation (Pan et al. 2004; 
Pan et al. 2005a; Pan et al. 2005c; Tzaban et al. 2002). The results from these 
laboratory prion stains were quite similar to those from vCJD Th or FC of MM1 
sCJD.  
 
3.4.3 PrPSc/PrPres in CJD brains: sedimentation profiles in sucrose gradient   
3.4.3.1 Two possible indicators for PrPSc in CDI: D/N ratio and [D-N] value 
In abnormal prion protein (PrPSc), the binding site for the mAb 3F4 is hidden and 
becomes accessible after denaturation (Safar et al. 1998). Therefore, CDI 
fluorescence signals obtained from native samples represent PrPC and those obtained 
from denatured samples represent total PrP irrespective of its conformation. For the 
analysis of fractionated samples without any proteolytic treatment, the distribution 
profiles of PrPSc in the gradient were inferred from the ratios of TRF counts between 
native and denatured aliquots (D/N ratios). Although the difference of TRF counts 
between the two folding states (D-N value) is a highly useful indicator for the 
presence of PrPSc, [D-N] value does not seem to be appropriate for the analysis of 
fractions for the following reasons: 1) PrPC is not distributed uniformly and mainly 
observed in top few fractions, particularly in fraction 1; 2) CDI signals of 
neurological control brains containing only PrPC increase slightly after denaturation; 
3) the combination of (1) and (2) make it difficult to estimate the distribution of PrPSc 
in the gradient based on the distribution of [D-N] value in the gradient, particularly in 
the samples with low levels of PrPSc.  
 
3.4.3.2 PK digestion of sucrose fractions 
In this study, in addition to the CDI analysis of undigested sucrose fractions, 
proteolytic treatments for the sucrose fractions were performed with 2.5µg/ml PK or 
50µg/ml PK. While the former condition of proteolysis was introduced mainly to 
investigate further the distribution of PrPSc (particularly in the top fractions) by CDI, 
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the latter condition of proteolysis was performed to investigate the distribution of 
PrPres in the gradient.  
 
One significant limitation of applying PK digestion to the sucrose fractions is the 
varying concentration of protein between them, as shown in section 3.3.4. In the 10 - 
60% sucrose gradient employed in this study, a major proportion of protein was 
recovered in the early few fractions. The amount of protein can have substantial 
effect on the efficiency of proteolytic digestion of protein (Notari et al. 2007). The 
highly varying concentration of sucrose between the eleven fractions of the gradient 
(from 0% to 60%) may additionally affect PK activity. Therefore, the relative 
efficiency of PK activity does not appear to be identical between the eleven fractions. 
The efficiency of PK activity is thought to be higher in the intermediate or bottom 
fractions with significantly lower levels of protein, which is further strengthened by 
the emergence of three-band proteolytic fragments migrating ~ 20 - 30KDa even 
after digesting fractions with 2.5µg/ml PK. It has to be mentioned here that amino-
terminal region of PrPSc was shown to be highly susceptible to proteolysis with 
relatively low concentrations of PK (10 - 20µg/ml PK), despite progressive further 
truncation in higher concentrations of PK (Notari et al. 2007; Yull et al. 2009).   
 
Accordingly, substantial loss of PrPSc signals in CDI after treatment with 2.5µg/ml 
PK can to be partly explained by the viewpoint described above. Since a fraction of 
PK-sensitive PrPSc was found to be highly susceptible to the digestion even with 
5µg/ml PK (Pastrana et al. 2006), the loss of PrPSc signals in the intermediate and 
bottom fractions following 2.5µg/ml PK can also be a reflection of loss of a subset of 
PK-sensitive PrPSc. Collectively, the results obtained following digestion with 
2.5µg/ml PK are not thought to be a full reflection of PrPSc distribution in the 
gradients. Nonetheless, this mild condition of proteolysis is still useful in examining 
the presence of PrPSc in the top fractions of the gradient by digesting PrPC found 
mostly in those fractions.  
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When compared to those obtained following hydrolysis with 2.5µg/ml PK, further 
great loss of PrPSc signals following standard condition of proteolysis (50µg/ml PK, 
1 hour and 37°C) is thought to be the result of hydrolysis of PK-sensitive fraction of 
PrPSc. Additionally, the great loss of PrPSc signals after treating fractions with 
50µg/ml PK can be associated with digestion of some of PrPres considering the 
followings: 1) the immunoreactivity of PrPres obtained following standard proteolysis 
becomes gradually reduced over a wide range of higher concentrations of PK (Notari 
et al. 2007; Yull et al. 2009); 2) the relative efficiency of PK digestion is thought to 
be higher in fractionated samples than that in brain homogenates due to difference in 
the level of protein (Notari et al. 2007)  
 
3.4.3.3 PrPSc/PrPres sedimentation profiles in sucrose gradient: between size and 
density  
When tissues of vCJD FC or Cb were fractionated in the sucrose gradient and the 
sedimentation profiles of PrPSc were examined by CDI, PrPSc was mainly recovered 
in the bottom three fractions leaving very low levels of PrPSc in the intermediate 
fractions; the sedimentation profiles of PrPSc from these two regions of vCJD brains 
were not influenced by the mild proteolytic treatment of individual fractions. The 
distribution of PrPres in the gradient was similar to that of PrPSc determined by CDI. 
When fractions from vCJD Th were examined by CDI, PrPSc was present throughout 
the gradient although PrPSc signals were still strongest in the bottom three fractions; 
the presence of PrPSc in the top fractions became clear after treating them with 
2.5µg/ml PK. The results from Western blot analysis of undigested or PK-digested 
fractions were also identical to those of CDI. Similar to observation obtained from 
vCJD FC, PrPSc/PrPres molecules from FC of MM1 sCJD were also predominantly 
recovered in the bottom three fractions of the gradient and not detectable in the top 
three fractions; a minor difference in FC between the two phenotypes was seen in the 
intermediate fractions, in which PrPSc species were a bit more abundant in MM1 
sCJD than vCJD.  
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The separation of prion protein in the 10 - 60% sucrose gradient employed in this 
study can be a function of distinct molecular densities, sizes and shapes. In previous 
studies, the separation of PrP molecules achieved in the 10 - 60% sucrose gradient 
was shown to correlate with their sizes determined by gel filtration (Tzaban et al. 
2002; Yuan et al. 2006). Thus, the distribution of PrP molecules in the gradient can 
reflect their sizes, although additional experiment like size exclusion 
chromatography was not conducted in this study. Considering the results from 
Tzaban et al. and other relevant studies, the sizes of aggregates of abnormal PrP 
observed in the intermediate and bottom fractions can range from less than 600 KDa 
to more than 20,000 KDa or to that of prion rods composed of as many as 1,000 PrP 
molecules (Prusiner et al. 1983; Silveira et al. 2005; Tzaban et al. 2002). Similarly, 
in an electrophoresis study on agarose gels (conducted before the discovery of PrP), 
scrapie infectious agents were reported to form a continuum of aggregate sizes 
ranging from 1,000 KDa to more than 20,000 KDa (Prusiner et al. 1980b), which 
was considered to be consistent with previous findings showing that sedimentation 
coefficients of scrapie agents ranged from 30S to more than 300S (Prusiner et al. 
1978; Prusiner et al. 1980a). By contrast, recent studies have proposed ß-helical PrP 
trimers as minimal structures of PrPSc (DeMarco and Daggett 2004; Govaerts et al. 
2004). Similarly, inactivation curves of scrapie infectivity by ionizing radiation 
implied that the infectious particle might consist of PrP dimers (Bellinger-Kawahara 
et al. 1988). Therefore, the PrPSc species present in the top fractions of the gradient, 
which were identified only in Th samples of vCJD, may correspond to the fraction of 
PrPSc with the sizes of PrP dimmers or trimers.   
 
However, it remains unclear whether aggregates containing PrP molecules consist 
exclusively of PrP. If PrP aggregates contain chemical species like lipids, the 
separation of PrP molecules in sucrose gradients may be influenced by their buoyant 
densities in addition to their sizes. Both PrPC and PrPSc were found to have strong 
affinity for lipids like cholesterol- and sphingolipid-enriched membrane domains 
(named "rafts") (Safar et al. 2006; Taraboulos et al. 1995; Vey et al. 1996). Although 
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both Sarcosyl and NOG are known to solubilize lipid rafts, PrPSc may be bound to 
abnormal membrane structures that behave differently from physiological 
membranes (Brown and Rose 1992; Tzaban et al. 2002). In agreement with this 
possibility, Klein et al. showed that sphingolipids were still easily detectable even in 
highly purified prion rods obtained after harsh extraction using detergents and 
chloroform-methanol (Klein et al. 1998). Moreover, recent studies have shown that 
lipid can be involved in the formation of PrPSc as a cofactor facilitating the 
conversion of PrPC into PrPSc (Wang et al. 2007; Wang et al. 2010). This kind of 
possibility can be more significant in the analysis of fractionated samples from vCJD 
Th, in which PrPSc (both PK-sensitive and PK-resistant) was observed throughout the 
gradient including the top first fraction. Although PrPSc molecules in hamster scrapie 
were reported to stay in the light fractions (including the earliest fraction) of the 10 - 
60% gradient, they were found to be sensitive to proteolysis (Pastrana et al. 2006). 
Therefore, a level of aggregation size may be needed for PrPSc to acquire PK-
resistance (Pastrana et al. 2006; Tzaban et al. 2002). In this context, if the separation 
of PrP molecules in the gradient was influenced by their buoyant densities, PK-
resistant fraction of PrPSc observed in the top fractions of vCJD Th would be most 
probable candidate PrP species.  
 
3.4.3.4 Further speculations on regional difference of vCJD brains  
In vCJD, the sedimentation profiles of PrPSc in the sucrose step gradient were 
significantly different between FC/Cb and Th. Although it remains to be determined 
whether the distinct sedimentation properties of PrPSc between regions of vCJD have 
any biological significance, several things are worth being discussed.  
 
First, the PrPSc species emerging in the intermediate fractions of the gradient after 
ultracentrifugation was significantly more abundant in vCJD Th than the two other 
regions. This significant abundance of PrPSc in the intermediate fractions from vCJD 
Th can be easily identified in the CDI analysis of undigested fractions or of fractions 
digested with 2.5µg/ml PK, and in the WB analysis of fractions digested with two 
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different concentrations of PK. The PrPSc species recovered in the intermediate 
fractions is thought to quite possibly represent oligomeric forms of PrPSc (Tzaban et 
al. 2002). There is growing evidence showing the importance of oligomeric forms of 
PrPSc in prion pathogenesis. In prion disease, small aggregates of PrPSc may be more 
relevant to neurotoxicity than large aggregates species (Caughey and Lansbury 2003), 
as observed in other neurodegenerative diseases (Kaylor et al. 2005; McLean et al. 
1999; Okamoto et al. 2003; Walsh et al. 2002).  In a study comparing the particle 
size of PrPres and their prion infectivity, relatively small oligomeric species of PrPres 
particles were found to be most efficient in disease initiation (Silveira et al. 2005). 
Lastly, the accumulation of oligomeric forms of PrPSc was shown to impair 
proteasome activity, which was suggested to lead to neuronal loss (Kristiansen et al. 
2007). It is of note that the posterior thalamus of vCJD brains is pathologically 
featured by severe neuronal loss accompanied by marked astrocytosis (Ironside et al. 
2000; Ironside et al. 2002); moreover, hyperintensity on MRI scanning in this brain 
region is one of important diagnostic criteria of vCJD (Zeidler et al. 2000).   
 
Second, the deposition patterns of abnormal PrP in vCJD brains are significantly 
different between regions (Ironside et al. 2000; Ironside et al. 2002). In cerebral and 
cerebellar cortex, PrP immunostaining was detected in the form of multiple florid 
plaques, multiple smaller plaques and amorphous deposits. In thalamus, there is a 
liner and perineuronal pattern of PrP deposits with occasional plaques. Therefore, the 
results of PrP immunostaining suggest that the size of PrP deposits in vCJD brains 
could be bigger in cerebral or cerebellar cortex than thalamus. Alternatively, PrPSc in 
the thalamus of vCJD might be in a tighter relation with cell membrane, which can 
lead to the presence of membrane products bound to PrPSc even after detergent 
extraction. In this context, it will be interesting to investigate sedimentation profiles 
of PrPSc from CJD brains showing Kuru plaques (MV2 sCJD) or prominent 




The third thing is the biological strain typing of vCJD agent. Transmission studies 
using a panel of wild-type mice demonstrated that BSE in cattle and vCJD in humans 
were caused by the same prion strain (Bruce et al. 1997). Subsequent studies using 
various transgenic mice models have strongly supported that vCJD is caused by the 
BSE agent (Hill et al. 1997; Scott et al. 1999). A recent large-scale transmission 
study using a standard panel of wild-type mice confirmed that vCJD is associated 
with one strain of BSE agent (Ritchie et al. 2009). Although a possibility was raised 
that the vCJD agent could propagate in two distinct prion strains following 
transmission into transgenic mice (Beringue et al. 2008), the biological properties of 
the vCJD agent were not largely altered in transfusion-related secondary 
transmission (Bishop et al. 2008) and histopathological characteristics and PrP 
biochemistry were similar between primary and secondary vCJD cases (Head et al. 
2009b; Peden et al. 2004; Wroe et al. 2006). However, one limitation of these 
transmission studies which examined biological properties of vCJD agents lies in that 
they were mostly based on the analysis of frontal cortex and/or cerebellum. In this 
context, a study performed by Korth et al. was an exception because the thalamus of 
vCJD brains as well as frontal lobe was used for the transmission study into 
transgenic mice (Korth et al. 2003). Interestingly, inocula prepared from the 
thalamus of vCJD brains resulted in two distinct prion strains in subsequent passages, 
one of which was similar to the strain derived from the frontal cortex of vCJD brains 
(Korth et al. 2003). It remains unclear whether the distinct sedimentation properties 
of PrPSc between regions of vCJD brains are associated with the emergence of 
distinct prion strains reported by Korth and colleagues.    
 
3.4.4 Considerable additional experiments using fractionated samples  
In this study, the distribution profiles of PrPSc in the 10 - 60% sucrose gradients were 
investigated by CDI using undigested fractions or those digested with 2.5µg/ml PK 
and they showed overall correlation with PrPres distribution. Although CDI has its 
advantage in that it can measure both PrPC and PrPSc in prion-infected samples, the 
detection of PrPSc in CDI has been frequently performed by the combination with 
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NaPTA precipitation in order to minimize the intervention of PrPC (Bellon et al. 
2003; Jones et al. 2007; Safar et al. 2005a). Although NaPTA is widely used to 
enrich disease-associated PrP, a minor fraction of PrPC in normal human brains has 
been shown to be precipitated by NaPTA (Wadsworth et al. 2001; Yuan et al. 2006). 
Thus, it would be of interest to see whether a minor fraction of PrPC molecules 
identified in the intermediate and bottom fractions can be more efficiently 
precipitated by NaPTA. Additionally, it would be also interesting to compare the 
distribution profiles of PrPSc determined by the combination of CDI and NaPTA with 
those in this study, given a recent report that oligomeric form of PrPSc was not 
effectively retrieved by NaPTA precipitation (Sasaki et al. 2009). One technical 
point that needs to be mentioned is the variable concentration of sucrose between the 
eleven fractions (0% to 60%); thus it would be necessary to remove sucrose in each 
fraction by filtration or to lower its concentration into a level which is not influential 
in NaPTA precipitation.  
 
In the last decade, more than ten antibodies have been reported to be specific for 
PrPSc (Jones et al. 2009c; Korth et al. 1997; Lau et al. 2007; Moroncini et al. 2004; 
Paramithiotis et al. 2003; Servac et al. 2004; Solforosi et al. 2007; Zou et al. 2004). 
Recently, some of them were shown to recognize structural features shared by 
infectious and non-infectious aggregates of PrP (Biasini et al. 2008). It would be of 
interest to investigate the reactivity of these so-called "PrPSc-specific" antibodies 
with PrPSc molecules that are different in their sizes and/or their densities 
(particularly fractions from vCJD Th).   
 
A recent study by Silveira et al. showed that prion infectivity was influenced by their 
aggregate sizes (Silveira et al. 2005). While prion infectivity was peaked in small 
oligomers of PrPSc with 300 - 600 KDa, these activities became significantly lower in 
smaller and larger aggregates. The results from in vitro converting activity were also 
similar to those of in vivo assays. One limitation in this study is that they used 
purified PrPres particles, which is different in its structure from undigested PrPSc 
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molecules (McKinley et al. 1991; Pan et al. 1993). Additionally, various sizes of 
PrPres particles were generated by sonication but the relevance of these artificially 
disaggregated PrPres particles to the in vivo sizes of PrPSc aggregates remains unclear. 
In this context, it would be of interest to compare prion infectivity between the 










Conformational stability states of 
PrPSc measured by CDI in different 




It is known that protein structure can be probed by exposure to a chaotrope salt over 
an appropriate range of concentrations (Shirley 1995). On the basis of this concept, 
Peretz et al. developed an assay termed conformation stability assay (CSA), in which 
the stability of PK-resistant PrPSc is measured as a loss of resistance to protease 
digestion following exposure to increasing concentrations of GdnHCl (Peretz et al. 
2001). The increase of GdnHCl concentration lead to the dissociation of PrPSc 
aggregates and denaturation of its ß-sheet-rich structure, which renders PK-resistant 
fragment of PrPSc susceptible to proteolytic treatment (Peretz et al. 2001; Safar et al. 
1993). The concentration of GdnHCl required to make half of PrPSc susceptible to 
proteolytic treatment (GdnHCl1/2) was used as a measure to compare the stability of 
PK-resistant PrPSc between prion strains. Prion strains which were indistinguishable 
by electrophoretical mobility of PrPres could be separated by the GdnHCl1/2 values in 
the CSA (Peretz et al. 2001; Peretz et al. 2002). In the following studies from this 
group, it was shown that PrPSc from transgenic mice inoculated with synthetic prions 
was very highly resistant to GdnHCl-induced denaturation (Legname et al. 2005), 
and that GdnHCl1/2 values obtained from synthetic and naturally occurring prion 
strains propagated in mice correlated with their incubation periods (Legname et al. 
2006). Although this finding is important in that biochemical properties of PrPSc 
were addressed in relation with biological properties, a limitation of this 
methodology is the preclusion of protease-sensitive fraction of PrPSc due to the 
reliance on proteolysis (Legname et al. 2006).  
 
In this study, in order to overcome the limitation that CSA has, the stability of both 
PK-sensitive and PK-resistant fractions of PrPSc was measured by the conformation-
sensitive mAb 3F4 in CDI, instead of limited proteolysis. Aliquots of a PrPSc-
containing sample were firstly incubated with increasing concentrations of GdnHCl 
and then assayed by CDI. The recognition site of the mAb 3F4 is located in N-
terminus of PrP (residues 109-112 of human PrP), which is masked in the native 
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form of PrPSc but becomes accessible after denaturation (Bolton et al. 1991; Kanyo 
et al. 1999; Kascsak et al. 1987; Rogers et al. 1991; Safar et al. 1998). Thus, the 
conformational stability of PrPSc was measured as a loss of disease-associated 
structure in its 3F4 binding site following exposure to GdnHCl at various 
concentrations. Given the location of the mAb 3F4 epitope within PrP, the 
conformational stability measured by this methodology is thought to represent that of 
N-terminus of PrPSc.  
 
In order to investigate the conformational stability of PrPSc in CJD brains, tissues of 
frontal cortex from vCJD and MM1 sCJD case were compared. In some of vCJD 
cases, tissues of cerebellum and thalamus were also examined. Additionally, one 
case of VV2 sCJD and two GSS cases with P102L mutation were analysed using 
tissues of frontal cortex. 
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4.2 Materials and methods 
 
4.2.1 Human brain materials 
Thirteen variant CJD (vCJD) cases, fourteen sporadic CJD (sCJD) cases, two GSS 
cases with P102L mutation and five control (non-CJD) cases with other neurological 
disorders were analyzed in this chapter. Among the fourteen sporadic CJD cases, 
thirteen cases were MM1 subtype and the remaining one case was VV2. One GSS 
case showed typical three PrPres bands in addition to a PrP fragment of ~8 KDa, 
whereas the other GSS case produced a predominantly ~8 kDa proteolytic fragment. 
The details of these cases were described in Tables 2.1 to 2.4 in Chapter 2. In all 
instances the tissues used were grey matter-enriched frontal cortex (FC) and, 





Preparation of brain tissue  
Brain tissue homogenates were prepared in nine volumes (w/v) of phosphate-
buffered saline (PBS), pH 7.4, containing 2% Sarcosyl by two cycles of 
homogenization in the FastPrep instrument (Qbiogene). The homogenized brain 
samples were stored at -80°C until use.  
 
Enrichment of disease-associated PrP  
The 10% homogenates were diluted to 5% w/v using PBS containing 2% Sarcosyl 
(w/v) and were incubated for 10 minutes at room temperature on a shaking platform. 
The samples were then centrifuged at 500 × g for 5 minutes at 20°C and the 
supernatants were collected. For the enrichment of disease-associated isoform of PrP, 
one hundred microlitre aliquots of cleared brain homogenates in PBS containing 2% 
Sarcosyl were centrifuged at 20,800 × g for 1 hour at 4°C as described previously 
(Thackray et al. 2007a; Wadsworth et al. 2006). After careful aspiration of the 
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supernatants, pellets containing detergent-insoluble fraction of PrP were used for the 
analysis of denaturation transition induced by GdnHCl. On some occasions, pellets 
were resuspended in the starting volume (100 µl) of homogenization buffer to 
investigate the effect of this method in enriching PrPSc. 
 
Conformation-dependent immunoassay (CDI) 
Samples prepared in 2% Sarcosyl in PBS were divided into two parts; one part was 
mixed with same volume of PBS containing Complete EDTA-free® protease 
inhibitors (native sample, N) and the other part was mixed with the same volume of 
8M GdnHCl and incubated for 6 minutes at 81°C (denatured sample, D). Both N and 
D samples were adjusted using distilled water containing EDTA-free® protease 
inhibitors to a final concentration of GdnHCl of 0.35M in 435µl final volume. 
Subsequently, CDI was performed as described in section 2.2.3 without any 
modification.  
 
Denaturation transition of PrPC and PrPSc in CDI 
PrPSc in brain homogenates or in the pellets containing detergent-insoluble fraction 
of PrP was treated with GdnHCl at various concentrations as described previously 
(Peretz et al. 2001; Safar et al. 1998). The 10% brain homogenates were mixed with 
an equal volume of 2% Sarcosyl in PBS and incubated for 10 minutes at room 
temperature. After clarification at 500 × g for 5 minutes, aliquots of samples were 
mixed with GdnHCL at final concentrations ranging from 0 to 7M. Alternatively, the 
pellets containing detergent-insoluble fraction of PrP were resuspended in a solution 
containing GdnHCl at various concentrations (range: 0 - 7M). Samples containing 
different amounts of GdnHCl were incubated overnight at room temperature on a 
shaking platform and were adjusted using distilled water containing EDTA-free® 
protease inhibitors, to a final concentration of GdnHCl of 0.35M in 720µl of final 
volume. The extents of unfolding of PrPSc exposed to different concentrations of 
GdnHCl were measured by the CDI in triplicate. 
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CDI D/N ratio and [D-N] value 
Time-resolved fluorescence (TRF) counts obtained from CDI were used to generate 
D/N ratios and [D-N] values (Safar et al. 1998; Safar et al. 2005a). The folding state 
of PrPSc induced by overnight incubation at 7M GdnHCl or by incubation at 81°C in 
the presence of 4M GdnHCl was taken to be full denaturation (Safar et al. 1993; 
Safar et al. 1998). The D/N ratios were obtained by dividing TRF counts of 
denatured samples (D) by the counts of the corresponding native samples (N; 0M 
GdnHCl). For the generation of [D-N] values, TRF counts measured in the native 
state were subtracted from those measured in the denatured state.  
 
Determination of denatured fraction of PrPSc  
CDI results obtained from PrPSc-enriched pellets were used to determine denatured 
fractions of PrPSc after overnight incubation with particular concentrations of 
GdnHCl. For this, TRF counts obtained from an aliquot incubated in the absence of 
GdnHCl (0M GdnHCl) were firstly subtracted from those obtained from aliquots 
treated with GdnHCl at various concentrations. Then, denatured fraction of PrPSc at a 
particular concentration of GdnHCl was expressed as a relative value (%) of TRF 
counts at the concentration against the counts at 7M GdnHCl and was plotted against 
the corresponding concentrations of GdnHCl. 
 
 




Western blot (WB) analysis 
Polyacrylamide gel electrophoresis was performed using NuPAGE Novex gel system 
(Invitrogen) as described in section 2.2.3. Samples left undigested or digested with 
proteinase K (PK) at 50µg/ml for 1 hour at 37°C were mixed with NuPAGE LDS 
sample buffer to a final concentration of 1X. Subsequently, the samples were 
TRF CountsXM GdnHCL - TRF Counts0M GdnHCL
TRF Counts7M GdnHCL - TRF Counts0M GdnHCL
X 100
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incubated for 10 minutes at 100°C and then separated on a 10% Bis-Tris NuPAGE 
gel. The separated proteins were transferred to polyvinylidene difluoride (PVDF) 
membrane and subsequent immunodetection of PrP was performed as described in 
section 2.2.3 without any modification. 
 
Conventional conformation stability assay (CSA) 
For the study of stability of PrPres against GdnHCl-induced denaturation, aliquots of 
the 10% brain homogenates prepared in PBS were mixed with equal volume of 
GdnHCl giving a range of concentrations of GdnHCl (Peretz et al. 2001). After 2 
hour incubation of the mixtures at 37°C, samples were adjusted to a final 
concentration of 0.4M GdnHCl in Tris buffer (10mM Tris-HCl [pH 7.4], 0.5% NP-
40 and 0.5% sodium deoxycholate) and then digested with PK at 20µg/ml for 1 hour 
at 37°C. PK activity was terminated by adding Pefabloc at a final concentration of 
1mM. Proteins were then precipitated, by mixing the samples with five volumes of 
pre-chilled methanol and incubated at -80°C overnight. Samples were then 
centrifuged at 16,000 × g for 30 minutes at 4°C and the supernatants were carefully 
aspirated. The remaining pellets were resuspended with 25µl of 2X LDS buffer and 
boiled for 10 minutes. Proteins were analysed by Western blot as described above. 
 
Statistics 
Statistical analysis was performed with the student's t-test using TTest worksheet 




4.3.1 GdnHCl-induced denaturation of PrPSc in brain homogenates  
When the extents of unfolding of PrPSc induced by GdnHCl at different 
concentrations were measured by the conformation-sensitive mAb 3F4 in CDI, the 
resistance of PrPSc to GdnHCl-induced denaturation was reported to differ between 
prion strains propagated in hamsters (Safar et al. 1998). In order to investigate 
whether the stability of PrPSc against GdnHCl-induced denaturation also differs 
between distinct human CJD phenotypes, the brain homogenates from vCJD and 
MM1 sCJD cases were exposed to increasing concentrations of GdnHCl (range: 0 - 
7M GdnHCl) overnight before being assayed by CDI. TRF counts obtained from an 
aliquot incubated in the absence of GdnHCl were considered to represent PrPC, and 
those obtained from an aliquot incubated with 7M GdnHCl were thought to represent 
all PrP molecules present in a sample irrespective of their conformation. 
 
When the CDI results from neurological control (non-CJD) brains were compared 
between native (N; 0M GdnHCl) and denatured (D; 7M GdnHCl) states, 
fluorescence signals were similar between the two folding states or increased slightly 
after denaturation (Figure 4.1a). CDI D/N ratios in the three controls were in the 
range of 0.8 - 1.8 (Figure 4.1b). In contrast, when samples of vCJD and MM1 sCJD 
brains were analysed by CDI, there were significant increases in fluorescence counts 
after denaturation (Figure 4.1a). D/N ratios were usually higher in CJD samples than 
control samples (Figure 4.1b). The increase of fluorescence counts in CJD samples 
after denaturation is thought to result from the exposure of 3F4 binding site of PrPSc, 
which is hidden in native PrPSc. However, the degree of increase of CDI signals after 
denaturation was variable between individual CJD samples, implying variable 
amounts of PrPSc (Figure 4.1a). In one MM1sCJD case (MM1-1 in Figure 4.1), the 
change of CDI signal after denaturation did not seem distinguishable from 
neurological controls probably due to a low level of PrPSc in the sample. It is 
noteworthy that PrPC was readily detectable in CJD brains despite variation in its 
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amount and that CDI D/N ratios were greatly influenced by the amounts PrPC in 
these samples (for example, compare vCJD1 with MM1-3 in Figure 4.1). The 
amounts of PrPC in the vCJD brains appeared larger than those in the brains of MM1 
sCJD or neurological controls, but direct comparison of PrPC amounts between 
groups (and individuals) requires caution when considering variations in sampling 
and the difference in age, post-mortem intervals, gender, etc. between individual 
cases.  
 
To look at unfolding of PrP molecules more precisely, samples from non-CJD, vCJD 
and MM1 sCJD brains were incubated with a range of GdnHCl concentrations 
(range: 0 - 7M) and the extents of unfolding of PrP molecules were measured by 
mAb 3F4 binding in CDI. TRF counts at each concentration of GdnHCl were 
expressed as a relative value (%) to those at 7M GdnHCl. In the non-CJD brains 
containing only PrPC, no significant changes in fluorescence counts were observed 
although minor irregular fluctuating variation was noticeable irrespective of the 
concentrations of GdnHCl (Figure 4.2a). In the same context, D/N ratios of non-CJD 
brains were overall unchanged by increasing concentrations of GdnHCl (Figure 4.3a). 
In contrast, CJD brains showed clearly different denaturation patterns compared to 
control brains. In both vCJD and MM1 sCJD brains, the CDI signals gradually 
increased with increasing concentrations of GdnHCl and reached their plateaus at the 
concentration of 3 M GdnHCl (Figures 4.2b and 4.2c). This result implies that the 
exposure to 3M GdnHCl allowed mAb 3F4 access to its epitope in most of PrPSc 
molecules present in the CJD samples, and that most of them lost their disease-
related structure to this condition of treatment at least in their N-terminus. The MM1 
sCJD case (MM1-1 in Figure 4.1), which was indistinguishable from non-CJD brains 
in fluorescence counts in both N and D states and thus in D/N ratio, was different in 
its denaturation profile from neurological control brains (compare squares of Figure 
4.2c with Figure 4.2a). Similar to the denaturation profiles, D/N ratios gradually 
increased with increasing concentrations of GdnHCl and reached their plateaus at the 
concentration of 3M (Figures 4.3b and 4.3c). Interestingly, while GdnHCl-induced 
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denaturation of vCJD brain samples appeared to result in an increase of TRF counts 
from 1M GdnHCl treatment, the increase of fluorescence counts in MM1 sCJD was 
not seen until the concentration of GdnHCl reached 1.5M. Although greatly different 
amounts of PrPC between cases made more precise comparison difficult, this 
observation suggests that there is difference between the two phenotypes of CJD in 





















Figure 4.1 Comparison of CDI results between native (N) and denatured (D) 
states. Three cases each from neurological control, vCJD and MM1 sCJD were 
analysed using brain homogenates prepared from frontal cortex. (a) Comparison of 
TRF counts measured in N state (0M GdnHCl treatment, white bars) and D state (7M 
GdnHCl, black bars). (b) Comparison of D/N ratio between non-CJD and CJD brains. 
TRF counts of D samples were divided by the counts of N samples to give D/N ratios. 
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Figure 4.2 Change of CDI TRF counts with exposure to increasing 
concentrations of GdnHCl. Brain homogenates prepared from frontal cortex were 
treated with increasing concentrations of GdnHCl (range: 0 - 7M) and measured by 
CDI. Three cases each from neurological control (a), vCJD (b) and MM1 sCJD (c) 
were analysed. Each symbol (squares, diamonds, triangles) represent individual cases 
of each phenotype. TRF counts at particular concentrations of GdnHCl were 
expressed as relative values (%) to those at 7M GdnHCl. Data shown represent the 



































































































Figure 4.3 Change of CDI D/N ratio with exposure to increasing 
concentrations of GdnHCl. Brain homogenates prepared from frontal cortex were 
treated with increasing concentrations of GdnHCl (range: 0 - 7M) and measured by 
CDI. Three cases each from neurological control (a), vCJD (b) and MM1 sCJD (c) 
were analysed. Each symbol (squares, diamonds, triangles) represent individual cases 
of each phenotype. CDI D/N ratios were obtained by dividing TRF counts in the 
native state (0M GdnHCl) into those at particular concentrations of GdnHCl. Data 
shown represent the average for triplicate wells except for non-CJD 4 (diamonds in 









































4.3.2 Enrichment of PrPSc by Sarcosyl extraction and centrifugation  
CDI revealed that readily detectable amounts of PrPC are present in CJD brains. 
However, the amounts of PrPC were variable between individual cases, which caused 
difficulty in comparing fractional transition of PrPSc according to the increase of 
concentration of GdnHCl not only between different forms of CJD but also between 
individual CJD cases. In order to measure the degree of GdnHCl-induced 
denaturation of PrPSc more preciously by minimizing the effect of PrPC, this study 
made use of the difference in detergent solubility of the two isoforms of PrP: PrPC is 
soluble in non-denaturing detergent, whereas PrPSc is insoluble (Meyer et al. 1986). 
In order to harvest detergent-insoluble fraction of PrP species, brain homogenates 
prepared in PBS containing 2% Sarcosyl were centrifuged at 20,800 × g for 1 hour as 
described previously (Thackray et al. 2007a; Wadsworth et al. 2006). After careful 
isolation of the supernatants, pellets were resuspended as described in section 4.2.2. 
The detergent-soluble (supernatants) and insoluble (pellets) fractions were assayed 
by CDI. The investigation of PrPres distribution in these fractions was performed after 
PK digestion.  
 
When brain materials from neurological controls were centrifuged following 
Sarcosyl extraction and were subjected to measurement in CDI in native state, most 
of fluorescent counts detected in brain homogenates were recovered in the 
supernatants leaving only trace of CDI signals in the pellets (Figure 4.4a). In both 
types of CJD brains, similar results were obtained although minor variations between 
cases were observed (Figure 4.4a). Since TRF counts obtained in the native state 
represent PrPC, most of the cellular isoform of PrP present in both CJD and non-CJD 
brain samples were thought to remain in the detergent-soluble (supernatant) fraction 
after Sarcosyl extraction followed by centrifugation. In order to determine the 
distribution of disease-associated conformer of PrP in the supernatants and pellets, 
fluorescence counts in the denatured state were divided by those in the native state 
(D/N ratios). In neurological controls, the D/N ratios were in the range of 0.8 - 1.6 
and were similar between brain homogenates, supernatants and pellets (Figure 4.4b). 
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In both vCJD and MM1 sCJD brains, the D/N ratios for the pellets were greatly 
increased compared to those for brain homogenates, but the D/N ratios for the 
supernatants were clearly lower than those for brain homogenates (Figure 4.4b). This 
result indicates that the majority of PrPSc precipitated in the pellet fraction, although 
the great increase of D/N ratios was thought to be attributed in part to the loss of 
PrPC in the pellets.  
 
Together with the fact that the epitope of mAb 3F4 is hidden only in PrPSc, another 
representative feature of PrPSc is its partial resistance to protease digestion. 
Proteinase K (PK) treatment of PrPSc leaves N-terminally truncated, PK-resistant 
form of PrPSc (PrPres). To investigate the distribution of PrPres in the supernatant and 
pellet fractions, these two fractions were analysed separately with and without PK 
treatment (Figure 4.5). Western blot analysis of supernatants and pellets before 
proteolysis shows the presence of PrP in both fractions. After digestion with PK, 
PrPres was mainly detected in the detergent-insoluble pellet fraction of both vCJD 
and MM1 sCJD brain samples, although weak 3 bands representing PrPres was 
recognizable in the supernatant fraction of vCJD sample (Figure 4.5).  
 
Collectively, the observation regarding the distribution of PrPC, PrPSc and PrPres after 
Sarcosyl extraction followed by centrifugation shows that this method is efficient in 



















Figure 4.4 Distribution of PrPC and PrPSc after Sarcosyl extraction and 
centrifugation. Brain homogenates were prepared from frontal cortex as described 
in section 4.2.2 and the supernatants and resuspended pellets were analysed by CDI. 
(a) Distribution of PrPC in supernatants and pellets. The amount of PrPC was 
investigated by CDI in the native state and relative distribution of PrPC between 
supernatants and pellets was expressed as percent (%). White bars: control; Grey 
bars: vCJD; Black bars: MM1 sCJD. (b) Comparison of D/N ratios between initial 
brain homogenates, supernatants and pellets. TRF counts of denatured samples were 
divided by the counts in the corresponding native samples to give D/N ratios. White 
bars: brain homogenates; Grey bars: supernatants; Black bars: pellets. Data shown 
























































Figure 4.5 Enrichment of PrPres in pellets after Sarcosyl extraction and 
centrifugation. The supernatant (Sup) and pellet (Pel) fractions obtained after 
Sarcosyl extraction and centrifugation were digested with 50µg/ml PK for 1 hour at 
37°C. The distribution of PrPres in both fractions was investigated by Western blot 
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4.3.3 Conformational stability of PrPSc: comparison between vCJD and 
sCJD  
Relative resistance of PrPSc or PrPres to GdnHCl-induced denaturation has been 
reported to characterize prion strains in hamster and mouse models (Legname et al. 
2006; Peretz et al. 2001; Safar et al. 1998). To investigate whether there are any 
differences in resistance to GdnHCl-induced denaturation between vCJD and sCJD 
PrPSc, the homogenates of frontal cortex prepared in 2% Sarcosyl in PBS were 
centrifuged and then pellets containing detergent-insoluble fraction of PrP were 
assayed by CDI following incubation with GdnHCl at different concentrations 
(range: 0 - 7M).  
 
As shown in Figure 4.6a, the levels of PrPSc were variable between samples when 
they were measured by the difference of TRF counts between native and denatured 
states in CDI ([D-N] value). In order to compare samples with different levels of 
PrPSc, denatured fractions of PrPSc at particular concentrations were expressed as 
relative values (%) against that at 7M GdnHCl (100%), which was taken to be fully 
denatured. When the normalized results of both vCJD and sCJD (MM1 and VV2 
subtypes) were plotted against the concentration of GdnHCl, the gradual unfolding of 
PrPSc formed a single sigmoidal curve with one major transition and the denaturation 
curves plateaued at around 3M GdnHCl (Figure 4.6b). However, the degrees of 
denaturation of PrPSc appeared distinct between vCJD and sCJD cases at lower 
GdnHCl concentrations. In vCJD cases, the major fractional transition was observed 
in the range of 1 - 2.5M GdnHCl (Figure 4.6b). Approximately 10% of the PrPSc was 
denatured by treatment with 1M GdnHCl and almost 90% of PrPSc was denatured in 
the concentration of 2.5M GdnHCl (Figure 4.6b). The concentration of GdnHCl 
required to denature half of the PrPSc molecules present, named GdnHCl1/2 value 
(Lau et al. 2007), was 1.809M GdnHCl (row of sample 1 in Table 4.1). In contrast, 
the major transition from native to denatured state in both types of sCJD was 
observed in the range 1.5 - 3M GdnHCl (Figure 4.6b). The denatured fraction of 
sCJD PrPSc seen after treatment with 1.5M GdnHCl was similar to that of vCJD 
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PrPSc after incubation with 1M GdnHCl. Fractional transition of PrPSc from native to 
denatured state in both sCJD types was overall 0.5M higher than that of vCJD. The 
discrimination between vCJD cases and sCJD cases was more prominent in the range 
of 1.5 - 2M GdnHCl. Statistical analysis confirmed that fractional transition was 
significantly different between vCJD and MM1 sCJD in the two concentrations of 
GdnHCl (P < 0.01 at 1.5M and P < 0.05 at 2M GdnHCl). The GdnHCl1/2 values for 
MM1 sCJD and VV2 sCJD were 2.342M and 2.308M, respectively (for MM1, see 
row of sample 1 in Table 4.2). These results overall show that PrPSc from frontal 
cortex of sCJD brains was more resistant to GdnHCl-induced denaturation than that 
of vCJD, implying that N-terminus of PrPSc is structurally more stable in sCJD than 






































Figure 4.6 GdnHCl-induced denaturation of PrPSc. (A) PrPSc-enriched pellets of 
frontal cortex tissue from vCJD, MM1 sCJD and VV2 sCJD cases were assayed by 
CDI. TRF counts obtained in the native state (0M GdnHCl) were subtracted from the 
counts in the denatured state (7M GdnHCl) to measure the amounts of PrPSc. In x-
axis, MM1 denotes MM1 sCJD and VV2 denotes VV2 sCJD. (B) The extent of 
unfolding of PrPSc between native (0M) to denatured (7M) state was investigated by 
CDI. Denatured fraction of PrPSc in each concentration of GdnHCl was calculated as 
described in section 4.2.2. In vCJD (white squares) and MM1 sCJD (black 
diamonds), data represent the average ± S.D. of three individuals. Data for VV2 
sCJD (black triangles) was based on one case. The result in every individual was an 
















































4.3.4 Conformational stability of PrPSc: variation between samples 
In order to compare the stability of PrPSc in the frontal cortex more precisely between 
vCJD and MM1 sCJD, additional samples from the same cases were analysed by 
CDI following treatment with increasing concentrations of GdnHCl. Two additional 
samples for each vCJD case and one additional sample for each MM1 sCJD case 
were investigated. Among the three cases of vCJD, different samples of vCJD3 were 
similar in their unfolding kinetics induced by increasing concentrations of GdnHCl 
and the GdnHCl1/2 values for this case were in the range of 1.785M ~ 1.933M 
(Figure 4.7b, Table 4.1). In contrast, the denaturation profiles of PrPSc induced by 
increasing concentrations of GdnHCl were significantly variable between samples of 
vCJD1 (Figure 4.7a). In the initial sample of vCJD1 less than 5% of PrPSc molecules 
were unfolded to the exposure to 1M GdnHCl, whereas more than 20% of PrPSc 
molecules from the 2nd sample of this case were denatured by the exposure to 1M 
GdnHCl. The difference between sample 1 and sample 2 was more prominent in the 
concentration of 1.5M GdnHCl; about 25% of PrPSc molecules were denatured in the 
sample 1, whereas more than 60% of PrPSc molecules were denatured in the sample 2. 
The GdnHCl1/2 value for the sample 1 was 1.993M, which is significantly higher 
than the sample 2 with the value of 1.297M (Table 4.1). The GdnHCl1/2 value for the 
sample 3 was 1.202M, which was the lowest among all the GdnHCl1/2 values 
obtained in this study from various tissues. vCJD2 case also showed some variability 
between samples in its extent to the denaturation of PrPSc, but was not as severe as 
the variability in vCJD1 (range of GdnHCl1/2 value: 1.511M ~ 1.911M) (Table 4.1). 
Contrary to sample-to-sample and case-to-case variations in vCJD, the unfolding 
kinetics of PrPSc in the frontal cortex of MM1 sCJD was relatively similar between 
the initial and additional samples (Figures 4.7c and 4.7d). The GdnHCl1/2 values 
were also relatively similar between the two samples each of three MM1 sCJD cases 
(Table 4.2). The investigation of additional samples showed that significant 
variations of PrPSc in the degrees of resistance to GdnHCl-induced denaturation are 
present in the frontal cortex of vCJD, but not in MM1 sCJD. However, the initial 
observation that PrPSc from MM1 sCJD brains was more resistant to GdnHCl 
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treatment than that of vCJD remains true even when variations in vCJD readings are 
taken into account. The additional groups of samples from the vCJD cases generally 
had higher or similar susceptibility to GdnHCl-induced denaturation than initial 
group of samples. When all tested vCJD and MM1 sCJD samples were considered, 
difference between the two disease phenotypes was highly significant for the 1.5M 
and 2.0M readings with P values of < 0.001. Overall, these results strengthen the 
suggestion that PrPSc in the frontal cortex of MM1 sCJD is more stable to a 
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Figure 4.7 Comparison of GdnHCl-induced denaturation of PrPSc between 
samples. Frontal cortex samples from individual brains (vCJD1[a], vCJD3[b], 
MM1-1[c], and MM1-3[d]) were treated with increasing concentrations of GdnHCl 
and assayed by CDI. Denatured fraction of PrPSc in each concentration of GdnHCl 
was calculated as described in section 4.2.2. The initial results (empty symbols, 
sample 1 in Tables 4 and 5) were compared with the results of additional samples 
(filled symbols, sample 2 in Tables 4 and 5). Data represent average ± S.D. of three 
to four independent experiments in triplicate except for the 2nd samples of vCJD3 and 
































































































































Table 4.1 GdnHCl1/2 values for PrP
Sc from frontal cortex of vCJDa 
ID vCJD1 vCJD2 vCJD3 Average 
Sample 1  1.993±0.018b 1.650±0.060b 1.785±0.129b  1.809±0.173 
Sample 2  1.297±0.162b 1.911±0.099b 1.821±0.020c  1.676±0.331 
Sample 3  1.202±0.066c 1.511±0.118c 1.933±0.031c  1.549±0.367 
Average 1.497±0.432 1.690±0.203 1.846±0.077 1.678±0.175d  
 
Note a. The GdnHCl1/2 values were interpolated using a best-fit of a second order polynomial 
curve in Excel.  
b. Data represent average ± S.D. of three to four independent experiments in triplicate. 
c. Data represent average ± S.D. for triplicate wells of one-time experiment except for 
3rd sample of vCJD3 (duplicate wells).   







Table 4.2 GdnHCl1/2 values for PrP
Sc from frontal cortex of MM1 sCJDa 
ID MM1-1 MM1-2 MM1-3 Average 
Sample 1 2.266±0.074b, c 2.350±0.043c, d 2.411±0.085d 2.342±0.073 
Sample 2 2.281±0.138d 2.115±0.026e 2.642±0.072e 2.346±0.269 
Average 2.274±0.011 2.232±0.166 2.527±0.163 2.344±0.159f
 
Note a. The GdnHCl1/2 values were interpolated using a best-fit of a second order polynomial 
curve in Excel.  
         b. Data represent average ± S.D. of two independent experiments in triplicate. 
 c. Results from two different samples are combined.  
         d. Data represent average ± S.D. of three independent experiments in triplicate. 
         e. Data represent average ± S.D. for triplicate wells of one-time experiment. 
         f. This average represents average ± S.D. for horizontal axis. 
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4.3.5 Analysis of additional cases at concentrations of 1.5M and 2M GdnHCl  
The analysis of multiple samples from three cases each of vCJD and MM1 sCJD 
revealed difference in the stability of N-terminal region of PrPSc. The discrimination 
between the two phenotypes was clear in the range of 1.5M ~ 2M of GdnHCl. In 
order to investigate further the discrimination based on the stability of PrPSc, 10 cases 
each from these two CJD phenotypes were analysed to determine their denatured 
fraction of PrPSc at these two concentrations of GdnHCl. After aliquots of samples 
were centrifuged and supernatants were carefully removed, pellets were resuspended 
to a final volume of 36µl with GdnHCl at different concentrations (0M, 1.5M, 2M, 
and 7M) and assayed by CDI. The denatured fractions of PrPSc at the concentrations 
of 1.5M and 2M GdnHCl were expressed as the relative values (%) of the TRF 
counts at these concentrations of GdnHCl against the counts at 7M GdnHCl (100%). 
As shown in Figure 4.8, the denatured fractions of PrPSc from the two phenotypes 
were clearly separated in both concentrations of GdnHCl. While the denatured 
fraction of PrPSc after incubation with 1.5M GdnHCl was lower than 20% in all 
MM1 cases, there was no case of vCJD with denatured fraction of PrPSc being lower 
than 20%. At the concentration of 2M GdnHCl, the two phenotypes were also 
separated around the point of 40% of denatured fraction. Statistical analysis 
confirmed that the degree of fractional denaturation was significantly different 
between vCJD and MM1 sCJD at both concentrations with P values of < 0.001 
(1.5M) and < 0.0001 (2.0M) respectively.  
 
The degree of denaturation of PrPSc in MM1 sCJD was similar between cases in both 
concentrations of GdnHCl, except for one case. In comparison, the extent of 
unfolding of PrPSc in vCJD was found to vary between cases, as shown by widely 
scattered data points in Figure 4.8a. This variable stability of vCJD PrPSc against 
GdnHCl-induced denaturation was in accordance with the results obtained from 


































Figure 4.8 Denatured fraction of PrPSc after treatment with 1.5M or 2M GdnHCl. 
Frontal cortex samples from vCJD or MM1 sCJD were treated with different 
concentrations of GdnHCl (0M, 1.5M, 2M, and 7M) and assayed by CDI. Denatured 
fraction of PrPSc in each concentration of GdnHCl was calculated as described in 
section 4.2.2. (A) Scatter diagram of denatured fraction of PrPSc from 10 vCJD cases 
(white diamonds) and 10 MM1 sCJD cases (black diamonds). The results from 
individual cases were plotted against the concentration of GdnHCl. (B) The averages 
of the 10 vCJD cases (white bars) and of the 10 MM1 sCJD (black bars) are shown 






























































4.3.6 Conformational stability of vCJD PrPSc: comparison between brain 
regions 
To examine the conformational stability of PrPSc in additional regions of vCJD 
brains, extracts of cerebellum and thalamus from three vCJD cases were analysed by 
CDI following GdnHCl-induced denaturation as described for frontal cortex. Similar 
to the results from vCJD FC, the denaturation profiles of PrPSc from both brain 
regions formed a single sigmoidal curve with one major transition around 1M ~ 
2.5M (Figure 4.9). In both regions, around 15 ~ 20% of PrPSc molecules were 
denatured at 1M GdnHCl and most of PrPSc molecules were denatured by the 
treatment with 2.5M GdnHCl. When the results from vCJD cerebellum and thalamus 
in Figure 4.9 were compared with those of frontal cortex in Figures 4.6 and 4.7, the 
denaturation profiles from the two regions did not seem to significantly differ from 
that of frontal cortex. Statistical analysis of the values obtained at 1.5M and 2.0M 
confirmed that none of these pair-wise comparisons achieved significance (P > 0.05). 
The GdnHCl1/2 values for vCJD cerebellum and thalamus were 1.643M and 1.445M, 
respectively (Table 4.3), which were within the range of the GdnHCl1/2 values for 











Figure 4.9 GdnHCl-induced denaturation of PrPSc from cerebellum or thalamus 
of vCJD brains. Extracts of cerebellum or thalamus from vCJD brains were 
centrifuged and the resultant pellets were exposed to increasing concentrations of 
GdnHCl. The degree of unfolding of PrPSc was measured by CDI and denatured 
fraction of PrPSc was calculated as described in section 4.2.2. Data represent the 
average ± S.D. of three individuals. The result from cerebellum was an average of 
three independent experiments in triplicate and the result from thalamus was an 




Table 4.3 GdnHCl1/2 values for PrP
Sc from cerebellum and thalamus of vCJDa,b 
Region vCJD1 vCJD2 vCJD3 average 
Cerebellumc 1.626±0.022 1.658±0.087 1.646±0.211 1.643±0.016 
Thalamusd 1.440±0.044 1.289±0.030 1.607±0.118 1.445±0.159 
 
Note a. The GdnHCl1/2 values were interpolated using a best-fit of a second order polynomial 
curve in Excel.  
         b. Data from both regions are based on the examination of one sample in all three cases.   
         c. Data represent average ± S.D. of three independent experiments in triplicate. 

































4.3.7 Conformational stability of PrPres 
PrPSc molecules in vCJD and sCJD (MM1, VV2) were distinguishable by their 
difference in the conformational stability as measured by access to the 3F4 epitope in 
CDI following incubation with GdnHCl at various concentrations. In order to 
investigate whether the stability of PK-resistant core fragment of PrPSc (PrPres) can 
also distinguish distinct human CJD phenotypes, the homogenates prepared from 
vCJD and MM1 sCJD brains were exposed to increasing concentrations of GdnHCl 
and then digested with PK as described previously (Legname et al. 2006; Peretz et al. 
2001). In CDI the extent of unfolding of PrPSc after treatment with GdnHCl was 
measured by access to the 3F4 epitope, whereas in this assay (named conformational 
stability assay; CSA) the degree of unfolding of PrPres was measured as a loss of 
resistance to PK-induced degradation, as measured by 3F4 binding in Western blot.   
 
When blots were detected by mAb 3F4, the amounts of PrPres from frontal cortex of 
both vCJD and MM1 sCJD cases were largely unchanged at concentrations up to 
1.5M GdnHCl. In vCJD, the major transition of denaturation of PrPres was observed 
between 2.0M and 3.0M GdnHCl and most of PrPres became susceptible to PK 
digestion after incubation with 3M GdnHCl (Figure 4.10a). In comparison, PrPres in 
MM1 sCJD was not greatly influenced by treatment with 2M or 2.5M GdnHCl. 
Exposure to 3M GdnHCl rendered a significant proportion of PrPres sensitive to 
proteolysis and PrPres was not detectable after treatment with 3.5M GdnHCl (Figure 
4.10a). These findings suggest overall that PrPres in MM1 sCJD is more stable to 
GdnHCl-induced denaturation than that of vCJD, in agreement with the relative 
stability of PrPSc between vCJD and MM1 sCJD shown by CDI. To investigate 
whether the mAb used for the detection of PrP has any influence on the result of 
CSA, another vCJD case was analysed in duplicate, using both the 3F4 and 6H4 
mAbs to detect the protease resistant prion protein. In both immuoblots, the decrease 
of PrPres became clear after treatment with 2.5M GdnHCl and exposure to 3M 
GdnHCl made most of PrPres susceptible to PK digestion, leaving only trace of PrPres 
(Figure 4.10b)    
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Figure 4.10 Conformational stability of PrPres from frontal cortex of vCJD and 
MM1 sCJD brains. Brain samples were treated with increasing concentrations of 
GdnHCl (0 - 4M, as indicated) and then subjected to PK digestion at the 
concentration of 20μg/ml for 1 hour at 37°C. After methanol precipitation of protein, 
samples were analysed by Western blotting. (A) PrPres from vCJD and MM1 sCJD 
were probed with anti-PrP mAb 3F4. This image was obtained by scanning on a 
storm 860. (B) Duplicate blots from another vCJD case were probed with the mAb 
3F4 recognizing N-terminal region of PrP or with the mAb 6H4 recognizing PrP core 
region. 
 
















4.3.8 Conformational stability of PrPSc in GSS cases with P102L mutation 
To examine the conformational stability of PrPSc in an additional phenotype of 
human prion disease, two GSS cases that carried the P102L mutation linked to 
methionine at codon 129 but differed radically in their PrPres Western blot profiles 
were examined by CDI following incubation with GdnHCl at various concentrations. 
For analysis, detergent-insoluble pellet fraction of PrP was prepared using frontal 
cortex tissue. In both GSS cases, the denaturation curves of PrPSc formed a single 
sigmoidal curve with one major transition and reached their plateaus at the 
concentration of 3M GdnHCl (Figure 4.11). However, the degrees of unfolding of 
PrPSc appeared distinct between the two GSS cases at lower concentrations of 
GdnHCl. In the case showing typical three bands of PrPres in addition to a small 
fragment of ~8 KDa, the major fractional transition of PrPSc from native to denatured 
state was observed in the range of 1.5 - 3M GdnHCl (GdnHCl1/2: 2.399M). In 
comparison, the major fractional transition was seen in the range of 1 - 2.5M 
GdnHCl in the other case with proteolytic fragments of predominantly ~8 KDa 
(GdnHCl1/2: 1.877M). Therefore, the two P102L GSS cases that differed radically in 
their PrPres profiles were also distinct in the stability of PrPSc against GdnHCl-





















Figure 4.11 Comparison of denaturation profiles of PrPSc between two GSS 
cases with different PrPres patterns. PrPSc denaturation profile from a GSS case 
with typical three-band PrPres (empty squares) was compared with that from another 
GSS case with proteolytic fragments of predominantly ~8 KDa (filled squares). 
Extracts of frontal cortex from the two cases were centrifuged and the resultant 
pellets were incubated with increasing concentrations of GdnHCl. The extent of 
unfolding of PrPSc between native (0M) to denatured (7M) state was investigated by 







































4.4.1 GdnHCl-induced denaturation of brain homogenate containing mixed 
PrP conformers  
Initially, in this study, crude brain homogenates were assayed by CDI following 
incubation with various concentrations of GdnHCl. In contrast to the samples from 
control brains, CJD samples containing both PrPC and PrPSc showed gradual increase 
of CDI signals according to the increase of GdnHCl, implying fractional transition of 
PrPSc from native to denatured state. Similar to the observation in hamster prion 
strains (Safar et al. 1998), most of PrPSc molecules in both vCJD and MM1 sCJD lost 
their disease-associated structure in the 3F4 epitope with the exposure to the 3M 
GdnHCl. Although it appears that the 3F4 binding site of PrPSc in vCJD started being 
exposed in lower concentration of GdnHCl than that of MM1 sCJD, variations in the 
level of PrPC between samples/cases make more precise comparison difficult.  
 
4.4.2 Conformational stability of PrPSc: analysis of detergent-insoluble 
fraction of PrP 
In order to measure the extent of unfolding of PrPSc more precisely by avoiding the 
interference of PrPC, this study utilized detergent-insoluble fraction of PrP. As 
described previously (Meyer et al. 1986; Thackray et al. 2007a; Wadsworth et al. 
2006), PrPC molecules in both control and CJD brains were mostly present in the 
detergent-soluble supernatant fraction and a major proportion of PrPSc in CJD brains 
was recovered in the detergent-insoluble pellet fraction.   
 
The analysis of PrPSc (or detergent-insoluble fraction of PrP) from frontal cortex 
tissues has shown that gradual unfolding of PrPSc by increasing concentrations of 
GdnHCl produced a single sigmoidal curve with the major transition occurring 
between GdnHCl concentrations of 1M and 3M. The denaturation curve for vCJD 
was displaced to the left when compared to sCJD (MM1 and VV2) and the 
GdnHCl1/2 value in vCJD was ~ 0.65M lower than those of both subtypes of sCJD. 
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Further comparative analysis of multiples cases at the concentrations of 1.5M and 
2.0M GdnHCl also displayed clear separation between vCJD and MM1 sCJD. 
Therefore, it appears evident that PrPSc in MM1 and VV2 subtypes of sCJD is 
structurally more stable against GdnHCl-mediated denaturation than that of vCJD 
when measured by access to the 3F4 epitope in CDI. Although the difference 
between vCJD and MM1 sCJD is clear and reproducible, a degree of inter-sample 
and/or inter-case variability was also observed in the frontal cortex of vCJD. This 
variability may reflect genuine micro-heterogeneity in PrPSc stability, or it may 
reflect confounding factors associated with cellular and molecular properties of the 
tissue sampled. Intriguingly, the stability of PrPSc in the GSS case characterized by 
PrPres of 20 - 30KDa is closely similar to that of sCJD, whereas the stability of PrPSc 
in the other GSS case with proteolytic fragment of predominantly ~8KDa is similar 
to that of vCJD.  
 
Although this study examined the stability of the "detergent-insoluble" fraction of 
PrP and was conducted in a limited number of disease phenotypes and/or cases, 
taken together, the results suggest that the structural stability of PrPSc as determined 
by CDI is not uniform among human prion diseases and is at least partly independent 
of the conventional Western blot PrPres type (fragment size) and the PRNP genotype 
(pathogenic mutations and codon 129). This notion is further supported by a recent 
study that investigated the stability of PrPres in sCJD with MM genotype at codon 
129 (Cali et al. 2009). It would be of interest to investigate whether further 
meaningful distinctions can be made between examples of the full range of human 
prion diseases, including other subtypes of sCJD, fatal familial insomnia and the 
more recently described protease sensitive prionopathy. 
 
Similar to the findings in this study, a recent study characterizing PrPSc-specific 
peptides also reported that PrPSc in vCJD was more sensitive to GdnHCl-mediated 
denaturation than PrPSc in MM1 sCJD (Lau et al. 2007). In the study by Lau and 
colleagues, CJD brain samples were treated with increasing concentrations of 
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GdnHCl and subsequently incubated with beads coated with a PrPSc-specific peptide. 
When the peptide-bound PrP molecules were examined by sandwich ELSIA 
employing a capture antibody recognizing C-terminal region of PrP, the difference in 
GdnHCl1/2 values was ~ 0.6M between the two forms of CJD (Table 4.4) (Lau et al. 
2007). Thus, the result based on PrPSc-specific peptide is very closely similar to that 
of this study, despite the difference in methodology between the two studies. 
Moreover, the unfolding pattern of PrPSc shown by the two studies is practically 
identical to each other in that they formed a single sigmoidal curve with one major 
transition, although Lau's denaturation curves were turned upside down compared to 
this study’s due to the difference in methodology (Lau et al. 2007). 
  
4.4.3 Conformational stability of PrPres   
The conformational stability assay based on the CDI has shown that the 3F4 epitope 
of PrPSc is more stable in sCJD (MM1 and VV2 subtypes) than that of vCJD, but this 
result may not necessarily mean that C-terminus of PrPSc is also more stable in sCJD 
than vCJD. To explore this possibility, one vCJD and one MM1 sCJD cases were 
examined by CSA, in which the degree of susceptibility to GdnHCl-induced 
denaturation is measured as a loss of resistance to PK-induced degradation. 
Consistent with the results based on the CDI, CSA has also shown that PrPres in 
MM1 sCJD is more resistant to GdnHCl-induced denaturation than that of vCJD.  
 
However, unlike PrPres in vCJD and MM1 sCJD, the region-dependent 
conformational stability of PrPres was reported in the Chandler strain in a recent study 
(Shindoh et al. 2009); the region comprising residues 81 and 137 of PrPres in this 
laboratory strain was found to be denatured by GdnHCl at relatively lower 
concentration and thus more easily became PK-susceptible, whereas the remaining 
C-terminal region was highly resistant to GdnHCl-induced denaturation. Thus, the 
GdnHCl1/2 values determined by mAbs recognizing amino acids 81 and 137 were 
significantly lower than those determined by mAbs recognizing C-terminal region (~ 
1.8M versus ~ 3.5M). Interestingly, the loss of the region encompassing amino acids 
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81 and 137 led to the almost complete loss of prion infectivity, although the intensity 
of PrPres bands composed of the remaining C-terminal region was compatible to that 
of PrPres starting at residue 81 (Shindoh et al. 2009). It is of note that the low 
infectivity in the synthetic prions, the amyloid form of mouse recombinant PrP 
spanning residues 89-230, was also explained by the proteolytic liability of the 
region spanning residues 90-138, which is almost identical to the region described by 
Shindoh et al. (Bocharova et al. 2005; Legname et al. 2004)  
 
Cali et al. examined the stability of PrPres using CSA in sCJD with MM genotype at 
codon 129 (Cali et al. 2009). In this study, PrPres in MM1 sCJD was found to be 
significantly more stable than that of MM2 with the difference in GdnHCl1/2 values 
of ~1.3M (Table 4.4). Therefore, the results from Cali's study is consistent with this 
study in that type 1 PrPres is more stable than type 2 PrPres in CJD with MM genotype 
at codon 129. Another group of investigators examined the stability of PrPSc from 
bank voles which were inoculated with various kinds of natural TSE sources 
(Pirisinu et al. 2009). The methodology used to measure the stability of PrPSc by 
Pirisinu et al. was different from this study as well as CSA; while the conventional 
CSA measures the extent of unfolding of PrPSc as a loss of resistance to PK-induced 
degradation, the conformational stability assay employed by Pirisinu et al. assesses 
the degree of unfolding of PrPSc as a loss of detergent insolubility (Pirisinu et al. 
2009). Interestingly, the higher structural stability of PrPres in MM1 sCJD (as 
compared to MM2 sCJD) was found to be conserved when these diseases were 
transmitted to bank voles (Table 4.4). This positive correlation in the conformation 
stability of PrPSc between sCJD and bank voles propagating sCJD prions strongly 
supports the notion that this biochemical parameter plays an important role in 
determining biological properties of prion strains (Colby et al. 2009; Legname et al. 
2006). 
 
4.4.4 Conformational stability of PrPres: importance in determining disease 
incubation periods  
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The conformational stability of PrPres was found to correlate with incubation periods 
of synthetic and laboratory prion strains that have been propagated in mice (Legname 
et al. 2006); generally, the prion strains with higher stability of PrPres exhibited 
longer incubation periods. The hypothesis that incubation time is a function of PrPSc 
stability (in addition to the known factors such as titre, route and PrP expression level 
and sequence) was further tested by artificially producing an array of synthetic PrP 
amyloids differing in their conformational stability and then testing their biological 
properties (Colby et al. 2009). The results showed that a more labile PrPSc 
conformation correlated with faster replication and shorter incubation periods. How 
such considerations might relate to human prion diseases is unclear at this point in 
time, however the finding that vCJD PrPSc is less stable than that of sCJD may be 
interpreted as a further reason for concern regarding the potential for secondary 
transmission of the promiscuous BSE/vCJD prion strain.  
 
4.4.5 Conformational stability of PrPSc/PrPres: limitation in inferring the 
conformational state 
Despite the emerging importance of conformational stability as a biochemical 
parameter that is associated with disease incubation periods, its limitation is also 
evident in inferring conformational state of PrPSc. For example, the conformational 
stability of PrPSc expressed as the GdnHCl1/2 value was indistinguishable between 
MM1 and VV2 subtypes of sCJD, despite their phenotypic difference (Parchi et al. 
1999b; Parchi et al. 1996); a GSS case with P102L mutation characterized by the 
presence of PrPres of 20 - 30KDa was also indistinguishable from the two subtypes of 
sCJD. Similarly, the stability of PrPres measured by CSA was shown to be similar 
between laboratory prion strains that differ in disease phenotype and/or in the 
fragment size of PrPres (Makarava et al. 2010; Peretz et al. 2001; Peretz et al. 2002). 
Thus, the similarity in the stability of PrPSc does not necessarily mean the 
propagation of a same prion strain. Although the stability of PrPSc/PrPres alone is of 
limited use in discriminating prion strains, however, this methodology may be useful 
in distinguishing prion strains that are phenotypically distinct but not distinguishable 
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by one-dimensional gel electrophoresis as shown in previous studies (Peretz et al. 
2001; Peretz et al. 2002).  
 
4.4.6 Speculation on the effects of detergent in protein conformation 
In this study, the detergent of N-laurylsarcosinate sodium salt (Sarcosyl) was used at 
the concentration of 2% for the preparation of brain homogenates, which may 
interfere with the tertiary and quaternary structures of PrPSc aggregates by disrupting 
hydrophobic interactions (Tanford 1968). This possibility is supported by a recent 
study that showed the differential susceptibility of PrPSc to Sarcosyl-induced 
denaturation between mouse-adapted scrapie strains (Thackray et al. 2007b). This 
detergent is also known to induce the aggregation and fibril formation of PrPC 
molecules at low concentrations (0.001 - 0.1%), enhancing ß-sheet secondary 
structure (Xiong et al. 2001).  
 
4.4.7 Speculation on the mechanism of PrPSc denaturation by GdnHCl 
Chaotropic agents like GdnHCl disrupt hydrogen bonds that are responsible for the 
secondary structure (α-helices and ß-sheets) of proteins (Tanford 1968). Since 
hydrogen bonding also helps maintain tertiary and quaternary structures of proteins, 
chaotropic agents can also affect these structural aspects. Thus, the GdnHCl-induced 
denaturation of PrPSc molecules can occur at least in two different levels: loss of 
secondary structure (i.e. uncoiled into an irregularly coiled polypeptide) and loss of 
tertiary/quaternary structure (i.e. dissociation of PrPSc aggregates).  
 
In a previous study that examined dissociation/unfolding pathways of PrPSc in 
hamster prion strains during exposures to ascending concentrations of GdnHCl 
(Safar et al. 1993), the GdnHCl-induced denaturation of PrPSc molecules was 
reported to consist of a four-step pathway: (a) aggregates → (b) dissociated folded 
monomer → (c) partially unfolded intermediate → (d) unfolded monomer. The 
dissociation of PrPSc aggregates into folded monomers occurred with the midpoint of 
transition at 1.5 - 2.0M GdnHCl, followed by the state of stable intermediate 
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(midpoint of transition: ~ 3.5M GdnHCl). Given that the hidden recognition site of 
mAb 3F4 becomes accessible in most of the PrPSc molecules following incubation 
with 3M GdnHCl, the degree of unfolding of PrPSc molecules measured by CDI 
probably reflects the degree of dissociation of aggregated PrPSc. However, the loss of 
ß-sheet structure following incubation with GdnHCl may also contribute to the CDI-
based denaturation profiles, since the region with the 3F4 epitope acquires high ß-
sheet content during the conversion of PrPC into PrPSc (Huang et al. 1995; Langedijk 
et al. 2006) and the acquisition of ß-sheet structure makes the 3F4 epitope 
inaccessible (Safar et al. 1998). Despite these speculations, the exact mechanism by 
which GdnHCl denatures PrPSc remains elusive (Legname et al. 2006).  
 
4.4.8 Summary 
In summary, this study has addressed the conformational stability of PrPSc in 
different phenotypes of human prion disease using the conformation-sensitive mAb 
3F4 in CDI, which reveals that this biochemical parameter may represent another 
marker of PrPSc structure that is not directly associated with the PrPres type and/or the 
PRNP genotype. Given the relevance of conformational stability to disease 
incubation periods (Colby et al. 2009; Legname et al. 2006), the analysis of 
conformational stability of PrPSc in human prion diseases is believed to help 
understand molecular aspects relevant to determining disease phenotypes.  
 221



















1.850 2.450 N.Da N.Da 
human 
brain 




N.D. 2.760 1.420 N.Da 
human 
brain 










Note a. N.D = not determined 
         b. Lau et al. used sandwich ELISA to detect PrPSc following capture with a PrPSc-
specific peptide. Two different capture antibodies were used in the sandwich ELISA. 
The results shown in this table are based on the capture antibody recognizing C-
terminus of PrP. When the antibody recognizing N-terminus was used in sandwich 
ELISA, the difference in the GdnHCl/2 value between vCJD and MM1 sCJD was 
~0.85M (vCJD: 1.6M, MM1: 2.44M). It is worth noting that the recognition site of 
Mar-1 used as a capture antibody in CDI recognizes C-terminus of PrP associated 


























5.1 Summary of findings  
The main goal of this study was to investigate disease-associated prion protein 
(PrPSc) accumulated in CJD brains through biochemical approaches that differ in 
principle from conventional Western blot analysis of PK-resistant fragments of PrPSc 
(PrPres). For this, pathological human brain materials were examined by assays 
including conformation-dependent immunoassay (CDI), sucrose gradient 
centrifugation and stability assay combined with CDI. These novel biochemical 
approaches have allowed for the analysis of conformational and size classes of PrPSc, 
thus providing a more complete description of PrPSc species occurring in human 
brains affected with prion disease.  
 
5.1.1 PrPC in CJD brains 
Since the binding site of the mAb 3F4 employed as a detector in CDI is not 
accessible in native PrPSc in contrast to PrPC, CDI fluorescence signals obtained from 
native samples represent PrPC. Therefore, CDI can distinguish PrPC from PrPSc in 
CJD brains. When multiple samples from different forms of CJD brains were 
analysed by CDI, PrPC was readily detectable in all examined CJD samples 
irrespective of disease phenotypes or brain regions. To the best of my knowledge, 
this study is the first direct approach to a description of PrPC present in human brains 
infected with prions. The presence of PrPC in CJD brains is perhaps to be expected 
because PrPC serves as a precursor protein of PrPSc and thus its presence is a 
prerequisite for the replication of PrPSc (Bueler et al. 1993; Caughey and Raymond 
1991). Moreover, the ubiquitous presence of PrPC in CJD brains appears to provide 
additional support for the notion that PrPC is closely linked to the neurotoxicity 
observed in prion-infected brains (Brandner et al. 1996; Mallucci et al. 2003).   
 
In this study, PrPC is defined as PrP molecules with the 3F4 epitope accessible in 
CDI. If topological variants of PrP such as cytosolic PrP (cyPrP) and a 
transmembrane form of PrP with its N-terminus exposed to the cytosol (ctmPrP) are 
accessible by the mAb 3F4 (which looks quite possible), they will be classified as 
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"PrPC" in CDI. Accordingly, PrP molecules defined as "PrPC" in this study are 
thought to contain not only secreted form of cell-surface PrP but also those aberrant 
PrP species. A proportion of PrPC from the thalamus of vCJD or frontal cortex of 
MM1 sCJD was found to migrate to the heavier fractions of the sucrose gradient, 
which may be associated with the aggregates formed from those topological variants 
(Ma and Lindquist 2001). Given that transgenic mice expressing cyPrP and/or ctmPrP 
were found to develop fatal neurodegeneration (Chakrabarti and Hegde 2009; Hegde 
et al. 1998; Ma and Lindquist 2002; Stewart et al. 2005), they may contribute to the 
disease pathogenesis. These aberrant PrP species can be more important in several 
genetic forms of human prion disease such as FFI, which do not accumulate 
substantial amount of PrPSc in the brain despite fatal clinical disease (Almer et al. 
1999; Brown et al. 1995; Parchi et al. 2000a). Moreover, neuronal loss and gliosis in 
diseased human brains do not appear to be directly associated with the local burden 
of PrPSc (Parchi et al. 1995; Parchi et al. 2000a). Therefore, it would be interesting to 
investigate the level of these topological variants of PrP in prion-affected human 
brains and to determine their sedimentation profiles in the sucrose gradient. For this, 
an antibody that selectively recognizes them by virtue of their uncleaved ER-
targeting signal peptide may be methodologically helpful (Stewart and Harris 2003).  
  
5.1.2 PrPSc in CJD brains: comparison between 3F4-based CDI and 
resistance to limited proteolysis 
When PrPSc as defined by the accessibility of 3F4 binding site (in CDI) was 
compared with that defined by resistance to limited proteolysis (in WB) using 
multiple samples with different regional origins from various CJD phenotypes, there 
was a good overall correlation between the two possible biochemical criteria that 
define PrPSc. However, the occasional discordance between the two measurements of 
PrPSc was also evident between samples from the same brain. Interestingly, in all 
three vCJD cases, PrPres (based on PK-resistance) was more abundant in the thalamus 
despite similar or higher levels of PrPSc (based on CDI) in the cerebellum. The CDI 
analysis following limited proteolysis has shown that PK-sensitive form of PrPSc is 
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present to a significant level in CJD brains, although the estimated proportion of PK-
susceptible PrPSc to total PrPSc does not appear as high as the level reported by Safar 
and colleagues (Safar et al. 2005a). Taken together, the occasional disagreement 
between the two biochemical measurements of PrPSc can be most likely explained by 
non-uniform distribution of PK-sensitive isoform of PrPSc in individual prion-
infected brains. Currently, it remains to be determined whether PK-sensitive PrPSc is 
a metabolic intermediate in the formation of PK-resistant PrPSc or whether it 
represents another pathogenic isoform of PrP, which is specific to CJD brain, but is 
not associated with metabolic pathway leading to the formation of PK-resistant PrPSc 
(Tremblay et al. 2004; Tzaban et al. 2002). Serial transmission of PK-sensitive 
synthetic prions, which were generated by polymerizing recombinant mouse PrP into 
amyloid fibers did not lead to the formation of PK-resistant PrP (Colby et al. 2010). 
In naturally occurring prion diseases, it remains largely obscure how significantly 
PK-sensitive fraction of PrPSc contributes to the biological properties of prions such 
as disease infectivity and strain property (Cronier et al. 2008; Deleault et al. 2008).    
 
5.1.3 Distribution profiles of PrPSc between the three regions in CJD brains 
In this study, multiple brain samples with three different regional origins (frontal 
cortex, cerebellum and thalamus) from different CJD phenotypes were examined by 
CDI and WB (following limited proteolysis), which made it possible to compare the 
distribution profiles of PrPSc in the three brain regions between cases and phenotypes. 
When the three forms of CJD with MM genotype at codon 129 were compared, the 
topography of abnormal PrP appears to be different between vCJD and two MM 
sCJD subtypes. In the vCJD brains, abnormal PrP was more abundant in the 
cerebellum (based on CDI) or in the thalamus (based on PK-resistance). In contrast, 
both types of MM sCJD harboured more abundant amounts of abnormal PrP in the 
frontal cortex, except for one MM1 case showing similar levels of abnormal PrP 
between the three regions. Although it is not legitimate to generalize this observation 
due to the very small number of cases (three cases per phenotype), it should be 
stressed that the results obtained from both MM subtypes of sCJD are consistent with 
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previous studies in which distribution profiles of PrPres were examined in wider brain 
areas from more sCJD cases (Parchi et al. 1996; Schoch et al. 2006).  
 
Interestingly, one MV2 case (MV2-2) has shown the distribution profile of abnormal 
PrP which is distinct from the two other MV2 cases but is similar to those of MM2 
cases. Furthermore, this MV2 case has pathological features resembling MM2 
subtype of sCJD without showing any detectable kuru plaques in the cerebellum. 
This atypical MV2 case whose biochemical and neuropathological profiles are 
similar to MM2 subtype of sCJD does not appear to fit in with even an updated 
version of the classification system of sCJD (Parchi et al. 2009b). The identification 
of MM2-like MV2 case raises a question on whether sCJD can be fully classified 
into distinct subtypes based on the PRNP codon 129 genotype and PrPres type. This 
question has a common thread with whether sCJD comprises discrete clinico-
pathological entities or is a wide phenotypic spectrum of disease (Head and Ironside 
2009). It remains uncertain whether biochemical and neuropathological similarities 
between the MV2-2 and MM2 cases are associated with the propagation of the same 
prion strain.  
 
5.1.4 PrPSc in CJD brains: sedimentation profiles in the sucrose step 
gradient                                                                                                                                                                 
When fractionated in the 10 - 60% sucrose step gradient, PrP molecules from the 
non-CJD brains were mostly recovered in top few fractions, whereas those from CJD 
brains spread throughout the gradient, reaching the heaviest bottom fraction. When 
fractionated samples from different regions of vCJD brains were assayed by CDI, the 
distribution profiles of PrPSc in the sucrose gradient were significantly different 
between regions. While PrPSc from the frontal cortex and cerebellum of vCJD was 
mainly recovered in the bottom three fractions leaving very low levels of PrPSc in the 
intermediate fractions, PrPSc from the thalamus was present throughout the gradient 
although PrPSc signals were still strongest in the bottom three fractions. The 
sedimentation profile of PrPSc from the frontal cortex of MM1 sCJD was similar to 
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that of frontal cortex of vCJD, except that PrPSc species recovered in the intermediate 
fractions were a bit more abundant in MM1 sCJD than vCJD.  
 
It remains to be determined whether the separation of PrP molecules achieved in the 
10 - 60% sucrose gradient fully reflects their size or is influenced by their buoyant 
density. If PrPSc consists exclusively of PrP, its sedimentation property in the sucrose 
gradient will be a direct reflection of size. In this case, PrP species recovered in the 
intermediate fractions are believed to represent oligomeric forms of PrPSc with sizes 
as small as 600 KDa (Tzaban et al. 2002). The significant abundance of PrPSc in the 
intermediate fractions from the thalamus of vCJD is of particular interest because the 
oligomeric forms of PrPSc may be more relevant to neurotoxicity than large 
aggregates (Caughey and Lansbury 2003; Kristiansen et al. 2007; Simoneau et al. 
2007). The pathological feature seen in the posterior thalamus of vCJD (severe 
neuronal loss and marked astrocytosis) may be associated with the abundance of the 
oligomeric species of PrPSc in this region. It also appears possible that certain 
population of neurons may be more vulnerable to certain species of PrPSc such as 
oligomeric forms of PrPSc, which is conceptually similar to the selective neuronal 
vulnerability described in previous studies (Bouzamondo et al. 2000; Guentchev et al. 
1997; Guentchev et al. 1998; Guentchev et al. 1999). The PrPSc molecules identified 
in the top first fraction of the gradient (again in the thalamus of vCJD) may be as 
small as the size of PrP dimers or trimers, judging from the ionizing radiation study 
(Bellinger-Kawahara et al. 1988) or recently proposed trimeric PrPSc models 
(DeMarco and Daggett 2004; Govaerts et al. 2004).  
 
However, PrPSc is known to have strong affinity for lipids (Safar et al. 2006) and 
sphingolipids are still detectable in highly purified prion rods (Klein et al. 1998). In 
contrast to PrPC, PrPSc is not cleaved from plasma membrane by the enzymatic 
treatment with phosphatidylinositol-specific phospholipase C (PIPLC)(Safar et al. 
1991; Stahl et al. 1990). Moreover, lipids may facilitate the conversion of PrPC into a 
PrPSc-like conformation (Kazlauskaite et al. 2003; Wang et al. 2007) and act as a 
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cofactor facilitating the formation of prions (Wang et al. 2010). Taken together, 
PrPSc may contain lipids after the detergent extraction of the condition used. In this 
case, the sedimentation property of PrPSc-containing complex can be influenced by 
its buoyant density in addition to its size. This possibility appears to be more relevant 
to the thalamus of vCJD in which a significant proportion of PrPSc was identified in 
the top and intermediate fractions of the sucrose gradient. 
 
5.1.5 Conformational stability of PrPSc in CJD brains  
When PrPSc-enriched, detergent-insoluble fraction was first incubated with a wide 
range of concentrations of GdnHCl and then assayed by the 3F4-based CDI, the 
incubation with 3M GdnHCl was found to be enough to disrupt disease-associated 
structure in most of the PrPSc molecules, irrespective of disease phenotypes. 
However, the degrees of stability of PrPSc to GdnHCl-induced denaturation were 
distinct between vCJD and sCJD (MM1 and VV2 subtypes) at lower concentrations 
of GdnHCl. In vCJD, the major fractional transition of PrPSc from native to 
denatured state was observed in the range of 1.0 - 2.5M GdnHCl. In both types of 
sCJD, the major fractional transition was observed in the range of 1.5 - 3.0M 
GdnHCl. The average GdnHCl1/2 value in the frontal cortex of vCJD was 1.678M, 
which was ~0.65M lower than those of both sCJD phenotypes.  
 
Although this study examined the stability of the "detergent-insoluble" fraction of 
PrP and was conducted in a limited number of cases, the results strongly suggest that 
PrPSc in MM1 sCJD is more resistant to GdnHCl-induced denaturation than that of 
vCJD. A recent study performed by Cali and colleagues has shown that PrPres in 
MM1 sCJD is more stable than that of MM2 sCJD (Cali et al. 2009). If the three CJD 
phenotypes with MM genotype at codon 129 are considered, such a conformational 
difference may be attributable to the same molecular property that is responsible for 
the Western blot type 1 / type 2 PrPres difference. However, the VV2 sCJD case 
examined here shared the conformational stability of MM1 sCJD (but not that of 
vCJD), suggesting that the conformational stability measured by CDI is based on a 
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property of PrPSc that is different from the property of PrPres that determines the 
Western blot type. Consistent with this suggestion, the behaviour of stability of PrPres 
in natural and artificial mixtures of both PrPres types could not be simply explained in 
association with their types (Cali et al. 2009). Moreover, two GSS cases which share 
P102L mutation and MM genotype at codon 129 could be distinguished by the 
stability of PrPSc. While the stability of PrPSc in the GSS case characterized by type 1 
PrPres was similar to that of sCJD, the other GSS case with proteolytic fragments of 
predominantly ~8 KDa was found to be similar in stability to vCJD. Taken together, 
the stability of PrPSc as determined by CDI does not correlate fully with PrPres type or 
the PRNP genotype (codon 129 and the presence/absence of pathogenic mutation), 
suggesting that this biochemical parameter may represent a further dimension to a 
complete description of potentially phenotype-related properties of PrPSc in human 
prion diseases.   
 
5.1.6 A proteolytic fragment of ~8 KDa in MV2 sCJD 
When the thalamus from the MV2 case (MV2-2) showing atypical biochemical and 
neuropathological features was analysed by WB following proteolysis, a proteolytic 
fragment of ~8 KDa was detected in addition to the typical three bands of 21 - 30 
KDa. The PrPres profile seen in this case is closely similar to the profile reported in 
some GSS cases with P102L mutation, which have shown PK-resistant fragments of 
21 to 30 KDa in addition to a proteolytic fragment of ~8 KDa (Parchi et al. 1998; 
Piccardo et al. 1998). The prevalence of this low molecular weight fragment in sCJD 
remains to be determined. However, small proteolytic fragments of PrP may not be 
so uncommon in sCJD (Kascsak et al. 1993; Krebs et al. 2007; Piccardo et al. 1998) 
and thus their presence may not be an absolute biochemical indicator for GSS, which 
is further supported by similar observation in a FFI case (Hill et al. 2006). 
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5.2 Outstanding questions and future research 
This study focused on the analysis of vCJD, which is most important in public health 
terms in the UK, and MM1 subtype of sCJD which is the most frequently occurring 
form of human TSE. For a fuller understanding of prions in humans, it will be 
important to expand the novel biochemical approaches into other forms of human 
prion disease including untested subtypes of sCJD, FFI, GSS and the more recently 
described PSPr. It will be also important to investigate whether PrPSc complexity 
identified in this study can be related to biological properties such as disease 
infectivity or strain property. A comparative transmission study between CJD 
samples which have similar levels of total PrPSc but differ greatly in their PrPres 
levels (for example, Cb3 and Th3 samples in MV2-3 [see section 2.3.2.2.5]) may 
give an insight into the biological significance of PK-sensitive isoform of PrPSc in 
human prion diseases. The relationship between the size of PrPSc aggregates and their 
pathological activities may be partly answered by comparing sucrose fractions 
containing PrPSc species that differ in their size and/or density. In addition to these 
outstanding questions, three more specific questions of future interest are discussed 
in detail.  
 
5.2.1 Further analysis of size distribution of PrPSc in the thalamus of vCJD 
brains   
When the thalamus tissues of vCJD were fractionated in the 10 - 60% sucrose step 
gradient, PrPSc was identified throughout the gradient and PK-resistant fraction of 
PrPSc was readily detectable even in the top first fraction. This is in sharp contrast to 
the results obtained from the two other regions (frontal cortex and cerebellum) of 
vCJD brains in which PrPSc was mainly recovered in the bottom three fractions. 
Currently, it is unclear whether the distribution profile of PrPSc molecules obtained 
from the thalamus of vCJD is directly related to aggregate sizes. A growing body of 
evidence supports the notion that small oligomeric species of PrPSc are more relevant 
to prion infectivity and neurotoxicity than large aggregates (Caughey and Lansbury 
2003; Kristiansen et al. 2007; Silveira et al. 2005; Simoneau et al. 2007). Therefore, 
 231
it will be important to determine more precisely the size classes of PrPSc in the 
thalamus of vCJD, particularly when considering that severe neuronal loss with 
marked astrocytosis in this region is one of the diagnostic pathological features in 
vCJD (Ironside et al. 2000; Ironside et al. 2002). Traditional sizing methods such as 
size exclusion chromatography or filtration may be considered for further analysis of 
size classes of PrPSc (Caughey et al. 1995; Safar et al. 1990; Tzaban et al. 2002), 
however, their drawbacks in analysing large, insoluble PrPSc aggregates are also well 
recognized (Silveira et al. 2006). The techniques of field flow fractionation which 
are known to be capable of high-resolution separation over a wide size range of PrP 
aggregates may be more applicable in determining the size distribution of PrPSc in 
the thalamus of vCJD (Silveira et al. 2006; Silveira et al. 2005; Sklaviadis et al. 
1992).  
 
5.2.2 Further analysis of conformational stability of PrPSc  
Although a limited number of cases were examined in this study, the results indicate 
that PrPSc from vCJD is more susceptible to GdnHCl-induced denaturation than PrPSc 
from the two most frequently occurring forms of sCJD (MM1 and VV2).  In a recent 
study describing the stability of PrPres in sCJD with MM genotype at codon 129, 
PrPres from MM2 sCJD was shown to be significantly more sensitive to GdnHCl-
induced denaturation than PrPres from MM1 sCJD (Cali et al. 2009). One limitation 
of the stability assay performed by Cali and colleagues lies in that they relied on 
limited proteolysis in measuring the stability of PrPSc, which precluded the analysis 
of PK-sensitive isoform of PrPSc. In this context, it would be interesting to determine 
the conformational stability of PrPSc in MM2 sCJD using the CDI. Additionally, it 
would be of interest to compare the stability of PrPSc between MM2 sCJD and sFI. 
These two rare forms of human prion disease with MM genotype at PRNP codon 129 
are not distinguishable by one-dimensional gel electrophoresis despite their 
significant difference in disease phenotypes (Parchi et al. 1999a; Parchi et al. 1999b). 
Although they were reported to be distinguishable by two-dimensional gel 
electrophoresis, questions still remain about whether differences in the glycans are 
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sufficient to explain the significant phenotypic difference between the two forms of 
disease (Pan et al. 2005b; Pan et al. 2001). In this context, it would be worthwhile to 
investigate whether the stability of PrPSc can distinguish the two rare phenotypes of 
human prion disease.    
 
Conformational stability of PrPSc in individual prion strains was reported to correlate 
with their incubation periods (Legname et al. 2006). In a more recent study from the 
same group, synthetic prion strains with various incubation periods were produced 
by varying the conformational stability of recombinant PrP amyloids (Colby et al. 
2009). Moreover, the stability of PrPSc from different forms of sCJD showed a good 
correlation with the stability of PrPSc from bank voles inoculated with sCJD 
materials (Pirisinu et al. 2009). Accordingly, it is of interest to investigate the 
stability of PrPSc in CJD inocula, in recipient mice of primary transmission and of 
subsequent passage, and then to analyse how the stability of PrPSc can be related to 
disease incubation periods in interspecies and intraspecies transmission of CJD.  
 
5.2.3 Abnormal PrP species in FFI 
It is well known that FFI has very low levels of PrPSc in the brain despite fatal 
clinical disease (Almer et al. 1999; Brown et al. 1995). Even when the case (and 
region) showing highest level of PrPres accumulation was taken for comparison, the 
overall level of PrPres was 5 to 10 times lower than that detected in sCJD (Parchi et al. 
2000a). Furthermore, although FFI is pathologically characterized by thalamic 
degeneration accompanying marked neuronal loss and astrogliosis (Gambetti et al. 
2003), the level of PrPres in this region is similar to other brain areas or, in patients 
with longer disease duration, much lower than cerebral cortex (Parchi et al. 1995). 
The sporadic form of fatal insomnia (sFI), which shares similar clinical and 
pathological profiles with FFI, was also characterized by the accumulation of very 
low level of PrPres in the brain (Parchi et al. 1999a). Therefore, it is thought that 
pathological changes of neuronal loss and gliosis in the thalamus of FFI brains may 
not be directly associated with the local burden of PrPres (Collins et al. 2001; Parchi 
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et al. 2000a). In this context, it is of interest to investigate whether neuronal loss and 
astrogliosis observed in the thalamus of FFI can be associated with other forms of 
abnormal PrP species including:  
1) PK-sensitive isoform of PrPSc (defined as PrP species which has buried 3F4 
epitope but sensitive to proteolysis); 
2) aggregated form(s) of PrPC (defined as PrP species which has exposed 3F4 epitope 
but migrates to the heavier fractions of the 10 - 60% sucrose gradient); 
3) topological variants of PrPC such as cyPrP and ctmPrP (defined as PrP species 
whose 3F4 epitope is accessible but its ER-targeting signal peptide is not cleaved).  
 
The identification of an abnormal PrP species which is more directly associated with 
the neuropathological changes seen in the thalamus of FFI may help answer why the 
selective vulnerability of a subpopulation of GABAergic neurons is significantly 





5.3 Implications of this study  
The accumulation of PrPSc is the only unambiguous marker of prion infection 
established to date and PrPSc is the only known component of the infectious prions.  
PrPSc has been operationally defined by its biochemical properties such as 
insolubility in non-denaturing detergents and/or resistance to proteolytic degradation 
(Meyer et al. 1986). The property of PK-resistance has been thoroughly exploited to 
the extent that the terms of protease-resistant prion protein (PrPres) and disease-
associated prion protein (PrPSc) are sometimes used interchangeably (Caughey et al. 
2009). In the absence of a foreign nucleic acid genome associated with prion diseases, 
the strain phenomenon in prion diseases has been explained by the conformational 
difference of PrPSc according to the prion hypothesis (Prusiner 1998). Efforts to 
provide a molecular basis for the biological diversity of prions have focused on 
biochemical characterization of PrPSc. In human prion diseases including CJD, much 
evidence supporting conformation-based strain diversity has been gathered by 
Western blot analysis of PrPres. Such assays produce information on core fragment 
size and glycosylation site occupancy of PrPres. Variation in these parameters in 
combination with PRNP genotype has been invoked as the molecular basis to 
distinguish different disease phenotypes (Hill et al. 2003; Parchi et al. 1999b; Parchi 
et al. 1996). Considering recent findings on the complexity of PrPSc largely identified 
in laboratory prion strains, however, PrPres analysis alone may not provide a 
complete description of PrPSc present in CJD brains. In that context, this study 
identifies previously unrecognised heterogeneity in PrPSc in CJD brains through the 
use of assays that differ in principle from conventional Western blot analysis of 
PrPres. The novel biochemical approaches employed in this study have identified 
complexity of PrPSc in CJD brains, not only between different forms of human prion 
disease but also within individual cases of particular disease entities. Moreover, 
recent studies have reported that biochemical parameters such as PrPres stability and 
the size of PrPres aggregates can have significant effects on the biological properties 
of prions (Colby et al. 2009; Legname et al. 2006; Silveira et al. 2005). Therefore, 
the results from this study not only provide a more complete description of PrPSc 
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species occurring in CJD but also would contribute to a fuller understanding of the 
agents that cause the disease in humans. Understanding how the PrPSc complexity 
newly recognized in this study relates with the disease phenotypes and/or prion 
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Appendix 1. Neuropathology of CJD brains 
 
In order to characterize more precisely the 15 CJD cases used for biochemical 
analysis in section 2.3.2, three brain regions (FC, Cb and Th) from each case were 
examined using histopathological and immunohistochemical techniques (Note: 
Microscopic examination of the CJD brains was carried out under the supervision of 
Prof. James Ironside. Some of the description of pathological change may paraphrase 
him or his diagnostic reports).   
 
1.1 vCJD 
Florid plaques, a characteristic pathological feature in vCJD brains (Ironside et al. 
2000), were easily identifiable in frontal cortex and cerebellum in all three vCJD 
cases (Figure A1.1a). These florid plaques were composed of an eosinophilic dense 
core with radiating fibrils in the periphery and were surrounded by vacuoles 
(Ironside et al. 2000). In addition to florid plaques, spongiform degeneration was 
also present in all three regions.  
 
Immunohistochemistry for abnormal PrP revealed strong staining of florid plaques in 
the cerebral and cerebellar cortex in addition to numerous pericellular deposits 
(Figures A1.1b and A1.1c). In the thalamus, a widespread reticular PrP 
immunoreactivity was present often in a liner and perineuronal pattern along with 
































Figure A1.1 Neuropathology in vCJD. (a) Florid plaque in the frontal cortex from 
vCJD2 (hematoxylin and eosin). Original magnification: x400. (b) 
Immunohistochemistry for PrP in the frontal cortex from vCJD2 shows intense 
labelling of plaques and pericellular deposits. Original magnification: x200. (c) 
Immunohistochemistry for PrP in the cerebellar cortex from vCJD3 shows intense 
staining of florid plaques and smaller plaques in the granular layer and pericellular 
deposits in the molecular layer. Original magnification: x200. (d) 
Immunohistochemistry for PrP in the thalamus of vCJD1 shows a widespread 
reticular staining often in a liner and perineuronal distribution. Original 
magnification: x200. In all immunostained sections, PrP was labelled with the 




1.2 MM1 sCJD 
Previous studies reported that the spongiform change in MM1 subtype of sCJD was 
characterized by microvacuolation (Cali et al. 2009; Parchi et al. 1999b; Parchi et al. 
2009a). Similar to these observations, the three MM1 subjects analysed in this study 
also showed microvacuolar spongiform degeneration (Figure A1.2a). However, in 
one of the three cases (MM1-2), confluent type of spongiform change was also 
focally identified in the thalamus. Whilst the frontal cortex in MM1-1 and MM1-3 
showed a widespread severe spongiform change, the frontal cortex in the MM1-2 
was largely spared. Both the cerebellum and thalamus in the three cases showed mild 
to moderate fine spongiform changes.  
 
As reported previously (Parchi et al. 1999b; Parchi et al. 1996), the 
immunohistochemistry of the three MM1 sCJD cases was characterized by punctuate 
or synaptic pattern of PrP immunostaining (Figure A1.2c); in the granular layer of 
cerebellum, a rather coarser staining of PrP was present in a patchy pattern (Figure 
A1.2b). In the MM1-2 case which showed confluent type of vacuoles focally in the 
thalamus, a coarse/perivacuolar pattern of immunostaining was observed in the 
frontal cortex and thalamus (Figure A1.2d). In MM1-1, PrP deposits were 
demonstrated in the cerebellum and thalamus in which abnormal PrP was not reliably 





































Figure A1.2 Neuropathology in MM1 sCJD. (a) Microvacuolar spongiform change 
in the frontal cortex from MM1-6 (hematoxylin and eosin). Original magnification: 
x200. (b) Synaptic staining for PrP in the molecular layer of the cerebellum (bottom) 
with coarser positivity in the granular layer of MM1-1. Original magnification: x100. 
(c) Widespread synaptic positivity in the thalamus from MM1-6. Original 
magnification: x100. (d) A coarse and perivacuolar pattern of PrP deposition in the 
thalamus from MM1-2. Original magnification: x100. In all immunostained sections, 





1.3 MM2 sCJD 
In MM2 subtype of sCJD, the spongiform change was characterized by confluent 
vacuoles in addition to fine spongiform degeneration (Cali et al. 2009; Parchi et al. 
1999b; Parchi et al. 2009a). Although the three MM2 cases analysed in this study 
demonstrated confluent vacuolation, their pathological characteristics were more 
variable than those described in a previous study (Parchi et al. 1999b). In the case of 
MM2-1, mild confluent vacuolation was seen in the frontal cortex and thalamus. In 
the frontal cortex of MM2-2, there was marked cortical atrophy characterised by a 
severe loss of neurons and astrocytosis and there was also widespread spongiform 
change in this region which consisted of fine vacuoles with the occasional larger 
confluent vacuoles (Figure A1.3a). In the thalamus of MM2-2, there was mild 
vacuolation of predominantly microvacuolar type in addition to severe neuronal loss 
and gliosis. In MM2-3, the widespread spongiform degeneration in the frontal cortex 
was a mixture of both microvacuolation and the confluent larger vacuolation. The 
thalamus also demonstrated mild vacuolation. In all three cases, the cerebellum was 
mostly spared.   
 
In all three cases examined in this study, positive PrP staining was seen only in the 
frontal cortex. In MM2-1, PrP deposits were focally present in a perivacuolar pattern 
against a synaptic background (Figure A1.3c). In MM2-2, there was a 
diffuse/synaptic pattern of staining with occasionally enhanced signals around 
vacuoles; intriguingly, PrP immunostaining emerged in a predominantly synaptic 
pattern even in an area showing dominantly larger/confluent vacuolation (Figure 
A1.3b). In MM2-3, the PrP immunostaining showed a widespread, predominantly 
synaptic pattern of positivity, but enhanced PrP staining around vacuoles was also 





























Figure A1.3 Neuropathology in MM2 sCJD. (a) Spongiform change composed of 
large confluent vacuoles in the frontal cortex from MM2-2 (hematoxylin and eosin). 
Original magnification: x200. (b) Synaptic pattern of PrP immunoreactivity in the 
frontal cortex from MM2-2. Original magnification: x200. (c) Focal perivacuolar 
staining surrounded by mild synaptic PrP immunoreactivity in the frontal cortex from 
MM2-1. Original magnification: x200. (d) Coarse and perivacuolar PrP 
immunoreactivity against widespread synaptic PrP staining in the frontal cortex from 
MM2-3. Original magnification: x200. The immunolabelling of PrP was performed 
using the mAbs KG9 (sections b and c) or 3F4 (section d). All immunostained 






1.4 MV1 sCJD  
In the three MV1 patients, the histopathological changes in the three brain regions 
were overall similar to those seen in the MM1 patients. The spongiform change was 
characterized by microvacuoles (Figure A1.4a), but the larger, confluent type of 
vacuoles was also evident in the MV1-1 and MV1-2 cases (Figure A1.4b). Whilst the 
frontal cortex in MV1-1 and MV1-3 showed the appearance of widespread severe 
spongiform degeneration, the spongiform change in the frontal cortex of MV1-2 was 
relatively moderate. There was a variable degree of spongiform change in the 
thalamus and cerebellar cortex of the three MV1 patients. 
 
In all three cases, immunohistochemical staining for abnormal PrP demonstrated a 
positive reaction with a predominantly synaptic pattern of staining; in the granular 
layer of the cerebellum, a rather coarse distribution of PrP staining was observed. 
Additionally, the perivacuolar accumulation of abnormal PrP was also evident 
around the regions of confluent spongiform change in the frontal cortex of both 
MV1-1 and MV1-2 (Figure A1.4c). Moreover, the thalamus of MV1-2 had focally 
plaque-like dense deposits against a widespread synaptic positivity (Figure A1.4d). 
In MV1-2, a mild degree of PrP deposition was detected in the cerebellum in which 








































Figure A1.4 Neuropathology in MV1 sCJD. (a) Widespread microvacuolar 
spongiform degeneration in the frontal cortex from MV1-3 (hematoxylin and eosin). 
Original magnification: x200. (b) A focus showing large confluent vacuoles in the 
frontal cortex from MV1-1 (hematoxylin and eosin). Original magnification: x200. 
(c) Perivacuolar deposition of PrP around areas of confluent spongiform change in 
the frontal cortex from MV1-1. Original magnification: x200. (d) Plaque-like 
deposits against synaptic background in the thalamus from MV1-2. In all 







1.5 MV2 sCJD  
On microscopic examination, the histopathological changes observed in MV2-1 and 
MV2-3 cases were noticeably distinguishable from that of MV2-2. In both MV2-1 
and MV2-3 cases, the cerebellum showed kuru plaques predominantly present in the 
granular layer in addition to mild vacuolation in the molecular layer (Figure A1.5a). 
Widespread microvacuolar spongiform change was present in FC of MV2-1, whereas 
mild patchy spongiform change was identified in the FC of MV2-3. In both cases, 
severe spongiform degeneration was also evident in the thalamus. In MV2-2, the 
histopathological features were clearly different from the two other cases and 
appeared rather similar to typical MM2 cases. The widespread spongiform change in 
FC of MV2-2 was predominantly present in the form of “graph-like” confluent foci 
(Figure A1.6a) and severe confluent spongiform change was also observed in the 
thalamus. The cerebellum in this case was largely spared and no kuru plaques were 
detected.  
 
An immunohistochemical staining pattern for abnormal PrP was similar between 
MV2-1 and MV2-3, and readily distinguishable from that of MV2-2. In the 
cerebellum of the two former cases, kuru plaques against coarse immunoreactivity 
were present predominantly in the granular layer in addition to mild synaptic staining 
in the molecular layer (Figure A1.5b). In the frontal cortex of these two cases, there 
was a synaptic pattern of PrP accumulation with occasional plaque-like dense 
deposits and perineuronal staining (Figure A1.5c). In comparison with MV2-1, the 
frontal cortex of MV2-3 in which abnormal PrP was not reliably detectable by CDI 
and WB was largely spared with mild positivity in limited microscopic areas. In the 
thalamus, plaque-like dense deposits were seen against synaptic and coarser granular 
patterns of PrP staining (Figure A1.5d).  
 
In sharp contrast to these two cases, PrP immunostaining in MV2-2 showed strong 
positive reaction with a predominantly perivacuolar pattern of accumulation in the 
frontal cortex and thalamus (Figures A1.6b and A1.6d). The cerebellum of MV2-2 
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was largely spared showing no kuru plaques or plaque-like deposits; the focal 
deposition of PrP in the molecular layer was demonstrated in a coarse/perivacuolar 




























Figure A1.5 Neuropathology in MV2 sCJD. (a) Kuru plaques located in the 
granular layer of cerebellum from MV2-3 (hematoxylin and eosin). Original 
magnification: x400. (b) Intense staining of kuru plaques at the interface between the 
molecular layer and granular layer in the cerebellum from MV2-3. There is also 
synaptic immunoreactivity in the molecular layer. Original magnification: x200. (c) 
Widespread synaptic immunoreactivity along with the perineuronal staining in the 
frontal cortex from MV2-1. Original magnification: x200. (d) Plaque-like dense 
deposits against widespread mild synaptic immunostaining in the thalamus of MV2-1. 
Original magnification: x200. In all immunostained sections, PrP was labelled with 






















Figure A1.6 Neuropathology in a MV2 sCJD case with atypical pathological 
features. (a) Spongiform degeneration composed of large confluent vacuoles in the 
frontal cortex of MV2-2 (hematoxylin and eosin). Original magnification: x200. (b) 
Widespread intense perivacuolar PrP immunoreactivity in the frontal cortex from 
MV2-2. Original magnification: x100. (c) Coarse and perivacuolar immuostaining in 
the molecular layer of cerebellum from MV2-2. Original magnification: x100. (d) 
Intense perivacuolar deposition of PrP in the thalamus of MV2-2. Original 
magnification x200. In all immunostained sections, PrP was labelled with the mAb 







In the three cases of vCJD, the neuropathological features were similar to those 
described previously (Ironside et al. 2000). The pathological features of MM1/MV1 
cases were characterized by fine spongiform degeneration and synaptic PrP 
immunostaining, as described previously (Parchi et al. 1999b). Some of the 
MM1/MV1 cases showed focally confluent type of vacuoles along with perivacuolar 
PrP staining, in line with recent reports describing the mixed phenotypes in sCJD 
brains (Cali et al. 2009; Parchi et al. 2009b)(Table A1.1). The three MM2 sCJD 
cases also showed a mixture of both types of pathological features, but in the MM2-2 
case, abnormal PrP was detected predominantly in a synaptic pattern even in a region 
dominated by larger/confluent vacuolation (Table A1.1).  
 
Of the three MV2 cases, two cases (MV2-1 and MV2-3) showed typical 
neuropathology of MV2 subtype, which were characterized by the presence of kuru 
plaques in the cerebellum (Table A1.1). In contrast, the remaining case (MV2-2) did 
not show any kuru plaques or plaque-like PrP deposits in the cerebellum and this 
region was also largely spared from PrP immunostaining. The pathological change in 
the MV2-2 case was characterized by confluent vacuolation and perivacuolar PrP 
staining in the frontal cortex and thalamus; in this case, the cerebellum was largely 
spared except for focal distribution of coarse immunostaining in molecular layer. 
Collectively, the pathological changes observed in this MV2-2 case were somewhat 
similar to those of the MM2 subtype of sCJD described by Parchi et al (Parchi et al. 
1999b). (Given the suspicion that this might indicate an error in genotyping, the 




Table A1.1 Neuropathological features in different subtypes of sporadic CJD  





MM1-1 microvacuolation  
synaptic PrP staining 
----------  
MM1-2 microvacuolation  





MM1-6 microvacuolation  
synaptic PrP staining 
----------  
MM2-1 
cluster of vacuoles 




diffuse/synaptic PrP staining 
confluent vacuoles 
perivacuolar staining MM2 
MM2-3 
mixture of  microvacuoles 
and confluent vacuoles; 
mixture of synaptic and 
perivacuolar staining 
---------- 
- Cb is mostly spared 
- Th shows mild  
   vacuolation 
- No PrP staining in  
  Cb and Th 
 
MV1-1 microvacuolation  
synaptic PrP staining 
confluent vacuoles  
perivacuolar staining 
 
MV1-2 microvacuolation  
synaptic PrP staining 
confluent vacuoles  
perivacuolar staining 
- plaque-like deposits 
in Th 
MV1 
MV1-3 microvacuolation  




plaque-like PrP deposits 
synaptic PrP staining 
----------  
MV2-2 confluent vacuoles 
perivacuolar PrP deposits 
---------- 
- No detectable kuru  
plaques 




plaque-like PrP deposits 
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Journal: Journal of Virology 
Title: Distinct stability states of disease-associated prion protein (PrPSc) identified by 
conformation dependent immunoassay  
Authors: Young Pyo Choi, Alexander H. Peden, Albrecht Gröner, James W. 
Ironside, and Mark W. Head 
Abstract  
The phenotypic and strain-related properties of human prion diseases are, 
according to the prion hypothesis, proposed to reside in the physico-chemical 
properties of the conformationally altered, disease-associated isoform of the 
prion protein (PrPSc), which accumulates in the brains of patients suffering from 
Creutzfeldt-Jakob disease and related conditions such as Gerstmann Straussler-
Scheinker disease. Molecular strain typing of human prion diseases has focussed 
extensively on differences in the fragment size and glycosylation site occupancy 
of protease resistant prion protein (PrPres) in conjunction with the presence of 
mutations and polymorphisms in the prion protein gene (PRNP). Here we report 
the results of employing an alternative strategy that specifically addresses the 
conformational stability of PrPSc and that has been used previously to 
characterise animal prion strains transmitted to rodents. The results show that 
there are at least two distinct conformation stability states in human prion 
diseases, neither of which appears to correlate fully with PrPres type as judged by 
fragment size or glycosylation, the PRNP codon 129 status or the presence or 
absence of mutations in PRNP. These results suggest that conformational 
stability represents a further dimension to a complete description of potentially 
phenotype-related properties of PrPSc in human prion diseases. 
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Status: Accepted subject to minor revision 
Journal: Brain Pathology 
Title: Correlation of polydispersed prion protein and characteristic pathology in the 
thalamus in variant Creutzfeldt-Jakob disease: implication of small oligomeric 
species 
Authors: Young Pyo Choi, Albrecht Gröner, James W. Ironside, and Mark W. Head 
Abstract  
The vacuolation, neuronal loss and gliosis that characterise human prion disease 
pathology are accompanied by the accumulation of an aggregated, insoluble and 
protease-resistant form (termed PrPSc) of a host-encoded protein (PrPC). In variant 
Creutzfeldt-Jakob disease the frontal cortex and cerebellum exhibit intense 
vacuolation and the accumulation of PrPSc in the form of amyloid plaques and 
plaque-like structures. In contrast the posterior thalamus is characterised by intense 
gliosis and neuronal loss, but PrPSc plaques are rare and vacuolation is patchy. We 
have used sucrose density gradient centrifugation coupled with conformation 
dependent immunoassay to examine the biochemical properties of the PrPSc that 
accumulates in these different brain regions. The results show a greater degree of 
PrPSc polydisperal in thalamus compared to frontal cortex or cerebellum, including a 
subpopulation PrPSc molecules in the thalamus that have sedimentation properties 
resembling those of PrPC.  Much effort has focussed on identifying aspects of PrPSc 
biochemistry that distinguish between different forms of human prion disease and 
contribute to differential diagnosis. Here we show that PrPSc sedimentation 
properties, which can depend on aggregation state, correlate with, and may underlie 
the distinct neurodegenerative processes occurring in different regions of the variant 
Creutzfeldt-Jakob disease brain.  
 
